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Abstract	
	
Staphylococcus	aureus	is	a	Gram	positive	bacterium	which	is	predominantly	commensal,	but	which	can	also	be	a	human	and	animal	pathogen,	able	to	cause	serious	infections.	It	is	becoming	an	increasing	problem	due	to	it	becoming	resistant	to	modern	antibiotics.	In	common	with	most	bacteria,	S.	 aureus	 requires	 small	 quantities	of	 the	 essential	metal	copper,	 but	 they	 also	 experience	 toxicity	 when	 exposed	 to	 high	 concentrations	 of	copper,	 a	 metal	 that	 has	 been	 used	 for	 its	 antimicrobial	 properties	 for	 centuries.	However,	the	mechanism	of	such	toxicity	remains	elusive.		Here,	 the	 effect	 of	 copper	 toxicity	 on	 S.	 aureus	 has	 been	 investigated	 in	 order	 to	understand	how	excess	 copper	 ions	affect	 its	physiology.	The	growth	of	S.	aureus	was	found	 to	 be	 inhibited	 in	 media	 containing	 elevated	 copper,	 and	 the	 extent	 of	 this	inhibition	was	shown	to	be	dependent	on	the	type	of	growth	medium	used.	Analysis	of	soluble	extracts	from	S.	aureus	cells	exposed	to	elevated	copper	led	to	the	identification	of	 a	 cytoplasmic	 enzyme,	 GapA,	 which	 binds	 copper.	 GapA	 is	 a	 member	 of	 the	 well-characterised	 family	 of	 the	 glyceraldehyde-3-phosphate	 dehydrogenase	 (GAPDH)	enzymes,	and	 is	not	a	metalloprotein.	Copper	 inhibition	of	 the	activity	of	 the	S.	aureus	GapA	enzyme	was	demonstrated,	both	 in	S.	aureus	 cell	 extracts	and	with	 recombinant	enzyme	in	vitro,	using	a	specific	enzyme	activity	assay.		Analysis	 of	 the	 purified	 recombinant	 GapA	 enzyme	 in	 vitro	 demonstrated	 a	 copper	binding	 stoichiometry	 of	 one	 Cu(I)	 ion	 to	 each	 GapA	monomer	 using	 analytical	 size-exclusion	 chromatography	 and	 spectrophotometry,	 and	 evidence	 is	 presented	 that	suggests	 high	 affinity	 Cu(I)	 binding	 of	 biochemical	 relevance.	 Some	 preliminary	evidence	 is	provided	that	 the	Cu(I)	binding	site	on	the	GapA	protein	 includes	the	thiol	group	of	cysteine	151	located	within	the	active	site,	consistent	with	predictions	based	on	published	crystal	structures,	and	explaining	the	observed	copper-dependent	 inhibition	of	enzyme	activity.		This	is	the	first	evidence	of	copper	binding	to	a	non-metalloprotein	within	the	cytoplasm	of	S.	aureus	and	adds	to	mounting	evidence	that	aberrant	binding	of	copper	to	cytosolic	proteins	contributes	to	bacterial	copper	toxicity.			
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Chapter	1.	Introduction	
1.1	Preface	
Staphylococcus	aureus	(S.	aureus)	is	a	species	of	Gram-positive	bacteria	morphologically	classed	as	cocci,	which	grows	 in	small	clusters	resembling	a	bunch	of	grapes	(staphylē	being	the	Greek	for	grape	and	kókkos	 for	granule).	Typically	colonies	appear	golden	in	colour	 due	 to	 its	 production	 of	 the	 staphyloxanthin	 pigment	 (aureus	 being	 from	 the	Latin	 for	 golden)1.	 It	 exists	 commensally	with	 humans	 and	 other	mammalian	 species,	being	 found	 on	 the	 skin	 of	 millions	 of	 people	 without	 causing	 disease2.	 However,	 in	carriers	with	 compromised	 immune	 systems	 or	 due	 to	 increased	 virulence	 of	 current	strains,	S.	aureus	may	cause	a	wide	 range	of	pathological	 conditions,	 the	 symptoms	of	which	depend	heavily	on	 the	 locality	of	 the	 infection	and	 the	genetics	of	 the	pathogen	and	 host.	 Infections	 can	 result	 in	 a	 wide	 range	 of	 symptoms,	 from	 mild	 skin	 lesions	through	to	life-threatening	systemic	diseases	in	severe	cases.		The	 advent	 and	 eventual	 widespread	 use	 of	 antibiotics	 from	 the	 middle	 of	 the	 20th	century	saw	a	dramatic	fall	in	morbidity	due	to	S.	aureus,	a	trend	that	continued	until	the	end	of	the	century.	However,	penicillin	resistance	was	reported	as	early	as	19483,	with	initial	reports	of	methicillin	resistance	first	emerging	in	the	United	Kingdom	just	a	year	after	methicillin	was	brought	into	general	use	in	19604.	These	were	quickly	followed	by	further	reports	from	around	the	developed	world.	By	2014,	there	had	been	incidences	of	
S.	aureus	resistance	to	all	classes	of	clinically	available,	non-experimental	antibiotics5-7.		This	trend	of	broadening	and	increasing	antibiotic	resistance	presents	modern	medicine	with	the	concerning	prospect	of	returning	to	the	pre-antibiotic	world,	in	which	patients	with	virulent	S.	aureus	 infections	suffered	mortality	rates	of	around	80%8.	Without	an	adequate	increase	in	our	ability	to	treat	emerging	antibiotic	resistant	strains,	morbidity	and	mortality	from	S.	aureus	infection	is	likely	to	increase.		Modern	antibiotics	are	often	thought	of	as	the	only	defence	against	infectious	pathogens.	However,	other	agents	and	practices	that	have	a	significant	effect	on	the	incidence	and	spread	 of	 such	 diseases	 should	 also	 be	 considered	 as	 they	 may	 present	 effective	concurrent	or	alternative	remedies.			
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Recently,	 the	transition	metal	copper	has	been	deployed	for	use	 in	the	manufacture	of	clinical	devices	and	dressings	such	as	catheters	and	plasters.	Some	hospitals	have	also	trialled	the	use	of	copper-coated	door	handles,	copper-coated	surgical	trolleys	and	other	copper-coated	 utensils	 that	 are	 easily	 contaminated9,10.	 These	 practices	 have	 proven	effective	 at	 preventing	 surface	 contamination	 and	 therefore	 spread	 of	 S.	 aureus	 and	other	species	of	bacteria.		Copper	 is	 an	 effective	 wide-spectrum	 antimicrobial	 agent,	 but	 the	 antibacterial	mechanism	 of	 copper	 is	 poorly	 understood	 despite	 its	 increasing	 clinical	 usage.	 The	literature	 is	 awash	 with	 statements	 alluding	 to	 the	 production	 of	 reactive	 oxygen	species,	mis-metallation,	and	erroneous	binding	by	copper.	These	mechanisms	may	all	have	 a	 role	 to	play	 in	 copper	 toxicity,	 but	 thorough	 interrogation	of	 existing	 evidence	remains	 paramount	 and	 further	 research	 into	 the	 mechanisms	 of	 copper	 toxicity	 is	required.		 	Despite	 this	 bactericidal	 nature,	 copper	 is	 also	 a	 bio-metal;	 that	 is,	 it	 is	 utilised	 by	organisms,	including	S.	aureus,	for	the	essential	function	of	numerous	enzymes,	for	many	of	which	it	is	indispensable.			Faced	with	mounting	antibiotic	resistance	to	S.	aureus,	it	is	imperative	that	all	forms	of	antibacterial	agents	be	exploited	for	their	properties.	In	order	to	do	this	most	effectively	with	copper,	an	understanding	of	its	bactericidal	properties	and	its	mechanism	of	action	warrants	 further	 investigation,	 which	 will	 enable	 us	 to	 develop	 more	 cost-effective	copper-dependent	treatments	and	to	assess	the	risk	of	copper	resistance	developing	in	bacteria.	 A	 broad	 aim	 of	 this	 body	 of	 work	 is	 to	 develop	 a	 deeper	 understanding	 of	copper	toxicity	in	S.	aureus.		 	
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1.2	Staphylococcus	aureus	
1.2.1	Morphology	and	Pathogenesis		The	 Gram-positive	 bacterium	 S.	 aureus	 is	 a	 non-motile,	 pathogenic,	 cocci	 bacterial	species	that	can	cause	opportunistic	disease	in	numerous	mammalian	species	including	cows,	 horses,	 pigs	 and	 humans,	where	 it	 can	 have	 a	 significant	 impact	 on	 health.	 The	closely	 related	 non-pathogenic	 bacterium	 Staphylococcus	 epidermidis	 is	 commensal	 in	most	populations	(although	it	can	also	cause	disease	in	rare	cases11).	Equally,	S.	aureus	has	 also	 been	 found	 to	 be	 commensal	 on	 the	 skin	 in	 variable	 populations;	 	 a	 recent	European	 study	 found	 the	 rate	 of	 commensality	 to	 be	 between	 15	 and	 25%	 in	 9	countries	studied2.	It	is	unclear	how	commensal	strains	develop	pathogenicity.		Virulence	determinants	of	S.	aureus	include	catalase,	alpha-toxin,	gamma-toxin,	Panton-Valentine	 leukocidin	 (PVL)	 and	 phenol	 soluble	 modulins	 (PSMs),	 as	 well	 as	 those	belonging	to	the	MSCRAMM	(microbial	surface	components	recognizing	adhesive	matrix	molecules)	family12,13.	These	either	are	or	are	not	present	in	various	clonal	strains,	and	their	 presence	 or	 absence	 dictates	 strain	 virulence.	 Notably,	 PVL	 genes	 are	 actually	endogenous	 to	 a	 bacteriophage	 of	 S.	 aureus,	 and	 contribute	 to	 particularly	 aggressive	staphylococcal	necrotic	 lesion	 pathology	most	 commonly	 seen	 in	 USA300	 and	 related	strains	of	S.	aureus14,15.		Antibiotic	resistance	of	S.	aureus	is	well	documented	and	many	strains	are	now	susceptible	to	just	a	few	‘antibiotics	of	last	resort’7.		This	pathogen	is	a	major	cause	of	nosocomial	infections,	contributing	to	lengthier	stays	in	hospitals	and	sometimes	causing	secondary	systemic	disease	in	patients	that	can	be	fatal16.	 This	 detracts	 not	 only	 from	 patient	 welfare	 but	 also	 has	 high	 long-term	healthcare	costs.	In	the	UK	and	other	parts	of	the	developed	world,	recent	increases	in	hygiene	precautions	 have	 gone	 some	way	 in	 preventing	 nosocomial	 spread17,18,	 but	S.	
aureus	infections	remain	a	significant	problem.			More	recently,	outbreaks	of	community	acquired	S.	aureus	have	been	identified	as	being	caused	 by	 strains	 with	 separate	 genotypes,	 with	 different	 virulence	 factors	 to	 those	traditionally	 found	 in	 hospitals19.	 Yet	 these	 have	 been	 found	 to	 be	 increasing	 their	presence	 in	 hospital	 settings	 too20,21,	 demonstrating	 the	 rapidity	 at	 which	 different	strains	can	be	transferred	between	settings.	
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			Due	to	the	aforementioned	capability	of	S.	aureus	to	infect	farm	animals,	outbreaks	are	also	a	problem	for	the	agricultural	sector22.	Both	nosocomial	and	community	S.	aureus		infections	in	man,	alongside	livestock	epidemics,	place	a	heavy	healthcare	and	financial	burden	upon	their	respective	sectors,	making	new	strategies	for	effective	treatment	and	prevention	of	this	pathogen	a	high	priority	for	research.			
1.2.2	Nomenclature	and	Strains		The	 nomenclature	 regarding	 strain	 variants	 of	 S.	 aureus	 is	 complex.	 Historically,	healthcare	 associated	 (HA),	 community	 associated	 (CA)	 and	 livestock	 associated	 (LA)	samples	collected	around	the	world	have	been	recorded	separately,	often	according	to	different	 classification	 systems,	 meaning	 that	 there	 is	 no	 way	 of	 knowing	 the	relationships	of	all	documented	stains	without	very	significant	effort.	Laboratory	strain	collections	usually	derive	from	a	clinical	isolate,	extending	this	problem	to	these	groups	of	strains.	In	this	work,	use	has	been	made	of	several	strains	that	are	all	derivatives	of	the	parent	strain	S.	aureus	NCTC8325	(see	Table	2.1).		NCTC8325	was	 isolated	 in	 1960	 from	 a	 sepsis	 patient	 and	was	 chosen	 as	 a	model	 S.	
aureus	 strain	due	 to	 its	 sensitivity	 to	 all	 antibiotics	used	 at	 that	 time23.	As	part	 of	 the	Richard	Novick	 strain	 collection	 it	was	 designated	RN1.	 Subsequently,	 this	 strain	was	found	 to	 harbour	 a	 number	 of	 prophages	 as	 well	 as	 mutations	 in	 the	 rsbU	 and	 tcaR	genes.	Step-wise	removal	of	said	prophages	produced	the	strain	8325-4	(also	known	as	RN0450),	 and	 further	 targeted	 correction	 of	 the	 mutated	 rsbU	 gene	 gave	 rise	 to	SH100024.	These	modifications	of	RN1/NCTC8325	and	 its	derivatives	allow	SH1000	to	be	used	as	an	adequate	model	organism	when	compared	to	a	number	of	other	common	model	 strains	 in	 existence23.	 The	 restoration	 of	 a	 functional	 rsbU	 is	 particularly	noteworthy	due	to	its	complex	and	seemingly	global	regulatory	function.		
	The	 rsbU	 gene	 encodes	 a	 phosphatase	 that	 is	 part	 of	 the	 sigB	 operon	 that	 regulates	production	 of	 a	 secondary	 sigma	 factor,	 σB25.	 Sigma	 factors	 are	 important	 regulatory	proteins	that	form	a	holoenzyme	with	the	ribonucleic	acid	(RNA)	polymerase	core	unit,	allowing	transcription	to	 take	place.	S.	aureus	σB	is	 important	during	stationary	phase	and	under	particular	stress	conditions	for	appropriate	expression	of	numerous	genes25.	It	has	also	been	suggested	to	play	a	role	in	regulating	the	global	regulatory	operons	agr	
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and	 sar26	 as	 well	 as	 in	 antibiotic	 resistance27.	 Its	 absence	 results	 in	 a	 number	 of	phenotypic	 changes	 during	 infection	 models	 and	 in	 laboratory	 work,	 making	 its	presence	 essential	 for	 proper	 comparison	 to	 wild-type	 strains.	 Hence,	 care	 must	 be	taken	to	check	that	the	rsbU	status	of	strains	is	known.		‘NCTC’	 of	 NCTC8325	 is	 an	 acronym	 for	 National	 Collection	 of	 Type	 Cultures,	 the	institution	where	this	strain	was	first	recorded	in	the	UK,	and	‘RN’	of	RN1	are	the	initials	of	Richard	Novick	a	Professor	of	microbiology	who	specialised	in	the	study	of	S.	aureus;	these	strains	are	therefore	named	somewhat	arbitrarily.	An	international	standardised	method	of	naming	and	categorising	the	many	strains	of	S.	aureus	has	not	been	agreed.	However,	 methods	 of	 categorising	 them	 into	 some	 sort	 of	 genetic	 order	 have	 been	established	 and	 from	 these	 a	 convention	 for	 naming	 strains	 seems	 to	 be	 emerging	 –	something	which	would	very	much	aid	in	the	study	of	this	organism.	Four	methods	are	currently	 in	 use	 for	 the	molecular	 typing	 of	S.	 aureus;	pulsed-field	 gel-electrophoresis	(PFGE),	 spa	 typing,	 multi-locus	 sequence	 typing	 (MLST)	 and,	 for	 methicillin	 resistant	
Staphylococcus	aureus	(MRSA)	strains,	SCCmec	typing.			
1.2.3	Clinical	relevance,	Epidemiology	and	Commensality	The	study	of	S.	aureus	would	not	warrant	as	much	attention	as	it	receives	if	it	were	not	for	 the	pathogenic	nature	of	 the	organism.	S.	aureus	 is	 the	aetiological	agent	of	a	wide	range	 of	 diseases	 varying	 greatly	 in	 severity	 and	 manifestation,	 as	 demonstrated	 in	Figure	 1.1.	 Despite	 its	 description	 around	 a	 century	 ago	 and	 even	 with	 constant	improvements	 in	 healthcare	 and	 novel	 therapeutics,	 S.	 aureus	 remains	 a	 significant	nosocomial	problem	and	is	evolving	into	a	virulent	community-acquired	infection.			Much	of	what	we	know	about	S.	aureus	epidemiology	is	focused	on	its	occurrence	in	the	developed	 world,	 with	 little	 known	 about	 its	 presence	 or	 genetics	 in	 Africa,	 South	America,	 and	Asia	 (excluding	 Japan)28.	However,	 from	data	gathered	 it	 is	 thought	 that	approximately	 one-fifth	 to	 one-third	 of	 people	 carry	 S.	 aureus	 commensally28,	 mostly	nasally,	 although	 the	 carriage	 rate	 and	 strain	 variants	 carried	 can	 differ	 greatly	 from	region	 to	 region2,	 highlighting	 the	 genetic	diversity	 of	S.	 aureus.	 The	mechanisms	 that	dictate	whether	a	strain	will	be	commensal	or	pathogenic	are	complex,	being	governed	by	both	the	genetics	of	the	bacteria	and	host.	One	recent	study	observed	that	USA300,	
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the	pathogenic	MRSA	strain	currently	prevalent	in	the	United	States,	was	more	virulent	than	 a	 well-characterised	 commensal	 strain,	 A502;	 but	 resulted	 in	 a	 lower	 level	 of	interferon	 I	 (IFN	 I)	 signalling	 than	 its	 commensal	 counterpart.	 However,	 if	 the	commensal	strain	managed	to	bypass	the	mucosal	barrier	it	resulted	in	higher	mortality	in	 a	 mouse	 model	 than	 USA30029.	 Further	 research	 is	 required,	 but	 such	 studies	demonstrate	 a	 high	 likelihood	 that	 a	 large	 range	 of	 factors	 influences	 the	 virulence,	commensality	and	invasiveness	of	strains.		In	Europe,	North	America,	Australia	and	Japan,	where	S.	aureus	has	presented	a	major	challenge	 and	 expense	 to	 healthcare	 organisations,	 S.	 aureus	 exists	 as	 a	 collection	 of	various	 strains	 of	 methicillin	 sensitive	 and	 methicillin	 resistant	 S.	 aureus	 (MSSA	 and	MRSA	respectively)30.			The	precise	origins	of	 the	 first	MRSA	strains	are	unknown,	but	 it	was	 first	reported	 in	1961	 in	 the	 United	 Kingdom,	 and	 then	 quickly	 reported	 subsequently	 in	 the	 United	States,	Japan	and	Australia5.	Further	mutations,	plasmid	acquisition	and	horizontal	gene	transfer	 between	 strains	 has	 led	 to	 modern	 MRSA	 strains	 being	 widespread	 and	resistant	to	many	antibiotics.	Most	strains	remain	sensitive	to	the	glycopeptide	class	of	antibiotics,	 including	vancomycin,	although	some	with	reduced	sensitivity	 to	 these	are	emerging5,31.		Commensal	 clinical	 infections	 of	 individuals	 with	 deficient	 immune	 systems	 may	 in	cases	 lead	 to	more	 serious	 symptoms	 and	 diseases	 (examples	 of	which	 are	 shown	 in	Figure	 1.1).	 Notably,	 copper	 has	 been	 found	 to	 have	 a	 role	 to	 play	 within	 the	 innate	immune	 system	 that	 forms	 part	 of	 the	 host	 defences	 against	 S.	 aureus.	 The	 innate	immune	system	is	the	non-adaptive	part	of	the	immune	system	found	throughout	most	clades	of	life,	including	in	humans.			Numerous	 studies	have	shown	 that	 copper	deficiency	 in	humans	 leads	 to	neutropenia	and	to	the	impaired	capability	of	neutrophils	to	kill	bacteria,	this	has	been	shown	to	be	reversed	 upon	 dietary	 supplementation	 with	 copper32.	 	 What	 is	 less	 clear	 is	 the	mechanism	by	which	copper	exerts	 its	antimicrobial	activity	within	 the	phagosome	or	how	it	contributes	to	increased	defence	against	S.	aureus	infections	in	the	first	place.		
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As	 discussed	 later	 in	 section	 1.4.1,	 copper	 is	 thought	 to	 cause	 damage	 to	 biological	systems	via	two	main	routes;	catalysis	of	the	formation	of	reactive	oxygen	species	that	cause	further	downstream	damage	and	damage	to	proteins	via	direct	binding	of	copper.	Copper	accumulates	within	phagosomes	 inside	of	neutrophils	and	then	exerts	 its	 toxic	effects	 upon	 the	 bacterial	 cell	 upon	 phagocytosis33.	 Moreover	 ATP7A,	 a	 host	 copper	transporting	 protein	 found	 at	 the	 host	 pathogen	 interface,	 as	well	 as	 bacterial	 copper	efflux	 pumps	 have	 been	 found	 to	 play	 a	 significant	 role	 in	 bactericidal	 activity	 in	macrophages.	The	absence	of	the	former	results	in	reduced	bacterial	clearance	and	lack	of	the	latter	results	in	an	increase	in	clearance,	suggesting	that	the	presence	of	copper	is	a	strong	contributing	factor	 in	the	 immune	response,	 the	absence	of	which	can	 lead	to	increased	survival	of	bacteria	within	a	host	34.								 	
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Figure	 1.1.	 Conditions	 caused	 by	 S.	 aureus.	 Taken	 from	 Wertheim	 et	 al.35	 These	conditions,	 amongst	 others,	 can	 all	 be	 caused	 by	 S.	 aureus.	 Often,	 symptoms	 are	 the	result	of	the	location	of	infection.	Most	strains	of	S.	aureus	are	not	normally	pathogenic,	but	 may	 cause	 disease	 if	 the	 immune	 system	 of	 the	 host	 is	 compromised.	 The	 most	common	symptoms	of	pathogenesis	by	S.	aureus	are	carbuncles	and	sinusitis	which	can	often	be	cleared	by	the	host’s	own	defences,	without	the	need	for	clinical	intervention.			 	
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1.2.4	Methicillin	resistant	S.	aureus	–	MRSA		MRSA	is	usually	used	as	a	broad	term	for	a	large	number	of	strains	of	S.	aureus	that	have	acquired	resistance	not	just	to	methicillin	but	to	a	number	of	different	antibiotics	often	of	 different	 classes36.	 Since	 the	 advent	 of	 the	 first	 antibiotics	 in	 the	 1930s	 and	 1940s	bacteria	have	 evolved	multiple	defensive	mechanisms.	The	ability	of	 bacteria	 to	 share	genetic	information	via	inter-species	and	intra-species	horizontal	gene	transfer	as	well	as	 vertical	 gene	 transfer	means	 that	 as	 soon	as	one	 cell	 develops	 resistance	 to	 a	drug	there	is	potential	for	this	to	spread	to	others.		Methicillin,	 like	 other	 β-lactam-based	 antibiotics,	 functions	 by	 inhibiting	 the	manufacture	 of	 peptidoglycan,	 the	 complex	 macromolecular	 structure	 that	 forms	 the	bacterial	 cell	wall.	Before	methicillin	was	 introduced	 it	was	 found	 that	many	S.	aureus	strains	had	started	to	produce	a	β-lactamase	–	an	agent	that	is	able	to	break	down	these	antibiotics,	 which	 include	 penicillin.	 Methicillin	 was	 resistant	 to	 this	 enzyme	 due	 to	slight	 alterations	within	 its	 structure,	 but	 soon	 after	 its	 introduction	S.	 aureus	 strains	that	 produced	 an	 alternative	 methicillin-resistant	 enzyme	 began	 to	 appear,	 deemed	MRSA37.			
S.	 aureus	 has	 traditionally	 been	 thought	 of	 as	 a	 nosocomial	 infection,	 often	 being	referred	 to	 as	 healthcare-associated	 MRSA	 (HA-MRSA).	 However,	 it	 has	 been	 more	recently	found	that	a	number	of	strains,	unrelated	to	those	isolated	from	in-patients	or	those	 having	 had	 a	 recent	 stay	 in	 hospital,	 exist	 apparently	 in	 isolation	 within	 the	community.	These	strains	have	been	deemed	community	acquired	MRSA	(CA-MRSA)38.	These	demonstrate	high	variability	across	different	communities	but	frequently	it	is	the	case	that	CA-MRSA	carries	many	more	virulence	factors	than	HA-MRSA	and	has	caused	the	death	of	some	otherwise	healthy	individuals39,40.	Questions	remain	over	where	such	strains	have	come	 from.	 It	has	been	suggested	 that	 they	may	be	 ‘feral	descendants’	of	HA-MRSA	strains	but	it	appears	as	if	the	genetic	differences	between	strains	is	too	great	for	this	to	have	occurred	in	such	a	short	space	of	time38.		Figure	 1.2	 shows	 the	 time	 of	 introduction	 of	 various	 antibiotics	 compared	 with	 the	emergence	 of	 various	 resistant	 bacteria.	 Methicillin	 resistance	 occurred	 very	 quickly	after	its	initial	use	in	the	clinic.	However,	resistance	to	vancomycin	occurred	a	number	of	decades	after	 its	 introduction,	 firstly	 in	the	Enterococci,	and	then	in	Staphylococci.	 It	
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has	 been	 suggested	 that	 the	major	 gene	 responsible	 for	 vancomycin	 resistance,	 vanA,	was	transferred	from	Enterococci	to	Staphylococci	in	the	gut	of	a	co-infected	individual,	and	the	possibility	of	such	a	conjugative	event	has	been	confirmed	in	the	laboratory31.			Vancomycin	 resistant	 Staphylococcus	 aureus	 (VRSA)	 strains	 are	 not	 yet	 widespread	amongst	the	population	meaning	that	vancomycin	can	still	often	be	used	as	a	drug	of	last	resort.	However,	methicillin	 resistance	 is	widespread.	The	mechanism	of	 resistance	 in	this	 case	 is	 based	 upon	 acquisition	 of	 the	mecA	 gene	 that	 encodes	 penicillin	 binding	protein	2a	(PBP2a),	which	methicillin	cannot	inhibit,	in	place	of	PBP2,	which	is	inhibited	by	methicillin,	hence	peptidoglycan	synthesis	is	able	to	continue	using	PBP2a.	Detailed	explanations	of	the	mechanisms	and	regulation	of	mecA-mediated	resistance	have	been	provided	in	reviews	written	by	Stapleton	et	al.37	and	Deurenberg	et	al.41.				 	
11	
	
		
Figure	 1.2.	 Antibiotic	 and	 antibiotic	 resistance	 development	 timeline.	 A	 timeline	showing	the	years	of	development	of	various	antibiotic	therapies	(above	the	 line),	and	the	 years	 that	 various	 resistant	 bacterial	 strains	 emerged	 that	 were	 no	 longer	susceptible	 to	 treatment	with	 those	 therapies	 (below	the	 line).	Taken	 from	Tang	et	al.	201442.			 	
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1.3	Copper	homeostasis		In	almost	all	bacteria,	metal	homeostasis	involves	the	controlled	acquisition	of	essential	metals	 and	 the	 detoxification	 of	 excess	metal	 ions	 from	 cells.	 For	 some	metals	 active	metal	uptake	systems	are	known,	but	in	S.	aureus,	like	in	almost	all	bacteria,	no	copper	importer	 has	 been	 found.	 Thus	 copper	 homeostasis	 appears	 to	 involve	 only	 the	regulated	export	of	excess	copper	from	the	cytoplasm.			Research	 on	 bacterial	 copper	 homeostasis	 has	 largely	 been	 performed	 in	 model	organisms	such	as	Escherichia	coli	and	Enterococcus	hirae.	Therefore	much	of	what	we	know	about	S.	aureus	copper	homeostasis	has	foundations	in	genome	sequence	analysis	and	protein	sequence	comparisons,	although	some	preliminary	biochemical	analysis	and	mutational	 phenotyping	 has	 gone	 some	 way	 in	 confirming	 predictions	 of	 component	functions	in	some	cases.		
1.3.1	Copper	homeostasis	in	S.	aureus:	summary	of	current	understanding	
S.	aureus	copper	homeostasis	 is	primarily	mediated	via	 the	cop	operon,	which	 in	most	strains	encodes	two	neighbouring	genes;	the	copA	gene	encodes	the	membrane	protein	CopA,	a	copper	exporting	P-type	ATPase,	and	the	copZ	gene	encodes	the	soluble	protein	CopZ,	a	putative	copper	metallochaperone43.			Regulation	of	the	transcription	of	these	genes	is	controlled	by	CsoR,	a	copper-responsive	transcriptional	 de-repressor,	 which	 is	 encoded	 by	 a	 locus	 elsewhere	 within	 the	genome44,45.	 Transcribed	 concomitantly	 with	 csoR	 are	 two	 other	 genes,	 csoZ	 and	 a	hypothetical	gene	(NCBI	Reference	Sequence:	WP_001221404.1).			CsoZ	 is	 predicted	 to	 share	 some	 of	 the	 structural	 features	 of	 the	 copper	metallochaperones	and	was	thus	proposed	to	be	a	second	S.	aureus	metallochaperone.	Although	it	does	not	contain	the	typical	CXXC	binding	motif	found	in	CopZ	and	the	CopZ-like	N-terminal	domains	of	CopA,	 it	 does	 share	 sequential	 and	 structural	homology	 to	such	heavy-metal	associated	(HMA)	domains.			In	addition	 to	 these	conserved	copper	homeostasis	genes,	a	 few	strains	also	possess	a	plasmid-encoded	 system	 (NCBI	 Reference	 Sequence:	 NC_013322.1)44,	which	 confers	 a	hyper	 resistance	 phenotype	 to	 copper;	 this	 plasmid	 locus	 encodes	 another	 copper-
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exporting	 ATPase,	 CopB,	 and	 a	 multi-copper	 oxidase,	 designated	 mco,	 the	 precise	function	in	copper	detoxification	of	which	is	unclear44,46.		This	system	is	not	present	in	S.	
aureus	NCTC8325	or	its	derivatives..	
1.3.2	The	cop	regulon	of	S.	aureus	
S.	aureus,	much	like	the	model	system	E.	hirae,	encodes	a	cop	operon;	it	is	less	complex	genetically	 than	 that	 of	E.	 hirae,	with	 just	 two	 open	 reading	 frames	 (ORFs),	 copA	and	
copZ.	The	CopA	P-Type	ATPase	protein	of	S.	aureus	shares	49%	sequence	identity	with	CopA	of	E.	hirae.	It	has	been	initially	characterised	by	Sitthisak	et	al.	who	found	that	the	
copA	 gene	 in	 publically	 available	 S.	 aureus	 genomes	 (including	 NCTC8325,	 of	 which	SH1000	 is	 a	 derivative)	 had	 >99%	 sequence	 identity,	 and	 >75%	 sequence	 identity	compared	with	other	staphylococcal	species	at	the	nucleotide	level43.			Included	 in	 the	 amino-acid	 sequence	 of	 CopA	 (and	 more	 generally	 in	 copper-transporting	P-type	ATPases,	including	in	archaea	and	eukaryotes)	are	the	characteristic	N-terminal,	 soluble	 HMA	 domains,	 which	 contain	 a	 Cu(I)-binding	 CXXC	 amino	 acid	residue	motif.	The	 ferredoxin-like	 structure	of	 these	domains,	 and	 the	presence	of	 the	CXXC	motif,	are	also	shared	by	CopZ43,47.	An	individual	HMA	domain	consists	of	four	β-strands	and	two	α	helices	arrange	in	a	βαββαβ	sequence	(the	ferredoxin-like	fold),	with	the	 CXXC	 motif	 placed	 on	 the	 outside	 of	 the	 domain,	 allowing	 easy	 access	 for	 metal	binding48.	 These	 domains	 share	 high	 homology	 to	 CopZ	 and	 also	 to	 eukaryotic	metallochaperones	 such	 as	 Atx149,	 with	 which	 these	 domains	 interact	 in	 vitro.	Interestingly,	 the	P-Type	ATPases	 tend	 to	have	more	HMA	domains	 in	organisms	 that	are	more	complex,	with	some	eukaryotic	species	having	up	to	six,	whilst	bacterial	have	a	maximum	of	two.	It	is	unclear	whether	the	function	of	the	N-terminal	domains	of	CopA	is	regulatory	or	 if	 they	are	involved	in	metal	transfer	from	metallochaperones,	such	as	CopZ,	 to	 the	 transporter;	CopA	has	been	 shown	 to	 function	without	 the	HMA	domain,	which	suggests	a	regulatory	function50.	An	alternative	mechanism	of	copper	uptake	by	the	protein	has	been	suggested	based	upon	a	recently	published	crystal	structure47,	by	which	 copper	enters	 the	 channel	via	 a	 conserved	platform	region	within	 the	 ‘MA’	 and	‘MB’	designated	helices	of	the	transmembrane	domain	of	the	protein,	and	is	delivered	by	CopZ,	which	interacts	with	this	platform	region46.	Replacement	of	the	cysteine	residues	with	alanine	residues	within	a	motif	known	as	the	CPC	(cysteine-proline-cysteine)	metal	binding	motif	 of	 the	 transmembrane	 domain,	 renders	 CopA	 of	Archaeoglobus	 fulgidus	
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inactive,	but	 still	 correctly	 folded51,	 implying	 that	 the	CPC	motif	 is	directly	 involved	 in	transport	of	the	copper	ions.				The	 CopZ	metallochaperone	 of	 S.	 aureus	 is	 largely	 uncharacterised	 but	 shares	 a	 high	degree	of	homology	with	other	bacterial	CopZ	proteins,	as	well	as	the	eukaryotic	Atx152.	As	 in	 those	 examples,	 CopZ	 shows	 both	 sequence	 and	 structural	 homology	 to	 the	 N-terminal	HMA	domains	of	CopA,	of	which	 there	are	 two	 in	within	 the	 structure	of	 the	CopA	 proteins	 of	 S.	 aureus	 and	B.	 subtilis48,53.	 The	 structural	 similarity	 between	 CopZ	proteins	and	the	HMA	domains	of	P-type	ATPases	leads	to	a	strong	interaction	of	CopZ	with	 the	HMA	domain	of	CopA	 in	vitro	 and	 in	vivo54.	The	role	of	such	an	 interaction	 is	unclear.	 Although	 originally	 proposed	 to	 be	 involved	 in	 delivery	 of	 copper	 from	 the	metallochaperone	to	the	export	channel	via	the	HMA	domain,	it	is	now	thought	that	this	interaction	 could	 perform	 a	 regulatory	 role	 in	 copper	 homeostasis55.	 The	metallochaperone	 is	 also	 able	 to	 interact	 with	 a	 ‘platform’	 region,	 a	 charged	 helical	structure	 on	 the	 P-type	 ATPase,	 for	 delivery	 of	 copper	 as	 stated	 above50.	 A	 similar	mechanism	was	suggested	recently	of	the	S.	pneumoniae	CupA	metallochaperone,	which	is	unrelated	to	the	CopZ	family,	and	the	N-terminal	domain	of	the	S.	pneumoniae	CopA	ATPase,	which	shares	structural	similarity	with	CupA56,57.		Amongst	these	studies,	none	has	focussed	on	the	CopA	or	CopZ	of	S.	aureus	specifically,	apart	from	a	single	study	conducted	by	Sitthisak	et	al.	which	emphasised	focus	upon	the	regulation,	rather	than	biochemistry	of	these	components	(they	did,	however,	study	the	HMA	domain	of	the	S.	aureus	CopA).	Sitthisak	et	al.	used	comparative	genome	analysis	to	propose	 that	 CopA	 of	 S.	 aureus	was	 structurally	 similar	 to	 CopA	 proteins	 from	 other	organisms,	including	that	of	Legionella	pneumophila,	in	which	organism	crystal	structure	CopA	was	published	by	Gourdon	et	al50.	In	common	with	other	organisms,	the	CopA	of	S.	
aureus	 has	 two	 CopZ-like	 HMA	 domains,	 each	 containing	 a	 CXXC	 motif,	 and	 a	transmembrane	CPC	motif.		Sitthisak	 et	 al.	 also	 showed	 that	 expression	 of	 the	 cop	 operon	 was	 induced	 by	concentrations	of	copper	in	the	growth	media	as	low	as	5	µM	copper,	and	also	to	some	extent	by	the	presence	of	lead	and	ferric	ions43.	Expression	of	the	operon	has	also	shown	to	be	activated	by	silver	in	E.	coli58.	Concordantly,	growth	of	a	ΔcopA	mutant	was	more	
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sensitive	to	copper,	ferric	and	lead	ions	within	the	media	than	the	wild-type	(WT).	The	mutant	was	also	more	sensitive	to	hydrogen	peroxide,	but	not	to	paraquat,	both	forms	of	reactive	oxygen	species	(ROS).	This	was	suggested	to	be	due	to	a	build-up	of	copper	and	ferric	ions	within	the	cell	which	could	both	potentially	increase	levels	of	ROS	within	the	cytoplasm.		Of	the	work	performed	by	Sitthisak	et	al.	on	the	HMA	domains	of	S.	aureus	CopA,	most	notable	was	the	identification	of	binding	of	these	domains	by	iminodiacetic	acid-agarose	(IAA)	chromatography	to	copper	ions	(as	expected),	but	also	to	cadmium	and	cobalt,	but	not	to	lead	or	ferric	ions,	a	result	that	may	have	been	expected	due	to	the	described	 in	
vivo	 growth	 assays.	 Sitthisak	 et	 al.	 suggest	 that	 differences	 in	 intracellular	 conditions	may	 mean	 that	 such	 binding	 may	 not	 occur	 in	 vivo	 for	 the	 same	 metals.	 They	 also	suggest	that	efflux	of	ferric	iron	and	lead	may	not	require	binding	of	the	respective	ions	to	 the	 HMA	 domain,	 as	 they	may	 efflux	 directly	 through	 the	 transmembrane	 domain.	Sitthisak	 et	 al.	 recognise	 that	 binding	 of	 metals	 to	 the	 HMA	 domains	 of	 CopA	 is	 not	necessarily	 linked	 to	 expression	 of	 the	 CopA	 gene	 (which	 is	 now	 certainly	 thought	 to	occur	 via	 CsoR),	 although	 this	 idea	 is	 implied	 in	 their	 work;	 their	 investigation	 does	however	suggest	the	potential	capacity	of	CsoR	to	bind	to	ferric	and/or	lead	ions.		
1.3.3	S.	aureus	CsoR	In	2010,	Baker	et	al.	performed	transcriptomic	analysis	upon	S.	aureus	(SH1000)	and	did	not	 identify	 any	putative	 copper-dependent	 transcriptional	 regulator,	 despite	 seeing	 a	significant	copper-dependent	change	in	transcription	of	48	genes	(17	were	upregulated	and	31	downregulated)59.	A	year	later,	the	same	group	published	data	indicating	that	in	
S.	 aureus	 (Newman)	 the	 cop	 operon,	 as	 well	 as	 the	 cso	 operon	 itself,	 are	 under	 the	copper-dependent	 control	 of	 the	 CsoR	 transcriptional	 repressor44.	 This	 protein	 shows	24%	and	36%	amino	 acid	 sequence	homology	 to	 the	CsoR	proteins	of	Mycobacterium	
tuberculosis	 and	 B.	 subtilis	 respectively,	 and	 3	 residues	 shown	 to	 be	 important	 for	copper	binding	are	conserved	in	S.	aureus44,45,60.		CsoR	 constitutes	 a	 relatively	 new	 family	 of	 transcriptional	 regulators45,	 the	molecular	mechanism	 of	 which	 varies	 from	 other	 copper-dependent	 transcriptional	 regulators	such	as	CopY61.	In	S.	aureus,	the	CsoR	protein	has	been	found	to	have	a	Cu(I)	dissociation	
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constant,	KCu,	of	1018.1	M-1	in	vitro,	similar	to	the	copper	affinities	initially	determined	for	the	 equivalent	 regulators	 from	M.	 tuberculosis	 and	B.	 subtilis45,60,62.	 Despite	B.	 subtilis	CsoR	showing	higher	 in	vitro	affinities	 for	other	metals,	 these	metals	did	not	have	any	effect	upon	transcription	of	copAZ	compared	with	copper.	The	measured	stoichiometry	of	copper	binding	is	one	Cu(I)	ion	per	monomer	of	S.	aureus	CsoR61.	In	B.	subtilis	it	has	been	 shown	 that	 two	 CsoR	 tetramers	 bind	 DNA	 at	 a	 specific	 operator	 sequence	 to	repress	 transcription,	 and	 that	 upon	 binding	 copper	 their	 affinity	 for	 DNA	 is	 greatly	reduced,	a	feature	likely	to	be	conserved	in	the	CsoR	from	S.	aureus60,62.		Notably	 two	 further	 ORFs	 are	 encoded	 on	 the	 cso	 auto-regulatory	 operon,	 csoZ	 (see	above)	 and	 a	 hypothetical	 protein	 of	 unknown	 function	 or	 structure,	 NWMN_1989.	 A	blast	search	confirms	that	these	sequences	are	both	present	in	the	genomes	of	S.	aureus	Newman	and	8325.	It	is	currently	not	known	what	roles	(if	any)	these	ORFs	have	to	play	in	copper	homeostasis	or	why	they	are	encoded	at	a	different	 locus	to	the	cop	operon.	CsoZ	does	not	bind	copper	in	vitro	but	it	does	adopt	a	ferredoxin-like	fold	(Gus	Pelicioli-Riboldi,	Waldron	lab,	unpublished	data),	as	do	CopZ	and	the	HMA	domains	of	CopA63.		Collectively,	 the	proteins	 of	 the	cop	operon	maintain	 copper	homeostasis	 in	S.	 aureus.	The	 P-type	 ATPase	 CopA	 effluxes	 excess	 copper	 ions	 from	 the	 cell,	 maintaining	 the	cellular	 copper	 levels	 below	 a	 toxic	 threshold.	 The	 CopZ	metallochaperone,	 based	 on	homology	 to	 other	 systems,	 is	 predicted	 to	 sequester	 excess	 copper	 ions	 within	 the	cytosol,	and	to	transfer	 these	bound	 ions	to	CopA	for	 transport,	 thereby	maintaining	a	cytosol	devoid	of	‘free’	copper	ions.	The	expression	of	the	cop	operon	is	regulated	at	the	transcriptional	level	by	the	action	of	CsoR,	ensuring	that	copper	ions	are	detoxified	only	when	present	in	excess.	
1.4	Copper	toxicity		Despite	the	requirement	of	almost	all	organisms	for	relatively	small	amounts	of	copper,	above	certain	concentrations	it	causes	toxicity.	Toxicity	for	the	purposes	of	this	project	is	best	defined	as	a	concentration	of	copper	 in	 the	growth	environment	 that	results	 in	lower	 levels	of	bacterial	proliferation	 than	occur	 in	 its	 absence.	High	 levels	of	 toxicity	may	cause	cell	death	and	therefore	result	in	a	null-growth	phenotype,	but	this	is	not	the	only	 possible	 outcome	 of	 toxicity	 as	 cells	 are	 often	 able	 to	 divide	 at	 lower	 rates	 in	relatively	 concentrated	 copper	 solutions,	 and	 to	 recover	 upon	 its	 removal	 (i.e.	
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bacteriostatic).	Moreover,	copper	can	be	toxic	both	in	solution	and	as	a	solid	surface,	and	the	way	 in	which	 these	 forms	of	 toxicity	 take	 effect	may	vary.	Recently,	 research	 into	solid	nanoparticles	has	shown	these	also	have	a	toxic	effect,	and	studies	are	beginning	to	show	 that	 the	 innate	 immune	 system	 may	 utilise	 the	 toxicity	 of	 copper	 against	pathogenic	microorganisms.	All	of	these	are	relevant	for	antimicrobial	purposes	and	will	be	explored	here.	
1.4.1	Potential	mechanisms	Combined	knowledge	of	copper	chemistry	and	bacterial	copper	homeostasis	has	led	to	two	main	hypotheses	regarding	the	molecular	mechanisms	of	copper	toxicity:		1. Via	copper-catalysed	generation	of	ROS	that	subsequently	exert	toxicity.	2. Through	direct	binding	of	copper	to	proteins,	blocking	their	normal	function.	It	seems	likely	that	both	of	these	mechanisms	contribute	to	copper	toxicity,	as	they	are	not	mutually	exclusive.	 It	 is	conceivable	 that	a	ratio	between	them	and/or	an	order	of	occurrence	may	exist,	which	may	alter	depending	on	copper	concentration,	atmospheric	conditions,	and	solvent	composition	in	any	given	system,	as	well	as	a	specific	bacterial	species’	 innate	 abilities	 to	 counter	 each	 of	 these	 effects	 and	 their	metabolic	 state.	 An	excellent	example	of	variability	between	bacterial	species	is	provided	by	the	comparison	of	E.	coli	and	S.	pneumoniae.	S.	pneumoniae	produces	high	 levels	of	hydrogen	peroxide	(which	 is	known	 to	be	able	 to	deleteriously	 react	with	copper)64	as	part	of	 its	normal	metabolism,	and	experiences	relatively	high	levels	of	ROS	exposure	during	pathogenesis,	both	of	which	it	 is	able	to	cope	with	effectively.	One	way	in	which	it	has	done	so	 is	by	dispensing	with	many	of	 its	 iron-sulphur	(Fe-S)	cluster	containing	enzymes,	which	are	thought	 to	 be	 a	 main	 targets	 of	 damage	 by	 ROS65.	 E.	 coli	 does	 not	 face	 the	 same	onslaught	of	ROS	normally,	and	therefore	has	not	lost	these	enzymes,	which	have	been	shown	 to	 be	 a	major	 target	 of	 copper	 toxicity	 in	 that	 species66.	A	 complex	 picture	 of	copper	toxicity	quickly	emerges,	which	varies	between	species,	and	the	evidence	for	the	occurrence	of	each	of	these	causes	of	copper	toxicity	is	discussed	below.		 	
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Mechanism	of	
cell	copper	
damage	
Reported	in	
contact	
killing?	
Reported	in	
solution?	
Reported	in	S.	
aureus?	
References	
Depolarisation	of	membrane	 Yes	 No	 No	 67,	68	Copper	binding	to	non-native	proteins	 No	 Yes	 This	study	 This	study	Copper	induced	production	of	ROS	 No	 Yes	 Yes	 69,	44	Copper	induced	DNA	damage	 No	 Yes	 	 No	 70		
Table	1.1.	Detailing	the	various	mechanisms	of	cellular	damage	caused	by	copper	
in	 contact	 killing	 and/or	 solution,	 and	 whether	 this	 has	 been	 observed	 in	 S.	
aureus.
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1.4.2	ROS	catalysis	and	membrane	depolarisation	In	solution,	copper	may	exist	as	Cu(II)	or	Cu(I).	In	water,	Cu(I)	is	almost	insoluble	under	aerobic	conditions	and	forms	only	fleetingly,	if	at	all,	whereas	it	is	the	dominant	species	under	 reducing	 conditions.	 Both	 ions	 are	 extremely	 reactive	 and	 are	 known	 to	contribute	 to	 the	 Haber-Weiss	 and	 Fenton	 reactions	 (Figure	 1.3),	 which	 combine	 to	contribute	to	ROS	generation	inside	cells,	leading	to	the	formation	of	the	highly	reactive	hydroxyl	radical,	which	in	turn	has	been	shown	to	damage	DNA,	proteins	and	lipids69,71.		For	the	Fenton	reaction	to	occur	intracellularly	(and	so	for	Cu(I)-induced	ROS	damage	of	chromosomal	 DNA	 or	 intracellular	 lipid	 and	 protein	 components	 to	 occur),	 reactive	Cu(I)	needs	to	be	present	 in	 the	cytoplasm.	However,	 it	 is	widely	accepted	that	within	this	compartment	no	free	copper	exists72,	at	least	under	non-toxic	conditions.	This	hypothesis	has	been	brought	about	by	the	calculation	of	the	approximate	number	of	 atoms	 of	 copper	 that	 exist	 within	 an	 E.	 coli	 cell	 to	 be	 around	 10,00073,74	 and	 the	subsequent	 finding	 that	 the	 sensitivity	 of	 the	 transcriptional	 regulator	 of	 copper	homeostasis	 in	E.	 coli,	 CueR,	 is	 such	 that	 it	 can	 detect	 ‘free’	 copper	 ions	 present	 at	 a	concentration	 several	 orders	 of	 magnitude	 less	 than	 one	 atom	 per	 cell.	 Thus	 any	deviation	 from	the	 ‘normal’	amount	of	 copper	within	 the	cell,	 leading	 to	a	 single	 ‘free’	copper	ion,	would	result	in	the	upregulation	of	homeostatic	systems	(CopA	and	CueO,	a	postulated	copper	oxidase,	in	this	case)	to	remove	excess	copper.		Indeed,	 it	 has	 been	 found	 that	 CueR	 is	 regulated	 such	 that	 it	 constitutively	 allows	expression	 of	 these	 homeostatic	 components	 under	 normal	 laboratory	 culture	conditions,	but	further	expression	occurs	as	copper	rises72.	However,	it	remains	possible	that	 cytosolic	 copper	 could	 accumulate	 when	 cells	 are	 cultured	 under	 excess	 copper	conditions,	and	 the	copper	efflux	systems	are	overwhelmed	(i.e.	under	copper	 toxicity	conditions).		The	affinity	of	copper	for	CueR	in	E.	coli	and	CsoR	of	S.	aureus	are	similar,	meaning	that	such	 tight	 control	 of	 copper	 is	 probably	 also	 present	 in	 the	 latter	 case.	 Copper	 levels	within	the	cell	presumably	have	to	go	above	a	threshold	concentration	before	CopA	and	CopZ	of	S.	aureus	are	unable	to	cope	with	the	numbers	of	ions	of	copper	present.		The	 question	 remains;	 if	 there	 is	 no	 free	 copper	 present	 in	 the	 cell	 then	 how	 do	transcriptional	regulators	acquire	copper?	This	is	not	clear,	but	it	does	not	appear	that	
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CopZ	transfers	copper	to	the	regulator75;	the	extremely	high	affinity	of	these	regulators	for	copper	may	mean	that	 they	are	able	 to	acquire	copper	 from	other	copper	proteins	with	lower	affinity	without	a	specific	interaction.	Various	 studies	 have	 been	 performed	 to	 investigate	 the	 role	 of	 ROS	 catalysis	 in	 the	mechanism	 of	 copper	 toxicity59,76,77,	 but	 as	 of	 yet	 no	 conclusive	 conclusion	 has	 been	reached.	Indeed,	Macomber	et	al.	have	even	gone	so	far	as	to	state	that	it	is	not	the	cause	of	DNA	damage	in	E.	coli	treated	with	high	copper.	They	showed	that	E.	coli	cultured	in	elevated	copper	conditions	do	not	upregulate	genes	known	to	be	responsible	for	dealing	with	 ROS,	 even	 when	 these	 cells	 have	 been	 mutated	 to	 lack	 several	 of	 their	 copper	homeostasis	 components70.	 Letelier	 et	 al.	 demonstrated	 that	 whilst	 some	 oxidative	damage	 did	 occur	 in	 cells	 experiencing	 elevated	 copper,	 as	 measured	 by	 lipid	peroxidation,	what	was	much	more	likely	to	cause	permanent	cellular	damage	was	the	inhibition	of	a	wide	range	of	enzymes	that	occurred	through	 indiscriminate	binding	of	copper,	 and	 subsequently	 called	 for	 a	 ‘re-evaluation	 of	 the	 mechanisms	 underlying	copper-induced	toxicity	in	biological	systems’78.	In	 S.	 aureus	 specifically	 however,	 Baker	 et	 al.	 did	 find	 that	 copper	 induced	 a	 global	transcriptional	 response,	which	 included	 increased	 transcription	of	 enzymes	 that	deal	with	ROS.	 They	 did	 however	 see	 less	 growth	 in	 copper	 in	 the	WT	 than	 in	mutants	 of	various	 genes	 encoding	 enzymes	 that	 catalyse	 reactions	 that	 reduce	 ROS	 levels,	complicating	 the	 copper	 toxicity	 phenotype	 and	 suggesting	 that	 ROS	 might	 not	 be	 a	major	factor	in	copper	toxicity	in	this	organism.	Another	 copper-dependent	 oxidative	 effect	 observed	 in	 cells	 is	 lipid	 peroxidation	 of	membranes.	 However,	 Weaver	 et	 al.	 demonstrated	 that	 the	 damage	 caused	 to	membranes	 did	 not	 compromise	 their	 integrity	 and	 concluded	 that	 damage	 to	intracellular	macromolecules	could	be	what	was	killing	cells79.			 	
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Haber-Weiss	Reaction		Cu(II)	+	•O2-	à	Cu(I)	+	O2		
Fenton	Reaction		Cu(I)	+	H2O2à	Cu(II)	+	OH-	+	•OH		
Figure	 1.3.	 The	 Haber-Weiss	 and	 Fenton	 reactions	 of	 copper.	 These	 reactions	combine	to	produce	the	highly	toxic	species,	the	hydroxyl	radical.	Iron	can	substitute	for	copper	in	these	reactions,	with	ferric	and	ferrous	ions	replacing	cupric	and	cuprous	ions	respectively.			 	
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1.4.3	Copper	binding	to	non-copper	proteins			As	stated,	copper	is	able	to	bind	tightly	to	a	wide	range	of	ligands	non-specifically.	The	Irving-Williams	 series	 of	 divalent	metals	 states	 that	 Cu(II)	 will	 out-compete	 all	 other	essential	 divalent	 metal	 ions	 (Mg2+,	 Ca2+,	 Mn2+,	 Fe2+,	 Co2+,	 Ni2+,	 Zn2+)	 for	 their	 native	enzyme	binding	sites,	and	Cu(I)	is	also	extremely	competitive80,81,	especially	for	binding	sites	 that	 contain	 cysteine	 sidechains.	 Consequently	 as	 we	 have	 seen,	 bacterial	 cells	make	 use	 of	 copper	 homeostatic	 systems	 to	 limit	 cytosolic	 copper	 abundance	 (see	section	 1.4.2)	 and	 to	 confine	 binding	 to	 cuproproteins	 by	 copper-trafficking	 through	protein-protein	interactions,	ensuring	delivery	to	target	proteins	by	kinetic	control	and	thermodynamic	 affinity	 gradients81.	 By	 limiting	 copper	 availability	 in	 the	 cytosol	 and	producing	 a	 massive	 overcapacity	 for	 copper	 chelation,	 proteins	 compete	 to	 bind	copper,	 rather	 than	 copper	 competing	 with	 other	 metals	 for	 a	 given	 protein,	 which	would	lead	to	widespread	mis-metallation.	Toxic	 copper	 binding	 can	 be	 classed	 broadly	 into	 two	 categories:	 adventitious	 non-specific	 binding,	 which	 is	 usually	 weak	 and	 transient	 within	 the	 context	 of	 the	cytoplasm;	and	specific	copper	binding	 to	a	non-native	copper	site,	which	may	be	of	a	relatively	high	affinity	and	may	or	may	not	displace	another,	native	metal	ion.	Despite	 the	 risks	 of	 toxicity,	 we	 know	 that	 most	 cells	 acquire	 copper	 within	 the	cytoplasm	at	least	under	some	conditions;	this,	despite	the	mechanism	of	copper	import	being	unidentified	in	most	cases	(including	in	S.	aureus).	Thus,	 it	stands	to	reason	that	cells	 contain	 copper	 that	 is	 bound	 to	 intracellular	 chemical	 species	 and	 that	 below	 a	certain	 threshold	 these	 and	 their	 associated	 ions	do	not	 cause	 toxicity.	Which	 species	these	are	 remains	 to	be	precisely	answered,	but	 those	such	as	 the	abundant	histidine,	glutathione82,83	 or	 the	 comparable	 bacillithiol	 in	 Gram-positive	 bacteria	 such	 as	 S.	
aureus84,	 bacterial	metallothioneins85,86	 or	 other	 known	 copper	metallochaperones	 or	high	 affinity	 sites87,88	 are	 all	 candidates,	 as	 well	 as	 the	 standard	 copper	 homeostasis	proteins,	assumed	to	deal	with	the	majority	of	copper	present.	In	 a	 copper	 toxicity	 situation	 these	 homeostatic/detoxification	 binding	 sites	 must	presumably	 become	 saturated	 as	 excess	 copper	 begins	 to	 accumulate	 in	 the	 cell.	 The	chemical	properties	of	copper	suggest	that	it	will	soon	bind	to	other	proteins	within	the	cell,	and	which	proteins	it	binds	to	will	depend	on	the	same	factors	of	access,	allostery	and	 affinity	 as	 that	 which	 guides	 binding	 to	 native	 metalloproteins	 under	 non-toxic	
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conditions81.	Toxicity	targets	have	been	identified	in	some	organisms	(see	below),	but	it	is	clear	that	the	entire	picture	is	far	from	complete66,89.	Indeed	there	is	also	evidence	for	non-specific	adventitious	binding66.	In	 S.	 aureus	 initial	 copper	 increase	 leads	 to	 the	 transcription	 of	 the	 cop	 operon	 (See	section	3.4.2.1).	Subsequently,	a	hypothesis	can	be	formed	whereby	increased	copper	is	dealt	with	by	the	copper	homeostasis	machinery	and	does	not	bind	to	non-native	copper	ligands,	 because	 the	 affinity	 of	 CsoR	 is	 sufficiently	 tight	 that	 its	 metalation	 (and	subsequent	de-repression	of	 the	cop	 operon)	 should	be	an	early	event	under	elevated	copper	conditions.		Under	high	copper	concentrations,	are	cells	able	 to	attain	a	sufficient	concentration	of	production	of	CopZ	and	CopA	or	other	non-toxic	copper	binding	proteins	or	species	that	can	deal	with	copper	stress?	The	answer	from	growth	phenotypes	is	a	resounding	no59,	as	cells	are	not	able	to	survive	in	copper	conditions	above	defined	concentrations	which	differ	 depending	 on	 the	 species	 and	 conditions;	 and	 this	 presents	 a	 likely	 selection	pressure	for	copper	hyper-resistant	mutant	strains.		The	mixed	evidence	regarding	ROS	production	(see	above)	previously	thought	of	as	the	most	 likely	 mechanism	 of	 toxicity	 appears	 to	 support	 another	 route,	 namely	 protein	malfunction	 due	 to	 non-specific	 copper	 binding,	 as	 was	 first	 described	 in	 E.	 coli	 by	Macomber	and	Imlay66.		Here	 it	 was	 found	 that	 copper	 led	 to	 the	 degradation	 of	 iron-coordination	 centres	 in	several	 enzymes	containing	 iron-sulphur	 (Fe-S)	 clusters66.	An	auxotrophy	 in	branched	chain	 amino	 acid	 synthesis	 was	 observed	 in	 cells	 cultured	 in	 the	 presence	 of	 high	copper,	which	implied	such	Fe-S	cluster-containing	enzymes	are	required	when	cells	are	cultured	in	a	minimal	medium	lacking	selected	amino	acids.	Upon	supplementation	with	these	branched-chain	amino	acids	(isoleucine,	leucine	and	valine),	or	overexpression	of	the	vulnerable	enzymes	required	for	their	synthesis,	growth	is	restored.	However,	even	amino	acid	supplementation	was	unable	to	completely	restore	growth,	suggesting	that	other	 proteins	 involved	 in	 other	 metabolic	 pathways	 may	 also	 be	 targets	 of	 copper	toxicity.	Other	Fe-S	cluster	containing	enzymes	involved	in	carbon	metabolism	were	also	affected,	such	as	fumarase	A,	but	in	the	presence	of	glucose	or	other	sugars	that	are	able	to	be	metabolised	via	glycolysis	these	enzymes	are	expressed	at	low	levels	and	thus	are	
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not	deemed	major	targets	of	toxicity.	Throughout	their	work,	ROS	generated	by	copper	were	detected	but	were	not	found	to	be	the	cause	of	toxicity.	Further	 to	 this	work	performed	 in	E.	 coli,	 Chillappagari	 et	 al.	have	 also	 demonstrated	that	 iron	 sulphur	 cluster	 formation	 is	 affected	 by	 copper	 toxicity	 in	B.	 subtilis90.	 They	demonstrated	 that	 an	 essential	 Fe-S	 cluster	 scaffold	 protein,	 SufU,	 alongside	 other	proteins	necessary	for	Fe-S	cluster	biosynthesis	were	upregulated	strongly	in	a	probable	attempt	by	the	cell	 to	maintain	 levels	of	Fe-S	cluster	containing	proteins.	They	did	not	see	strong	upregulation	of	 the	perR	 regulon	 from	which	 they	concluded	 that	oxidative	stress	was	not	playing	a	major	role	 in	copper	toxicity	 in	B.	subtilis.	Djoko	and	McEwan	showed	similar	effects	of	copper	in	Neisseria	gonorrhoea,	demonstrating	in	this	case	that	the	copper-dependent	damage	of	Fe-S	clusters	mainly	affected	HemN,	an	enzyme	critical	to	 haem	 biosynthesis.	 Copper	 toxicity	 thereby	 gave	 rise	 to	 haem	 deficiency;	 haem	 is	necessary	 for	 the	 functioning	of	catalase	and	a	nitrate	reductase	 that	are	 important	 in	the	neutralisation	of	ROS91.	These	studies	contribute	to	the	identification	of	a	strong	link	between	iron	and	copper	homeostasis.		As	 evidence	 mounts	 that	 copper	 toxicity	 cannot	 be	 sufficiently	 explained	 by	 the	generation	of	ROS	 it	 is	becoming	clearer	 that	copper	binding	to	cellular	proteins	are	a	cause	of	the	toxic	effects	observed	in	high	copper	conditions.	The	subsequent	difficulty	for	investigators	lies	in	identifying	targets	and	then	demonstrating	that	these	targets	are	consequential	 in	 vivo.	 Further	 complications	 lie	 in	 the	 specific	 conditions	 in	which	 the	bacteria	 are	 cultured	 (or	 are	 found	 in	 the	 environment).	 For	 example,	 glucose	availability	 alters	 the	 abundance	 and	 importance	 of	 many	 metabolic	 enzymes	 within	bacteria,	impacting	upon	how	copper	may	cause	toxicity	under	those	conditions	relative	to	 low-glucose	 conditions.	 Identifying	 environmentally	 relevant	 conditions	 is	 also	 of	interest.	
1.4.4	Antimicrobial	copper	surfaces	Thus	far,	each	mechanism	has	involved	copper	in	solution,	which	in	aerobic	conditions	will	exist	as	the	Cu(II)	ion	and	in	anaerobic	conditions	as	the	Cu(I)	ion	which	are	able	to	react	freely	with	other	solutes	and	components	of	a	bacterial	cell	in	culture.	Within	a	solid	copper	surface,	whether	that	is	pure	copper	or	an	alloy	containing	copper,	the	metal	ions	are	locked	into	an	ionic	lattice	crystal	structure	that	is	difficult	to	disrupt,	meaning	that	interaction	of	copper	with	bacteria	here	may	be	very	different.	
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	A	 comprehensive	 review	 of	 solid	 copper	 surface	 toxicity	 was	 carried	 out	 in	 2011	 by	Grass	 et	 al.	 which	 discusses	 its	 potential	 antimicrobial	 mechanisms67.	 Studies	undertaken	 to	 test	 how	 long	 it	 takes	 to	 eliminate	 bacteria	 from	 a	 surface	 have	 used	various	 techniques	 to	 apply	 cells,	 and	 the	 biocidal	 effect	 of	 such	 application	 has	 been	termed	 contact	 killing.	 Consistently,	 these	 experiments	 have	 found	 that	 when	 ‘dry’	material	is	placed	onto	a	surface,	biocidal	activity	of	the	surface	is	exhibited	within	just	minutes.	 Alternatively,	 when	 using	 ‘wet’	 application,	 the	 bacteria	 were	 often	 able	 to	survive	 for	 hours.	 These	 types	 of	 experiments	 have	 been	 carried	 out	 on	 a	 range	 of	pathogenic	 bacteria,	 such	 as	 Salmonella	 enterica92,	 E.	 coli	 O15793,94	 (EHEC),	 Listeria	
monocytogenes95,	 Mycobacterium	 tuberculosis96,	 Clostridium	 dificile97,98	 and	 various	strains	 of	 S.	 aureus99,100,	 as	 well	 as	 on	 various	 pathogenic	 fungi	 including	 Candida	
albicans	and	Aspergillus	fumigatus101.		Experimentally,	 ‘wet’	application	provides	a	solvent	 in	which	copper	may	dissolve	and	potentially	access	the	cell,	as	cells	are	applied	suspended	in	a	growth	medium	to	a	piece	of	solid	copper	or	‘coupon’.	Consequently,	it	is	likely	that	these	cells	experience	toxicity	by	the	same	mechanism	as	those	in	liquid	culture,	at	least	to	some	extent,	just	of	a	much	reduced	volume.	Alternatively,	‘dry’	application	aims	to	remove	this	solvent	component.	This	 is	 done	 by	 using	 cells	 concentrated	 by	 centrifugation	 and	 then	 applied	 using	 a	cotton	swab.	In	their	2008	paper,	Espirito	Santo	et	al.	state	that	approximately	7%	of	the	material	applied	is	in	fact	liquid	(i.e.	wet)	but	that	the	coupon	is	completely	dry	within	5	seconds	of	application102.	However,	it	may	be	that	some	residual	solvent	remains	that	is	undetectable	or	that	5	seconds	is	a	long	enough	period	of	time	for	the	copper	surface	to	exert	 its	 toxicity	 upon	 dissolution	 into	 Cu(II)	 (cupric	 ions	 specifically	 due	 to	 the	prevalent	aerobic	conditions).			Completely	dry	application	seems	technically	unfeasible	or	at	least	extremely	difficult	to	guarantee,	as	all	bacterial	cells	will	be	hydrated	to	some	extent	or	would	not	be	viable.	One	 possibility	 is	 that	 ‘dry’	 application	 provides	 such	 a	 small	 volume	 of	 solvent	 that	resulting	 copper	 ion	 concentrations	 are	 extremely	 high,	 resulting	 in	 the	 rapid	 killing	times	observed.	On	the	other	hand,	how	solid	copper,	presumably	locked	in	crystalline	form,	 enters	 solution	 (requiring	 an	 oxidation	 event)	 or	 is	 able	 to	 react	 with	 a	 ‘dry’	bacterial	cell	is	not	clear	mechanistically.		
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	Oxidising	membranous	enzymes	could	play	a	role	in	releasing	copper	from	dry	surfaces,	although	 there	 is	 debate	 concerning	 the	 existence	 of	 such	 enzymes	 at	 this	 location.	Moreover,	research	has	shown	that	non-enzymatic	media	components	are	often	able	to	complex	 tightly	with	 copper,	 and	Molteni	 et	 al.	 showed	 recently	 that	 biocidal	 kinetics	were	 strongly	 affected	 by	 the	 composition	 of	 the	medium	 in	which	 resuspended	 cells	were	applied	to	a	copper	surface103,104,	with	water	showing	the	slowest	rate.	It	may	be	the	 case	 that	 relatively	 few	 copper	 ions	 are	 required	 to	 exert	 toxicity,	 meaning	 that	passive	dissolution	may	be	enough	to	reach	this	concentration	in	a	matter	of	hours,	and	therefore	active	decomposition	of	solid	copper	to	its	ions	is	not	needed.			A	 recent	 study	 using	 a	 honeycomb	 structure	 polymer	 that	 prevents	 bacterial	 contact	with	a	solid	surface	but	allows	solvent	access,	showed	that	direct	bacterial	contact	with	copper	did	not	affect	the	release	of	copper	ions	from	a	solid	copper	surface,	but	that	cells	not	in	direct	contact	experienced	reduced	biocidal	activity105.	Their	observation	that	the	toxicity	of	 copper	 ions	 increased	with	 the	presence	of	 an	 iron	 solid	 surface	 compared	with	glass	(without	the	presence	of	the	honeycomb	polymer)	led	them	to	conclude	that	direct	 contact	 of	 the	 bacteria	 with	 an	 iron	 surface	 contributes	 to	 membrane	permeability	which	allows	subsequent	cell	damage	by	copper	ions	that	enter	the	cell105.	Neither	 iron	 nor	 glass	 have	 been	 shown	 to	 induce	 contact	 killing,	 and	 other	metallic	surfaces	have	yet	to	be	tested	for	this	effect.	Notably,	E.	coli	cells	lacking	their	cop	operon	copper	homeostasis	components	showed	a	small	but	significant	decrease	in	killing	time	on	 copper	 surfaces,	 suggesting	 that	 intracellular	 copper	 has	 a	 role	 to	 play	 in	 the	mechanism102.		Thus	it	is	likely	that	contact	killing	is	mediated,	at	least	in	part,	via	the	same	mechanisms	as	that	observed	in	liquid	media	containing	excess	copper,	but	that	direct	contact	of	cells	with	 an	 iron	 or	 copper	 surface	 contribute	 to	 faster	 killing	 by	 allowing	 these	 ions	 to	access	the	intracellular	space	faster.	Such	speed	of	access	could	perhaps	be	mediated	via	membrane	 depolarisation,	 yet	 in	 light	 of	 findings	 made	 by	 Weaver	 et	 al.	mentioned	previously,	 such	 copper	 induced	 depolarisation	 would	 not	 also	 induce	 membrane	permeability	to	copper	(iron	was	not	investigated	here)79.	
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Recent	 studies	 have	 indicated	 that	 copper-induced	 cell	 membrane	 damage	 may	 be	 a	precursor	 to	 subsequent	 intracellular	 copper	 toxicity	 events105,	 and	 peroxidation	 of	membrane	lipids	and	resulting	membrane	protein	malfunction	are	well	documented	and	are	known	precursors	of	 increased	cell	permeability71,106,107.	These	facts,	when	aligned	with	evidence	that	reactive	copper	is	most	likely	to	be	found	in	the	periplasm	of	E.	coli,	point	 to	 a	 potential	 mechanism	 whereby	 copper-induced	 cell	 membrane	 damage	facilitates	 the	 accumulation	 of	 increased	 levels	 of	 cytoplasmic	 copper,	 where	 it	 can	damage	intracellular	species	as	shown	to	occur	in	the	presence	of	copper	in	vitro66,107.		
1.5	GAPDH	enzymes	The	 focus	 of	 this	 thesis	 is	 upon	 the	 binding	 of	 copper	 to	 a	 cytoplasmic	 enzyme	 in	 S.	
aureus.	 That	 cytoplasmic	 protein	 is	 a	 member	 of	 the	 glyceraldehyde-3-phosphate	dehydrogenase	 (GAPDH)	 family	 called	GapA,	 and	 is	 referred	 to	 as	SaGapA	 throughout	this	 work	 with	 regards	 to	 the	 enzyme	 specific	 to	 S.	 aureus.	 This	 binding	 is	 the	 first	documented	case	of	copper	binding	to	a	protein	in	the	cytoplasm	in	S.	aureus	that	is	not	a	metalloprotein	(see	results).	Copper	toxicity	mediated	by	damage	of	Fe-S	clusters	in	E.	
coli	did	not	document	copper	binding,	only	copper-mediated	damage	to	the	function	of	the	 Fe-S	 cluster	 containing	 enzymes.	 Thus	 this	 binding	 is	 also	 potentially	 the	 first	documented	case	of	copper	binding	to	a	non-metalloprotein	in	the	cytoplasm	in	bacteria	more	generally.		GapA	is	just	one	enzyme	within	the	glycolytic	pathway,	but	it	performs	the	rate-limiting	step.	 It	 is	 the	 only	 enzyme	 within	 the	 glycolysis	 pathway	 which	 produces	 NADH,	producing	two	NADH	molecules	for	each	molecule	of	glucose	that	enters	the	pathway,	as	each	 glucose	 monomer	 results	 in	 two	 molecules	 of	 the	 substrate	 of	 GapA,	glyceraldehyde	3-phosphate.		GapA	converts	glyceraldehyde	3-phosphate	(G3P)	into	1,3–bisphosphoglycerate.	It	uses	NAD+	as	a	cofactor	which	it	reduces	to	NADH,	and	the	reaction	also	requires	phosphate	and	releases	a	proton	(Figure	1.4).	The	enzyme	sits	within	the	glycolysis	pathway	that	is	evolutionarily	conserved	throughout	all	domains	of	life.	The	S.	aureus	homologue	GapB	may	perform	the	reverse	reaction,	utilising	NADPH	which	it	converts	to	NADP+,	 in	the	gluconeogenesis	 pathway.	 GapA	 is	 not	 known	 to	 require	 copper	 or	 any	 metal	 for	catalysis.	
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SaGapA	is	a	member	of	the	GAPDH	family	of	enzymes.	This	family	of	enzymes	is	widely	conserved	in	both	prokaryotes	and	eukaryotes,	with	some	of	the	ancient	genes	thought	to	have	been	transferred	from	eubacteria	to	eukaryotes	in	the	distant	past108.	Although	the	primary	function	of	GapA	is	thought	to	be	the	reaction	that	it	performs	in	glycolysis,	it	has	also	been	documented	as	having	several	potential	‘moonlighting’	functions	which	are	 broad-ranging	 and	 not	 fully	 understood109,110.	 These	 include	 binding	 to	 and	regulation	of	 the	 function	of	 other	proteins,	 involvement	 in	 apoptosis,	 and	 interaction	with	telomeres	in	eukaryotic	cells109.	The	highly	conserved	nature	of	the	protein	would	suggest	 that	 at	 least	 some	 of	 these	 functions	 may	 also	 be	 conserved	 across	 species.	Indeed,	 in	 S.	 aureus	 a	 fraction	 of	 SaGapA	 has	 been	 found	 to	 be	 localised	 to	 the	extracellular	 surface.	 The	 route	 that	 this	 fraction	 uses	 to	 reach	 such	 a	 location	 is	unknown	 as	 the	 gapA	 gene	 possesses	 no	 pre-sequence;	 likewise	 the	 function	 of	 this	enzyme	fraction	remains	elusive,	although	it	has	been	shown	to	be	enzymatically	active	(though	presumably	lacks	access	to	its	cofactor	and	substrate	at	this	location)	and	may	play	 a	 role	 in	 adhesion,	 demonstrating	 that	 S.	 aureus	GapA	may	 also	 have	 additional	moonlighting	roles111-113.	 	
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Figure	1.4.	The	overall	reaction	performed	by	S.	aureus	GapA.	GapA	is	a	member	of	the	 glyceraldehyde-3-phosphate	 dehydrogenase	 (GAPDH)	 family	 of	 enzymes,	 and	phosphorylates	its	substrate,	glyceraldehyde	3-phosphate	(G3P),	producing	NADH.			 	
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1.6	GapA	of	S.	aureus	The	GapA	enzyme	is	a	key	component	of	the	S.	aureus	glycolytic	pathway.	Its	theoretical	molecular	weight	(MW)	is	approximately	36.29	kDa,	and	it	is	thought	to	form	a	tetramer	with	 a	 total	mass	 of	 ~145	 kDa.	 The	 reaction	 that	 it	 performs	 is	 shown	 in	 Figure	 1.4,	which	is	the	rate-limiting	step	in	glycolysis.		The	gene	(gapA)	encoding	the	GapA	protein	is	part	of	the	glycolytic	operon.	This	operon	is	 controlled	 by	 the	 action	 of	 the	 transcriptional	 regulator	 GapR	 on	 the	 operator	sequence	directly	upstream	of	gapA113,	and	gapA	is	followed	by	several	other	glycolytic	genes	(shown	in	Figure	1.5).	The	enzyme	shares	around	40%	sequence	homology	with	another	GAPDH	family	enzyme	expressed	by	S.	aureus,	GapB,	which	has	been	found	to	be	important	in	gluconeogenesis,	performing	the	opposite	reaction	to	GapA113.		GapA	from	S.	aureus	has	been	previously	characterised	and	crystallised	by	Mukherjee	et	
al.	 who	 demonstrated	 two	 essential	 residues	 within	 the	 active	 site	 of	 the	 enzyme;	 a	histidine	(His178)	and	a	cysteine	(Cys151)	residue114,	the	importance	of	these	residues	for	 the	 subsequently	 reported	 interaction	 of	 SaGapA	 with	 copper	 is	 discussed	 in	 the	following	chapters.		This	same	study	focused	in	detail	upon	the	catalytic	mechanism	of	GapA,	inferring	from	crystal	 structures	 of:	 the	 apoprotein;	 the	 protein	 with	 the	 substrate	 bound;	 and	 the	protein	with	the	substrate	and	cofactor	bound.	The	sequence	of	conformational	changes	undergone	by	the	protein	as	it	converts	its	substrate	glyceraldehyde	3-phosphate	(G3P)	to	 its	 product	 1,3-bisphosphoglycerate	 (1,3-BPG)114	 has	 thus	 been	 defined	 to	 some	extent.	 It	 has	been	demonstrated	 that	G3P	binds	 initially	 to	His178,	 and	 then	 forms	 a	direct,	 covalent	 hemithioacetal	 bond	with	 Cys151.	 A	 thioacyl	 complex	 is	 then	 formed,	and	 the	 G3P	 forms	 a	 ‘flip-flop’	 maneuvre	 which	 releases	 NADH	 before	 a	 new	 NAD+	cofactor	enters	the	active	site;	a	second	phosphate	group	is	then	added	to	the	substrate	and	 the	product	1,3-BPG	 is	 formed	and	 released	 from	 the	enzyme.	Further	details	 are	provided	in	Mukherjee	et	al.114.		Oxidation	 of	 the	 catalytically	 crucial	 Cys151	 residue	 of	 SaGapA	 has	 been	 reported	 to	occur	after	treatment	of	S.	aureus	COL	with	hydrogen	peroxide,	in	a	proteomic	study	by	Weber	 et	 al.115,	 which	 in	 turn	 inactivates	 the	 enzyme.	 Oxidation	 of	 the	 thiol	 group	 of	
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Cys151	 to	 a	 sulfonic	 acid	 group	 was	 detected	 by	 mass	 spectrometry	 under	 these	conditions.	Notably,	Weber	et	al.	also	found	that	the	oxidised	protein	was	not	repaired	by	 cells	when	 the	peroxide	 stress	was	 removed,	 but	 that	 the	 reduced	GapA	had	 to	be	synthesised	 de	 novo,	 nor	 did	 it	 appear	 that	 the	 oxidised	 protein	 was	 degraded.	Enzymatic	 activity,	 as	 measured	 by	 an	 in	 vitro	 assay,	 demonstrated	 that	 the	 GapA	activity	was	absent	when	only	oxidised	protein	was	present,	but	returned	concomitantly	with	the	reappearance	of	reduced	GapA.	A	growth	arrest	was	also	apparent	in	the	period	before	new	SaGapA	was	synthesised,	whereas	when	GapA	abundance	recovered,	growth	continued.	 All	 of	 these	 experiments	 were	 conducted	 in	 the	 presence	 of	 glucose;	conditions	in	which	GapA	is	essential	for	growth	(see	below).		One	 potential	 difficulty	 in	 the	 study	 of	Weber	 et	 al.	 is	 the	 stability	 of	 peroxide	 stress	conditions.	 Hydrogen	 peroxide,	 when	 added	 to	 growth	 media	 in	 small	 amounts,	 is	quickly	degraded	or	is	converted	to	water	and	oxygen	by	catalase	produced	by	cells.	In	order	to	detect	the	effects	of	hydrogen	peroxide	over	a	longer	time	period,	Deng	et	al.116	used	a	steady	state	system	which	constantly	kept	hydrogen	peroxide	at	the	same	level	within	 the	 media,	 which	 again	 contained	 glucose.	 Using	 this	 system	 they	 observed	increased	transcription	of	glycolytic	as	well	as	pentose	phosphate	pathway	(PPP)	genes,	as	 well	 as	 a	 host	 of	 other	 genes	which	 had	 not	 previously	 seen	 to	 be	 upregulated	 in	experiments	using	a	single	dose	of	hydrogen	peroxide	added	at	the	beginning	of	culture.	A	 steady	 state	 system	 is	 thought	 to	 be	more	 analogous	 to	 conditions	 experienced	 by	bacteria	within	phagosomes117.		Due	to	such	studies	GapA,	and	GAPDH	enzymes	in	general,	are	starting	to	be	considered	with	more	importance	than	previously,	both	as	central	nodes	in	carbon	metabolism	and	potentially	 as	 enzymes	 with	 metabolic	 regulatory	 functions.	 In	 addition,	 GAPDH	enzymes	 from	diverse	organisms	have	been	shown	to	have	wider	cellular	 functions	as	well	(termed	‘moonlighting’	roles).	A	review	from	2012	summarised	recent	studies	that	have	demonstrated	that	GAPDH	proteins	may	bind	to	DNA,	be	involved	in	transcription,	bind	to	telomeres	in	mammalian	cells	and	be	involved	in	apoptosis109,	vastly	expanding	the	potential	roles	which	have	previously	been	considered	for	GAPDH	function.		If	 GapA	 is	 indeed	 involved	 in	 the	 regulation	 of	 carbon	 metabolism	 in	 response	 to	stresses	such	as	hydrogen	peroxide,	it	would	be	valuable	for	cells	to	modulate	its	activity	
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in	vivo.	Several	groups	have	identified	that	the	thiol	of	Cys151	can	be	modified	 in	vivo.	Different	outcomes	of	 this	modification	have	been	observed	which	may	or	may	not	be	regulatory;	 (1)	 that	 the	oxidised	 thiol	group	of	 the	active	site	 cysteine	 (Cys149)	 in	 rat	GAPDH	 is	able	 to	perform	a	different	 reaction	 to	 the	unoxidised	 form,	 resulting	 in	 the	breakdown	 of	 1,3	 bisphosphoglycerate	 (the	 product	 of	 the	 normal	 reaction	 shown	 in	Figure	1.4)	to	3-phosphoglycerate118;	(2)	that	the	S-thiolated	active-site	cysteine	residue	of	Saccharomyces	 cerevisiae	GAPDH	would	be	 completely	 inactivated,	 but	may	protect	the	 enzyme	 from	 oxidation	 during	 ROS	 stress,	 allowing	 eventual	 dethiolation	 by	glutaredoxin119,120;	and	(3)	that	the	oxidised	enzyme	is	completely	inactivated,	resulting	in	growth	arrest	and	loss	of	ATP	production	until	new	enzyme	is	synthesised	by	the	cell,	as	has	been	reported	in	S.	aureus115.			Whether	oxidised	S.	aureus	 	GapA	 is	able	 to	catalyse	secondary	glycolytic	reactions,	as	suggested	by	Danshina	et	al.118	in	yeast,	has	not	been	directly	tested.	Strikingly	however,	arrest	of	growth	and	ATP	production	on	inactivation	of	GapA	by	peroxide	would	suggest	that	this	enzyme	is	essential115.	This	is	not	always	the	case,	as	S.	aureus	deletion	mutants	are	 still	 able	 to	 grow	 in	 glucose-depleted	media,	 in	which	 they	 are	 able	 to	metabolise	carbon	sources	that	do	not	require	an	active	glycolytic	pathway.	Overall,	it	is	clear	that	oxidation	 of	 the	 active	 site	 cysteine	 residue	 of	GapA	does	 result	 in	metabolic	 changes	within	S.	aureus,	the	nuances	of	which	have	yet	to	be	fully	characterised.		With	regards	to	virulence	of	S.	aureus	it	has	been	demonstrated	that	GapA	is	essential	in	a	fruit	fly	model113.	It	has	also	been	suggested	that	the	extracellular	fraction	of	the	GapA	protein	 pool	 is	 involved	 in	 bacterial	 adhesion	 to	 eukaryotic	 cells111,112.	 Therefore,	despite	 the	 non-essentiality	 of	 GapA	under	 some	 growth	 conditions,	 it	 can	 be	 seen	 to	offer	 a	 potential	 antimicrobial	 target	 that	 attenuates	 virulence,	 and	 its	 inhibition	may	function	synergistically	with	other	biocidal	agents.			 	
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Figure	 1.5.	 The	 putative	 glycolytic	 operon	 of	 S.	 aureus.	 This	 figure	 is	 based	 upon	homologous	 genomic	 regions	 in	 Lactobacillus	 plantarum,	 Lactobacillus	 sakei	 and	 B.	
subtilis121,122	 The	 genes	 shown	 are:	 the	 operon	 repressor	 (gapR),	 glyceraldehyde-3-phosphate	dehydrogenase	A	 (gapA),	 phosphoglycerate	kinase	 (pgk),	 phosphoglycerate	mutase	 (pgm),	 triose-phosphate	 isomerase	 (tpi)	 and	 enolase	 (eno).	 The	 sizes	 of	 the	transcripts	are	shown	below	each	gene	to	the	nearest	0.1	kilo	base	pairs	(kb).		 	
gapR	 gapA	 pgk	pgk	 pgm	 tpi	
1.0	kb	 1.0	kb	 0.7	kb	1.2	kb	 1.5	kb	 1.3	kb	
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Figure	1.6.	The	crystal	structure	of	S.	aureus	GapA	tetramer.	This	figure	showing	the	crystal	 structure	 of	 a	monomer	 of	 S.	 aureus	GapA	was	 adapted	 from	 published	 X-ray	crystallography	 data	 (Protein	 Data	 Bank	 (PDB)	 ID	 =	 3lc7)	 acquired	 by	 Mukherjee	 et	
al.114.	The	cartoon	representation	is	coloured	by	spectrum	from	N	terminal	(blue)	to	C	terminal	(red).	This	image	was	produced	using	PyMol	by	Anna	Barwinska-Sendra.	
	
	 	
Chain	O Chain	R 
Chain	Q Chain	P 
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1.7	GapA	and	carbon	metabolism	in	S.	aureus		Carbon	metabolism	 in	 any	 organism	 is	 complex	 and	 involves	many	 enzyme-catalysed	reactions	that	deal	with	a	vast	number	of	nutrients	that	are	found	in	the	environment.	Here	 we	 focus	 upon	 central	 carbon	 metabolism;	 that	 is,	 glycolysis	 and	 surrounding	pathways	 including	 the	 pentose	 phosphate	 pathway	 (PPP)	 and	 the	 tricarboxylic	 acid	(TCA)	 cycle.	 It	 is	 through	 these	 pathways	 that	 S.	 aureus	 initially	 produces	 the	 main	energy-carrying	molecules	of	the	cell;	ATP,	NADH	and	NADPH.	Figure	1.7	demonstrates	glycolysis	 in	 S.	 aureus.	 Other	 potential	 pathways	 of	 energy	 generation	 are	 the	phosphoenolpyruvate	 sugar	 phosphotransferase	 system	 and	 the	 methylglyoxal	glycolytic	bypass	(the	latter	of	which	may	or	may	not	operate	within	S.	aureus).		
1.7.1	Glycolysis	Glycolysis	 is	 a	 core	 part	 of	 central	 carbon	 metabolism.	 It	 begins	 with	 the	phosphorylation	 of	 glucose	 before	 producing	 a	 number	 of	 sugar	 intermediates	 and	eventually	 feeding	 its	 final	 product,	 pyruvate,	 into	 the	 TCA	 cycle.	 One	 of	 the	 sugar	intermediates	includes	the	substrate	of	GapA,	glyceraldehyde	3-phosphate.			During	glycolysis	energy	 is	produced	and	stored	 in	 the	molecules	ATP	and	NADH.	For	each	 glucose	 molecule	 that	 is	 metabolised	 by	 the	 pathway,	 a	 net	 gain	 of	 two	 ATP	molecules	(2	are	consumed	and	4	are	produced)	and	two	NADH	molecules	is	made.	Both	ATP	and	NADH	are	then	utilised	by	the	cell	to	perform	energy-requiring	reactions.			When	the	S.	aureus	cell	has	access	to	glucose,	glycolysis	is	the	primary	catabolic	pathway	occurring.	The	presence	of	 glucose	has	a	broad	effect	upon	most	bacteria,	 causing	 the	repression	of	up	to	10%	of	genes123.	These	repressed	genes	are	mostly	those	which	help	the	 cell	 to	metabolise	 carbon	 sources	 that	 are	 not	 glucose	 or	 glucose	metabolites.	 In	essence	S.	aureus,	along	with	other	bacterial	species,	has	evolved	to	utilise	glucose	first	and	foremost	if	it	is	present,	and	only	to	activate	the	genes	required	to	deal	with	other	carbon	 sources	 if	 glucose	 is	 absent.	 This	 process	 is	 known	 as	 carbon	 catabolite	repression	(CCR).		When	 glucose	 is	 present	 in	 the	 growth	 medium	 a	 S.	 aureus	 ΔgapA	mutant	 will	 not	grow113.	 This	 is	 due	 to	 CCR.	 The	 cell	 switches	 off	 alternative	 carbon	 source-utilising	
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genes	 and	 relies	 exclusively	 upon	 glycolysis,	 which	 does	 not	 function	 as	 one	 of	 its	complement	of	enzymes,	GapA,	is	not	being	produced	in	the	mutant.	In	such	a	situation	alternative	carbon	metabolism	is	available,	but	the	cells	are	preventing	themselves	from	utilising	it	by	prioritising	glycolysis.		Conversely,	when	we	grow	a	S.	aureus	ΔgapA	mutant	in	a	medium	that	doesn’t	contain	glucose,	it	is	able	to	grow	using	alternative	carbon	sources.	Whilst	glucose	is	recognised	as	the	primary	carbon	source	for	cells	by	this	evolved	mechanism,	a	secondary	source	is	not	as	well	established.	The	regulation	of	genes	is	controlled	in	a	less	restricted	way	in	this	 instance	 than	during	catabolite	repression,	making	use	of	whichever	other	energy	sources	are	available.	One	study	has	demonstrated	some	order	of	preference,	beginning	with	gluconate	and	followed	by	succinate,	ribose,	lactate	and	finally	acetate,	but	this	was	the	extent	of	the	carbon	sources	used124.			If	 GapA	 is	 inactivated,	 then	 alternative	 routes	 of	 carbon	metabolism	 can	 be	 used,	 but	only	in	the	absence	of	glucose.	There	are	numerous	other	pathways	that	can	be	utilised	by	S.	aureus	 in	order	to	survive	 if	glycolysis	 is	not	 functioning.	As	mentioned,	 the	PPP,	TCA	 cycle,	 the	 phosphoenolpyruvate	 sugar	 phosphotransferase	 system	 and	 the	methylglyoxal	glycolytic	bypass	are	all	ways	 in	which	the	cell	can	continue	to	produce	energy.	Each	of	these	offers	the	potential	to	produce	at	least	one	of	the	energy	carrying	molecules	(ATP,	NADH	or	NADPH)	which	can	be	used	to	sustain	the	cell.		 	
37	
	
		
Figure	1.7.	The	glycolytic	pathway.	The	metabolites	and	enzymes	of	glycolysis	(shown	in	bold)	given	alongside	the	reaction	(with	triose	phosphate	 joined	to	 its	reaction	by	a	dashed	 line)	 that	 they	 perform	 within	 the	 glycolytic	 pathway.	 GapA	 (shown	 here	 as	glyceraldehyde	phosphate	dehydrogenase	and	highlighted	in	red)	follows	the	reaction	of	fructose	bisphosphate	aldolase	which	splits	the	hexose	sugar	fructose	1,6-bisphosphate	into	two	triose	sugars.			 	
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1.7.2	The	pentose	phosphate	pathway	The	PPP	 is	 a	 branch	of	 carbon	metabolism	 that	 is	 used	by	 cells	 to	produce	 important	metabolites	 such	as	amino	acid	precursors,	 as	well	 as	NADPH,	a	 cofactor	utilised	by	a	number	of	enzymes	mainly	involved	in	anabolic	pathways125.	NADPH	is	also	important	in	 maintaining	 a	 pool	 of	 reduced	 bacillithiol	 within	 the	 Gram-positive	 bacterial	 cell,	which	is	required	for	dealing	with	oxidative	stress	and	is	the	equivalent	of	glutathione	found	in	many	bacteria,	acting	as	one	of	the	main	reductant	pools	with	the	cell84,126.	Thus	the	pathway	may	be	of	particular	benefit	with	regards	to	high	levels	of	copper	entering	cells	 in	 terms	 of	 any	 oxidation	 caused	 by	 copper	 catalysis	 of	 the	 Fenton	 reaction.	 A	caveat	of	the	PPP	is	that	it	runs	concurrently	to	the	first	phase	of	glycolysis,	that	is,	the	glycolytic	 pathway	 until	 glyceraldehyde-3	 phosphate	 is	 produced	 (the	 substrate	 of	GapA).	Thus	it	does	not	provide	an	alternative	route	to	the	latter	stages	of	glycolysis	and	ultimately	 into	 the	TCA	cycle	which	 is	a	source	of	abundant	energy	 to	cells,	as	well	as	precursors	to	numerous	important	metabolites.		
1.7.3	The	tricarboxylic	acid	cycle	and	other	energy	generating	pathways		The	TCA	 cycle	 is	 a	 large	 and	 important	 part	 of	 central	 carbon	metabolism.	Numerous	enzymes	 are	 involved	 in	 the	 cycle	 which	 provides	 several	 intermediates	 that	 are	important	for	further	biosynthesis	of	amino	acids	and	other	complex	molecules.	It	also	provides	cells	with	energy	in	the	form	of	4	NADH	molecules	(it	also	provides	1	molecule	of	 guanosine	 triphosphate	 (GTP),	 and	 ATP	 in	 some	 instances,	 although	 if	 ATP	 is	produced	then	only	3	NADH	molecules	result)	for	each	pyruvate	molecule	which	enters	the	pathway.	The	 cycle	 is	 repressed	under	 glucose-replete	 conditions	 and	 is	 activated	under	 growth-limiting	 conditions	 and	 when	 glucose	 is	 not	 present,	 under	 which	gluconeogenesis	to	phosphoenolpyruvate	and	pyruvate	provides	routes	to	biosynthesis	of	multiple	intracellular	metabolites	derived	from	glycolytic	intermediates127.	This	cycle	therefore	provides	an	important	energy	generation	route	when	glucose	is	not	present.			Other	 pathways	 that	 are	 a	 potential	 source	 of	 energy	 are	 the	 phosphoenolpyruvate	sugar	phosphotransferase	system	(PTS)	and	the	methylglyoxal	glycolytic	bypass128,129.			The	 PTS	 is	 intimately	 linked	 to	 CCR	 and	 is	 able	 to	 generate	 pyruvate	 from	phosphoenolpyruvate	which	can	then	feed	into	other	carbon	catabolism	pathways130.	It	is	 a	 system	 that	 is	 used	by	many	bacterial	 species	 to	 sense	 available	 nutrients	 and	 to	
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control	 expression	 based	 upon	 this	 availability	 (the	 essence	 of	 CCR)	 via	 a	phosphorylation	 cascade.	 This	 is	 an	 important	 source	 of	 control	 of	metabolism	but	 in	terms	 of	 energy	 production,	 it	 does	 not	 directly	 generate	 energy	 carrying	 molecules	although	phosphoenolpyruvate	can	enter	other	generating	pathways.		The	 methylglyoxal	 glycolytic	 bypass	 is	 a	 potential	 bypass	 of	 the	 normal	 glycolytic	pathway	 in	 S.	 aureus131,132.	 It	 is	 unclear	 if	 all	 of	 the	 enzymes	 necessary	 for	 the	 entire	pathway		to	occur	in	S.	aureus	are	present	but	it	does	occur	in	other	bacteria	such	as	E.	
coli,	 and	 Bacillus	 subtilis131-133	 and	 methylglyoxal	 is	 certainly	 an	 inadvertent	 and	spontaneous	byproduct	of	some	non-enzymatic	reactions	within	this	species134.		Each	 of	 these	 pathways	 (PPP,	 the	 TCA	 cycle,	 PTS	 and	 the	 methylglyoxal	 glycolytic	bypass)	 has	 something	 to	 contribute	 to	 carbon	metabolism,	 allowing	 the	 cell	 to	 exert	flexibility	when	in	a	position	of	nutrient	deprivation	or	when	a	step	in	standard	carbon	metabolism	 is	 blocked,	 such	 as	 we	 have	 hypothesised	 with	 GapA	 when	 S.	 aureus	 is	experiencing	copper	stress.		
1.8	Summary	of	Introduction	A	poor	understanding	of	copper	toxicity	in	bacteria	in	general	and	more	specifically	in	S.	
aureus,	which	is	an	increasingly	important	pathogen,	 led	to	the	investigation	of	copper	toxicity	 within	 this	 organism.	 Preliminary	 metalloproteomic	 analysis	 resulted	 in	 the	preliminary	 identification	of	SaGapA	as	a	potential	 copper	binding	non-metalloprotein	in	 the	 cytoplasm,	 the	 first	 of	 its	 kind.	 This	 project	 has	 undertaken	 the	 further	investigation	of	the	potential	for	copper	binding	of	SaGapA.		 	
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1.9	Aims	and	Objectives		
SaGapA	 having	 been	 identified	 as	 a	 potential	 copper	 binding	 target	 via	 preliminary	work,	the	aims	of	this	study	were	to	confirm	this	enzyme	as	a	bona	fide	copper	binding	target	 in	 vivo.	 Investigation	 of	 copper	 binding	 in	 vitro	 in	 order	 to	 establish	understanding	of	the	binding	mechanism	was	a	further	aim.		
1.9.1	Specific	objectives		
In	vivo		
• To	characterise	the	effects	of	copper	on	the	growth	of	S.	aureus	SH1000.	
• To	investigate	the	copper	accumulation	of	cells	grown	in	elevated	copper.	
• To	confirm	that	SaGapA	binds	copper	in	vivo	under	elevated	copper	conditions.	
• To	establish	whether	copper	inhibits	SaGapA	in	vivo.	
• To	investigate	the	consequences	of	copper	binding	to	SaGapA	in	vivo.		
In	vitro		
• To	establish	that	copper	binds	to	recombinant	SaGapA.	
• To	investigate	the	binding	mechanism	of	copper	binding,	if	established.	
• To	establish	whether	copper	inhibits	SaGapA	in	vitro.		 	
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Chapter	2.	Materials	and	Methods		
2.1	Bacterial	strains,	growth	assays	and	conditions	All	of	the	strains	used	in	this	study	are	 listed	in	Table	1.	Cells	were	grown	in	 lysogeny	broth	(LB)	(10	g	L-1	tryptone,	5	g	L-1		yeast	extract,	10	g	L-1	NaCl),	tryptic	soy	broth	(TSB)	(17	g	L-1	tryptone,	5	g	L-1	 	NaCl,	2.5	g	L-1	K2HPO4,	0.25	%	(w/v)	glucose),	Tris	minimal	medium	 (TM)	 (12.1	 g	 L-1	 Tris(hydroxymethyl)aminomethane	 (Tris),	 1	 x	 salts	 (25	 x	stock:	 145	 g	 L-1	 NaCl,	 92.5	 g	 L-1	 KCl,	 27.5	 g	 L-1	 NH4SO4,	 3.56	 g	 L-1	 Na2SO4,	 6.8	 g	 L-1	KH2PO4),	5	%	(w/v)	casamino	acids,	0.5	µg	ml-1	pantothenic	acid,	10	µg	ml-1	biotin,	50	µM	thiamine,	500	µM	MgCl2,	100	µM	CaCl2,	10	µM	niacin,	4	µg	ml-1	tryptophan,	11	µg	ml-1	cysteine),	Townsend-Wilkinson	medium	(TWM),	(K2HPO4.H2O,	7000	mg	L-1;	NaH2PO4,	2300	mg	L-1;	 (NH4)2SO4,	1000	mg	L-1;	 citric	acid,	210	mg	L-1;	MgSO4.7H2O,	493	mg	L-1;	MgCl2,	 50	mg	 L-1;	 thiamine,	 1	mg	 L-1;	 niacin,	 1.2	mg	 L-1;	 pantothenic	 acid,	 2.5	mg	 L-1;	biotin,	0.005	mg	L-1;	L-amino	acids;	alanine,	60	mg	L-1;	arginine,	50	mg	L-1;	aspartic	acid,	90	mg	L-1;	cysteine,	20	mg	L-1;	glutamic	acid,	100	mg	L-1;	glycine,	50	mg	L-1;	histidine,	20	mg	L-1;	isoleucine,	30	mg	L-1;	leucine,	90	mg	L-1;	lysine,	50	mg	L-1;	methionine,	10	mg	L-1;	phenylalanine,	 40	mg	 L-1;	 proline,	 10	mg	 L-1;	 serine,	 30	mg	 L-1;	 threonine,	 30	mg	 L-1;	tryptophan,	10	mg	L-1;	tyrosine,	50	mg	L-1;	valine,	80	mg	L-1)	or	Tris-succinate	medium	(TSM)	(as	TM	with	the	addition	of	the	desired	concentration	of	succinate).			Additional	 carbon	 sources	 were	 added	 to	 a	 final	 concentration	 of	 1%	 (w/v)	 unless	otherwise	stated	(see	results).	All	media	was	adjusted	to	a	pH	of	7.5	prior	to	autoclaving.	
E.	coli	strains	were	grown	in	LB.	When	required,	ampicillin	(100	µg	ml-1),	kanamycin	(50	µg	ml-1)	 or	 tetracycline	 (10	 µg	ml-1)	were	 added	 to	 bacterial	 growth	media.	 Bacterial	cultures	were	grown	at	37°C	with	shaking	(180	rpm)	unless	otherwise	stated.	Growth	analysis	was	performed	in	a	plate	reader.	Cultures	were	prepared	by	diluting	overnight	starter	cultures	to	a	starting	OD595	of	0.05	and	then	adding	300	µl	of	each	culture	to	a	sterile	 96	 well	 plate	 with	 a	 lid,	 placed	 in	 a	 plate-reader	 (Fluorostar	 Optima,	 BMG	Labtech)	and	analysed	at	595	nm,	at	37	˚C	with	orbital	shaking.		
2.2	Overexpression	and	Purification	of	rSaGapA	Cloning	 of	 the	 open	 reading	 frame	 (ORF)	 of	gapA	 into	 pLEICS-03,	which	 introduces	 a	hexa-histidine	 tag	 (His-tag)	 to	 the	 N-terminal	 of	 the	 protein,	 has	 been	 described	previously113.	 The	 vector	 was	 purified	 using	 a	 plasmid	 miniprep	 kit	 (Sigma)	 and	transformed	into	the	E.	coli	strain	BL21.	The	transformants	were	cultured	in	LB	at	37	°C,	
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and	 expression	 was	 induced	 when	 an	 optical	 density	 at	 595	 nm	 (OD595)	 of	 0.6	 was	reached	 using	 1	 mM	 isopropyl-β-D-thiogalactopyranoside	 (IPTG)	 for	 6	 hours	 in	 an	orbital	 shaker	 (180	 rpm)	 at	 37	 ˚C	 (different	 expression	 conditions	 were	 tested,	 see	Chapter	4)		Cells	were	harvested	by	centrifugation	 (3,939	g,	30	mins,	4	 ˚C),	 resuspended	 in	buffer	(150	mM	NaCl,	40	mM	4-(2-hydroxyethyl)-1-piperazineethanesulfonic	acid	 (HEPES),	5	mM	 dithiothreitol	 (DTT),	 pH	 7.5	 in	 de-ionised	 (DI)	 water)	 before	 lysis	 by	 sonication.	Insoluble	material	was	removed	by	centrifugation	(48,384	g,	30	mins,	4	˚C).	Protein	was	purified	 by	 Ni-nitrilotriacetic	 acid	 (NTA)	 affinity	 chromatography	 (5	 ml	 His-Trap	column,	 GE).	 The	 column	 was	 equilibrated	 initially	 with	 5	 column	 volumes	 of	 buffer	(150	 mM	 NaCl,	 40	 mM	 HEPES,	 5	 mM	 DTT,	 pH	 7.5	 in	 DI	 water)	 containing	 20	 mM	imidazole	and	once	the	soluble	lysate	had	been	loaded	onto	the	column	it	was	washed	with	 5	 column	 volumes	 of	 the	 same	 buffer	 containing	 20	 mM	 imidazole.	 The	 tagged	enzyme	was	eluted	using	buffer	(as	previous)	containing	300	mM	imidazole,	elution	was	halted	after	protein	concentration	had	fallen,	as	measured	the	by	UV-vis	trace	on	AKTA	fast	protein	liquid	chromatography	(FPLC)	equipment.		The	 His-tag	was	 cleaved	 from	 GapA	 using	 tobacco	 etch	 virus	 (TEV)	 protease	 (Sigma)	added	at	a	quarter	of	the	final	concentration	of	protein	(as	measured	by	Bradford)	and	another	 step	of	NTA	affinity	 chromatography	performed	 to	 remove	TEV	protease	 and	any	un-cleaved	protein,	which	bound	 to	 the	 column.	The	cleaved	protein	did	not	bind	using	buffer	containing	20	mM	imidazole.		Further	 purification	 of	 GapA	 was	 achieved	 by	 size-exclusion	 (SE)	 chromatography	(Superdex	200	Increase	10/300	GL	column)	using	buffer	(as	previous)	on	an	AKTA	FPLC	(flow-rate	1	ml	min-1).	This	was	carried	out	upon	pooled	fractions	from	the	second	stage	of	Ni-NTA	affinity	containing	rSaGapA.			Size	 exclusion	 chromatography	 was	 followed	 by	 a	 final	 step	 of	 anion	 exchange	chromatography	 (1	 ml	 Q-HP	 column,	 GE),	 which	 was	 carried	 out	 under	 rigorously	anaerobic	 conditions	 in	 an	 N2	 glovebox,	 to	 remove	 the	 reductant	 DTT	 from	 the	 final	purified	sample	prior	to	copper	binding	experiments.	The	wash	buffer	(150	mM	NaCl,	40	mM	 HEPES,	 pH	 7.5	 in	 DI	 water)	 and	 the	 final	 elution	 buffer	 (600	 mM	 NaCl,	 40	 mM	
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HEPES,	 pH	 7.5	 in	 DI	 water)	 did	 not	 contain	 DTT.	 Before	 application	 to	 the	 anion-exchange	column,	the	protein	was	treated	with	1	mM	(bathocuproine	disulphonate)	BCS	to	ensure	the	removal	of	any	residual	copper	and	1	mM	tris(2-carboxyethyl)phosphine	(TCEP)	 to	 ensure	 that	 the	 protein	 was	 completely	 reduced.	 Protein	 was	 quantified	where	necessary	using	Bradford	 reagent	using	a	 (bovine	 serum	albumin)	BSA	protein	standard	 for	 construction	 of	 a	 standard	 curve	 from	 0	 to	 20	 µg	 ml-1	 in	 2.5	 µg	 ml-1		graduations	 135	 (Thermo	 Scientific),	 or	 using	 absorbance	 at	 280	 nm	 using	 a	spectrophotometer	 (Perkin	 Elmer)	 and	 an	 ε	 value	 of	 22,920	 (obtained	 using	 ExPasy	ProtParam	open	source	software).	
2.3	DTNB	reaction	A	 stock	 solution	 containing	 100	 mM	 sodium	 phosphate	 and	 1	 mM	ethylenediaminetetraacetic	acid	(EDTA)	at	pH	8.0	was	prepared	and	20	mg	5,5’-dithio-
bis-(2-nitrobenzoic	 acid)	 (DTNB)	was	 dissolved	 in	 5	ml	 of	 the	 stock	 under	 anaerobic	conditions.	An	aliquot	(50	µl)	of	rSaGapA	of	unknown	concentration	was	added	to	900	µl	of	buffer	(150	mM	NaCl,	40	mM	HEPES),	containing	6	M	guanidine	hydrochloride	when	required,	 and	 mixed	 well	 within	 an	 anaerobic	 quartz	 cuvette	 (Hellma).	 A	 blank	 was	prepared	with	no	added	protein,	using	50	µl	of	sample	buffer	instead.	To	each	of	these	tubes,	50	µl	of	 the	DTNB	stock	 solution	was	added,	 again	under	anaerobic	 conditions.	Spectra	of	the	sample	were	then	obtained	using	a	UV/visible	spectrophotometer	(Perkin	Elmer),	with	the	concentration	of	thiols	calculated	using	the	value	of	the	absorbance	at	412	 nm.	 If	 the	 absorbance	 was	 not	 constant	 then	 samples	 were	 incubated	 at	 room	temperature	 until	 a	 further	 increase	 in	 absorbance	was	 not	 observed.	 The	 sample	 of	recombinant	protein	without	added	DTNB	or	guanidine	were	also	analysed	in	this	way,	with	an	entire	spectrum	being	taken	for	protein	quantification	at	280	nm,	allowing	the	two	protein	concentration	values	to	be	compared.	
2.4	Copper	quantification		A	 solution	 of	 approximately	 100	 mM	 tetrakis(acetonitrile)copper(I)	hexafluorophosphate	 (Sigma)	 was	 prepared	 anaerobically	 in	 acetonitrile	 and	 serially	diluted	 into	 buffer	 (150	 mM	 NaCl,	 40	 mM	 HEPES,	 in	 DI	 water,	 pH	 7.5)	 to	 a	 final	concentration	of	1	mM	Cu(I).	A	solution	of	100	mM	bathocuproine	disulphonate	(BCS)	was	prepared	anaerobically	 into	buffer	(150	mM	NaCl,	40	mM	HEPES,	 in	DI	water,	pH	7.5)	 and	 serially	 diluted	 in	 the	 same	buffer	 to	 a	 final	 concentration	 of	 20	µM	BCS.	An	aliquot	 (1	 ml)	 of	 20	 µM	 BCS	 was	 pipetted	 into	 an	 anaerobic	 quartz	 cuvette	 and	 a	
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UV/visible	spectrum	obtained	in	a	spectrophotometer	(Perkin	Elmer).	The	solution	of	1	mM	 tetrakis(acetonitrile)copper(I)	 hexafluorophosphate	 was	 placed	 in	 an	 anaerobic	syringe,	and	then	injected	in	2	µL	aliquots	into	the	BCS	solution	and	mixed	by	inversion.	Spectra	were	 taken	after	 each	 injection,	 and	 the	process	 continued	until	 the	observed	maximum	at	483	nm	reached	a	peak	value,	 i.e.	 the	BCS	was	 saturated	with	Cu(I).	The	change	in	absorbance	at	483	nm	with	each	injection	of	Cu(I)	was	used	to	calculate	the	concentration	 of	 [Cu(I)(BCS)2]	 complex	 formed	 using	 the	 published	 extinction	coefficient	(ε	=	13,300	M-1	cm-1)136.	
2.5	Unfolding	of	rSaGapA	and	fluorescence	spectroscopy		Three	protein	samples,	each	of	final	concentration	10	µM	rSaGapA,	were	prepared	from	a	concentrated	stock	in	buffer	(150	mM	NaCl,	40	mM	HEPES);	one	containing	8	M	urea;	another	containing	6	M	guanidine	hydrochloride;	the	third	containing	only	buffer.	Each	was	placed	into	a	fluorimetry	cuvette	in	turn	and	a	fluorescence	spectrum	acquired	in	a	spectrofluorometer	 (Eclipse	Model,	 Cary)	 using	 an	 excitation	wavelength	 (λex)	 of	 280	nm	and	detection	of	emission	at	300	to	450	nm.	Data	was	collated	for	comparison	of	the	wavelength	and	intensity	of	emission	maxima.			
2.6	Cu(I)	titration	of	rSaGapA	and	competition	assay	with	BCS	A	 solution	 of	 rSaGapA	 was	 prepared	 anaerobically	 in	 buffer	 (150	 mM	 NaCl,	 40	 mM	HEPES,	pH	7.5)	and	placed	in	an	anaerobic	quartz	cuvette	(Hellma).	A	Cu(I)	solution	of	20	µM,	prepared	and	quantified	as	described	(Section	2.4),	was	titrated	in	2	µl	aliquots	from	an	anaerobic	syringe	and	the	solution	mixed	by	inversion.	A	UV/visible	spectrum	was	taken	using	a	spectrophotometer	(Perkin	Elmer)	immediately	after	each	addition.		For	BCS	competition,	 two	solutions	were	prepared	anaerobically.	One	contained	16.66	µM	 µM	 BCS	 in	 buffer	 (150	 mM	 NaCl,	 40	 mM	 HEPES,	 pH	 7.5	 in	 DI	 water),	 the	 other	contained	 16.66	µM	BCS	 and	 5.9	µM	 rSaGapA	 in	 the	 same	 buffer.	 Each	 of	 these	were	placed	 in	 anaerobic	 quartz	 cuvettes	 and	 titrated	 with	 a	 stock	 solution	 of	 Cu(I),	 with	spectra	obtained	after	 each	addition	 as	described	above,	 each	addition	 adding	 to	1.79	µM	Cu(I)	to	the	solutions.	Spectra	collected	could	be	analysed	and	concentrations	of	the	[Cu(I)(BCS)2]	quantified	as	described	from	the	absorbance	at	483	nm.	
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2.7	SaGapA	and	rSaGapA	activity	assay	The	enzyme	activity	of	GapA	was	measured	using	an	assay	adapted	from	Purves	et	al.113.	A	 stock	 reaction	 buffer	 containing	 2	 mM	 nicotinamide	 dinucleotide	 (NAD+),	 2	 mM	glyceraldehyde	 3-phosphate	 (G3P)	 (Sigma),	 50	 mM	 sodium	 phosphate,	 1%	 (w/v)	triethanolamine,	150	mM	NaCl,	40	mM	HEPES,	pH	7.5	was	prepared.	Aliquots	in	which	individual	 reagents	 were	 omitted	 were	 also	 prepared	 as	 required	 for	 controls.	 The	protein	sample	(either	cell	lysate	or	purified	recombinant	protein)	was	added	to	initiate	the	 reaction,	which	was	measured	 spectroscopically	using	absorbance	at	340	nm.	The	concentration	of	NADH	produced	after	a	given	time	was	calculated	using	the	extinction	coefficient	of	NADH	at	340	nm	(ε	=	6,220	M-1	cm-1)137.	In	 the	 case	 of	 	 assaying	 SaGapA	 activity	 within	 a	 S.	 aureus	 cell	 lysate,	 the	 soluble	fractions	were	prepared	using	a	bead	beater	 (3	x	40	seconds,	with	1	minute	on	 ice	 in	between	each	cycle),	 followed	by	centrifugation	 (10	mins,	12,000	g,	 at	4˚C)	 to	 remove	insoluble	material.	 Total	 protein	 in	 the	 lysates	was	 quantified	 by	Bradford	 assay,	 and	then	 each	 sample	 was	 diluted	 into	 buffer	 (150	 mM	 NaCl,	 40	 mM	 HEPES,	 pH	 7.5)	 as	required	 to	 equalise	 the	 amount	 of	 protein	 for	 the	 assay,	 protein	 was	 diluted	 to	 a	concentration	 of	 50	 µg	ml-1	 in	 the	 case	 of	 lysate	 assays,	 before	 addition	 of	 185	 µl	 of	reaction	buffer,	unless	stated	otherwise.		When	using	 the	plate	 reader	 spectrophotometer	 (Biotek),	 15	µL	 of	 soluble	 lysate	was	added	to	each	well,	and	185	µl	of	reaction	buffer	added	immediately	before	the	readings	were	taken.	The	path	length	of	the	reaction	in	the	plate	was	accounted	for	via	use	of	a	conversion	 factor	 attained	 through	 construction	 of	 standard	 curves	 of	 NADH	 in	 the	plates	(see	Chapter	3).		In	 the	 case	 of	 measuring	 activity	 of	 purified	 rSaGapA,	 protein	 concentration	 was	calculated	via	absorbance	at	280	nm	or	by	Bradford	assay,	and	the	protein	was	diluted	as	required	into	buffer	(150	mM	NaCl,	40	mM	HEPES,	in	DI	water,	pH	7.5).	Aliquots	(15	µl)	of	rSaGapA	were	placed	into	the	multi-well	plates	and	the	final	volume	brought	up	to	200	µl	with	reaction	buffer	 immediately	before	 the	commencement	of	 readings	by	 the	spectrophotometer.	 In	 the	 case	 of	 rSaGapA	 activity	 assays	 performed	 in	 the	 cuvette	spectrophotometer	 (Perkin	 Elmer),	 a	 quartz	 cuvette	was	 used	 (Hellma).	 The	 rSaGapA	protein	was	added	to	the	cuvette	initially,	with	reaction	buffer	bringing	the	final	volume	
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to	1	ml	 immediately	before	readings	were	taken.	The	path	 length	of	 the	cuvette	was	1	cm.	All	readings	were	taken	at	340	nm.	
2.8	Mutagenesis	of	the	gapA	gene	in	construct	pLEICS-03	The	 gapA	 gene,	 in	 plasmid	 pLEICS03-SaGapA,	 was	 modified	 using	 a	 variant	 of	QuikChange	 Mutagenesis	 (Stratagene)	 by	 polymerase	 chain	 reaction	 (PCR)	 (PCR	number	1,	Table	2.2),	using	primers	that	introduced	a	codon	mutation	at	Cys151,	His178	and	 Cys96	 to	 create	 the	 plasmids	 (primer	 pairs	 shown	 in	 brackets	 after	 respective	vectors)	 pLEICS03-SaGapA(C151A)	 (QC	 PL03-GapA	 C151A	 For,	 QC	 PL03-GapA	 C151A	Rev),	 pLEICS03-SaGapA(H178A)	 (QC	 PL03-GapA	 H178A	 For,	 QC	 PL03-GapA	 H178A	Rev)	and	pLEICS03-SaGapA(C96A)	(QC	PL03-GapA	C96A	For,	QC	PL03-GapA	C96A	Rev)	respectively.	PCR	conditions	and	primers	are	shown	in	Tables	2.2	and	2.3	respectively.	After	 PCR,	 the	 template	 plasmid	 was	 digest	 using	 the	 DpnI	 enzyme	 that	 digests	methylated	 DNA	 but	 leaves	 un-methylated	 DNA	 intact.	 The	 digested	 plasmid	 was	transformed	 into	 E.	 coli	 DH5α	 and	 transformants	 selected	 on	 LB	 plates	 containing	kanamycin	 after	 overnight	 incubation	 at	 37	 °C.	 Transformants	 were	 cultured	 in	 LB	overnight,	and	plasmid	was	purified	 from	these	cultures	using	a	miniprep	kit	 (Sigma).	Confirmation	of	the	correct	mutation	being	present	was	by	restriction	digest	using	RsaI	(according	 to	 the	protocol	described	 in	 the	NEB	manual)	of	pLEICS03-SaGapA(C151A)	and	pLEICS03-SaGapA(C96A)	followed	by	agarose	gel	electrophoresis,	and	subsequently	by	DNA	sequencing	(performed	by	GATC).	The	verified	plasmids	were	later	transformed	into	E.	coli	BL21	cells	for	overexpression.		
2.9	 Genotypic	 verification	 of	 SH1000	 vs	 8325-4	 rsbU	 and	 SH1000	 vs	 SH1000	
ΔgapA	(gapA	mutated	by	insertion	of	a	tetracycline	resistance	cassette)	Cultures	 of	 wild	 type	 SH1000	 and	 8325-4,	 and	 of	 the	 SH1000	 ΔgapA	 mutant,	 were	cultured	overnight	in	TM	medium.	Tetracycline	(10	mg	ml-1)	was	included	in	the	growth	medium	of	the	SH1000	ΔgapA	culture	to	select	for	the	mutant.	Cultures	were	centrifuged	(10	minutes,	4000	g,	4	˚C)	and	cells	resuspended	in	500	µl	of	buffer	(150	mM	NaCl,	40	mM	HEPES,	pH	7.5).	Glass	beads	 (0.1	g)	were	added	 to	each	cell	 suspension	 in	a	2	ml	screw	cap	tube.	Cells	were	agitated	in	a	bead	beater	(3	x	40	seconds,	with	1	minute	on	ice	 in	 between	 each	 cycle)	 to	 lyse	 cells.	 Insoluble	 material	 was	 removed	 by	centrifugation	(5	minutes,	12,000	g,	4	˚C,	x	2).	Soluble	lysates	were	diluted	in	the	same	buffer	and	treated	with	a	PCR	clean-up	kit	(Sigma)	before	being	used	as	template	in	the	
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relevant	PCR	reaction	 (Table	2.1).	PCR	products	of	 the	amplified	gene	 (rsbU	 or	gapA),	generated	 using	 PCR	 conditions	 shown	 in	 Table	 2.2	 and	 primers	 shown	 in	 Table	 2.3,	were	separated	on	1	%	(w/v)	agarose	gels	containing	GelRed	(Biorad)	staining	agent	for	visualisation	and	imaging	of	bands	under	UV	light.	The	amplified	rsbU	gene	was	further	treated	with	 restriction	 enzyme	ApoI	 (according	 to	 the	protocol	 described	 in	 the	NEB	manual),	and	the	digested	sample	analysed	in	the	same	way	on	an	agarose	gel.	
2.10	Size	exclusion	analysis	of	rSaGapA	copper	binding	Aliquots	of	the	purified	rSaGapA,	with	and	without	addition	of	Cu(I),	were	applied	to	a	size	 exclusion	 column	 attached	 to	 an	 AKTA	 pump	 system	 (Superdex	 200	 Increase	10/300	GL	column).	Three	samples	of	approximately	17.5	µM	rSaGapA,	see	results	 for	precise	 concentrations,	 in	 150	 mM	 NaCl,	 40	 mM	 HEPES,	 pH	 7.5	 in	 DI	 water	 were	prepared	 anaerobically,	 with	 addition	 of	 0,	 0.9	 or	 1.5	 mole	 equivalents	 of	 Cu(I)	(prepared	 as	 described	 in	 section	 2.4).	 Each	 sample	 (0.5	 ml)	 was	 loaded	 onto	 the	column,	and	resolved	at	1	ml	min-1	 in	150	mM	NaCl,	40	mM	HEPES,	pH	7.5.	Fractions	(0.5	ml)	were	collected	and	analysed	 for	protein	content	by	Bradford	assay,	alongside	the	automated	A280	analysis	performed	by	the	AKTA.	Fractions	were	assayed	for	SaGapA	activity	as	required	(section	2.7)	and	by	ICP-MS	for	metal	content	as	required	(section	2.11).		
2.11	Inductively-coupled-plasma	mass-spectrometry	(ICP-MS)	ICP-MS	 is	 a	 method	 for	 the	 quantification	 of	 metals	 and	 some	 non-metals	 within	 a	sample	 at	 extremely	 low	 concentrations.	 It	 involves	 automated	 uptake	 of	 prepared	samples	which	are	then	ionised	within	a	plasma	before	the	quantities	of	the	ions	present	are	assessed	via	mass	spectrometry.		Samples	 were	 prepared	 by	 30	 x	 dilution	 in	 2.5	 %	 high-purity	 nitric	 acid	 (Merck)	containing	 internal	metal	standards	at	a	constant	concentration	of	20	parts	per	billion	(ppb)	(metals	used	as	standards:	Ag,	Pt).	Standards	curves	of	the	target	metals	(Cu,	Zn,	Mn,	Co,	Ni)	were	prepared	using	metal	standard	solutions	(BDH)	at	concentrations	of	0,	1,	5,	25,	50	and	100	ppb	 (Cu,	Zn,	Mn,	Co,	Ni),	matrix-matched	by	addition	of	 identical	buffer	 to	 that	present	 in	 the	samples,	and	analysed	alongside	each	set	of	samples.	Cell	lysates	 of	 S.	 aureus	 cells	 grown	 in	 varying	 copper	 concentrations	 were	 prepared	 as	described	 in	 their	 preparation	 for	 the	 GapA	 activity	 assay	 (section	 2.7),	 and	 were	digested	directly	in	high	concentration	(65%)	nitric	acid	before	dilution	prior	to	ICP-MS	
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analysis.	 Samples	 from	 size	 exclusion	 analysis	 were	 prepared	 as	 described	 in	 their	respective	method	sections	(sections	2.14	and	2.10).	
2.12	Glycerol	Stocks	All	 bacterial	 strains	 were	 stored	 as	 glycerol	 stocks	 at	 -80°C.	 Glycerol	 stocks	 were	produced	 by	 resuspension	 of	 overnight	 liquid	 cultures	 in	 1	ml	 sterile	 TSB	 or	 TM	 (for	ΔgapA	strains)	+	20%	(v/v)	glycerol,	and	stored	in	2	ml	screw	top	tubes.	Strains	were	recovered	 from	storage	by	plating	onto	appropriate	solid	medium	containing	required	antibiotics	and	grown	overnight	at	37°C.		
2.13	SDS	Polyacrylamide	gel	electrophoresis	(SDS-PAGE)		Samples	were	prepared	with	the	addition	of	4	x	SDS-PAGE	loading	buffer	(400	mM	DTT,	8	%	(w/v)	sodium	dodecyl	sulphate	(SDS),	0.4	%	(w/v)	bromophenol	blue,	40%	(w/v)	glycerol)	and	boiled	for	10	minutes.	Samples	were	adjusted	for	protein	concentration	by	Bradford	assay	as	required.		Gels	were	prepared	containing	12%		or	15%	(w/v)	acrylamide	in	the	case	of	the	running	gel	(one	5	%	acrylamide	stacking	gel	contained;	2.85	ml	dH2O,	0.57	ml	1	M	Tris,	pH	6.8,	20	 µl	 20%	 SDS,	 0.35	 ml	 29:1	 40%	 acrylamide:bis-acrylamide	 solution,	 38	 µl	 10%	ammonium	 persulphate	 (APS),	 5µl	 tetramethylethylenediamine	 (TEMED);	 one	 12%	acrylamide	running	gel	contained;	2.9	ml	dH2O,	4.0	ml	1M	Tris,	pH	8.8,	54	µl	20%	SDS,	3	ml	 29:1	 40%	 acrylamide:bis-acrylamide,	 54	 µl	 10%	 APS,	 10	 µl	 TEMED;	 water	 and	acrylamide	 concentrations	 were	 adjusted	 accordingly	 for	 15%	 acrylamide	 gels).	Electrophoresis	 took	place	 in	a	gel	 tank	(Biorad,	180	V,	60-90	minutes)	 filled	with	1	x	running	buffer	(248	mM	Tris,	1.92	M	glycine,	1%	w/v	SDS).	
2.14	Metalloproteomics	Cultures	(1	L	each)	of	SH1000	and	SH1000	ΔgapA	were	grown	in	TM	medium	containing	50	 µM	 CuSO4	 for	 6	 hours	 at	 37	 ˚C	 with	 shaking	 (180	 rpm).	 Cells	 were	 collected	 by	centrifugation	(3,939	g,	30	mins,	4	˚C)	and	then	resuspended	in	buffer	(150	mM	NaCl,	40	mM	HEPES,	pH	7.5).	Cells	were	lysed	by	freeze	grinding	under	liquid	nitrogen	in	a	pestle	and	 mortar	 before	 being	 transferred	 to	 an	 anaerobic	 chamber.	 Once	 thawed	anaerobically,	 samples	were	centrifuged	 (48,384	g,	30	mins,	4	 ˚C)	and	returned	 to	 the	chamber,	and	the	soluble	fraction	was	anaerobically	ultra-centrifuged	(80,	000	rpm,	30	mins,	4	˚C)	to	remove	all	insoluble	material.		
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Each	resulting	lysate	was	applied	to	a	fresh	anion	exchange	column	(Q-HP,	1	ml	column,	GE),	washed	 in	buffer	 for	5	column	volumes	 (40	mM	HEPES,	pH	7.5),	 and	 then	bound	proteins	were	eluted	with	2	x	1	ml	each	of	buffers	(40	mM	HEPES,	pH	7.5)	containing	increasing	 concentrations	 of	 NaCl	 (0,	 100,	 200,	 300,	 400,	 600,	 and	 1000	 mM,	sequentially).	Each	resulting	fraction	of	eluent	was	assayed	for	GapA	activity	and	tested	for	metal	concentration	by	ICP-MS	at	a	dilution	of	1	in	30	(see	sections	2.7	and	2.11).		The	 first	 1	 ml	 fraction	 that	 was	 eluted	 by	 400	 mM	 NaCl	 was	 found	 to	 contain	 the	majority	 of	 GAPDH	 activity	 in	 the	wild	 type	 extract,	 and	 therefore	 this	 fraction	 (from	both	 wild	 type	 and	 mutant	 extract)	 was	 further	 separated	 by	 size	 exclusion	chromatography	(flow	rate,	1	ml	min-1;	buffer,	150	mM	NaCl,	40	mM	HEPES,	pH	7.5	in	DI	water;	 column,	Superdex	200	 Increase	10/300	GL,	GE).	All	 resulting	 fractions	 (0.5	ml)	were	 again	 tested	 for	metal	 concentration	 by	 ICP-MS	 at	 a	 dilution	 of	 1	 in	 30	 and	 the	fractions	 around	 the	 SaGapA	 peak	 were	 tested	 for	 GapA	 activity	 and	 for	 protein	concentration	by	Bradford	assay.	Fractions	around	the	SaGapA	peak	were	also	analysed	by	SDS-PAGE	in	both	chromatography	steps	as	described.	
2.15	DNA	analysis	using	agarose	gel	electrophoresis	DNA	samples	(PCR	product,	restriction	digests,	etc.)	were	mixed	with	6	x	DNA	loading	buffer	 (Thermo	Scientific)	 and	 loaded	onto	 a	 1%	 (w/v)	 agarose	 gel	 composed	of	 TAE	buffer	 (40mM	 Tris,	 20mM	 acetic	 acid,	 and	 1	 mM	 EDTA	 in	 distilled	 water,	 pH	 8.0).	Electrophoresis	of	samples,	and	a	DNA	marker	ladder	(Thermo	Scientific),	took	place	in	a	gel	tank	(BioRad,	70	V,	45-80	mins).	
2.16	Transduction	of	8325-4	ΔgapA	and	verification		Transduction	of	the	ΔgapA	mutation	from	S.	aureus	8325-4	was	transduced	into	SH1000	to	create	the	novel	strain	SH1000	ΔgapA	using	the	method	described	by	Krausz	et	al.138.	The	strain	was	verified	by	amplification	of	the	gapA	gene	region	within	both	the	WT	and	mutant	strains	of	8325-4	and	SH1000.	The	SH1000	rsbU	background	was	also	confirmed	as	described	in	section	2.9.	PCR	protocols	and	primers	used	are	described	in	Tables	2.2	and	 2.3	 respectively.	 Amplification	 was	 followed	 by	 analysis	 by	 agarose	 gel	electrophoresis.		
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2.17	Atomic	Absorption	Spectroscopy	(AAS)	After	preparation	of	a	1	mM	stock	of	Cu(I)	(section	2.4),	10	 injections	of	2	µl	(20	µl	 in	total)	were	 injected	 from	 the	 anaerobic	 syringe	 into	 a	 1,980	 µl	 solution	 of	 2	%	 nitric	acid.	This	was	analysed	by	atomic	absorption	spectrophotometry	(Thermo	Scientific).	A	standard	 curve	 was	 constructed	 using	 a	 metal	 standard	 (BDH)	 for	 accurate	quantification,	in	2	%	nitric	acid,	with	concentrations	from	0	–	2	ppm	copper	in	0.2	ppm	increments	used.		
2.18	Transformation	of	bacterial	strains		DNA	concentrations	were	acquired	using	a	NanoDrop	(Thermo	Scientific).	The	desired	plasmid	 (prepared	 using	 a	 miniprep	 kit,	 Sigma)	 was	 diluted	 as	 required	 to	 a	concentration	of	between	20	and	120	ng	µl-1	as	measured	by	NanoDrop.	An	aliquot	(2	µl)	of	the	plasmid	solution	was	added	to	a	50	µl	aliquot	of	competent	cells	in	a	1.5	ml	tube.	Competent	 cells	 were	 prepared	 as	 described	 previously	 using	 the	 rubidium	 chloride	method139.	The	cells	 and	plasmid	were	gently	mixed	and	 then	 incubated	on	 ice	 for	20	minutes	before	being	heat	shocked,	using	a	heat	block,	 for	1	minute	at	42	˚C.	The	cells	were	placed	immediately	on	ice	for	2	minutes	before	950	µl	LB	was	added.	Tubes	were	incubated	with	shaking	at	37	 ˚C	 for	1	hour,	and	then	200	µl	spread,	using	sterile	glass	beads,	 onto	 the	 desired	 solid	medium	 containing	 required	 antibiotics	 on	 a	 Petri	 plate	(recipes	as	stated	in	section	2.1)	except	with	the	addition	of	15	g	L-1	bacterial	agar	in	all	cases,	antibiotics	added	after	sufficient	cooling	of	 the	 liquid	agar	had	occurred).	Plates	were	incubated	at	37	˚C	overnight	or	until	colonies	appeared.	 	
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Strain	Name		 Genotype		 Reference		
E.	coli	DH5α	 fhuA2	 lac(del)U169	 phoA	 glnV44	 Φ80'	
lacZ(del)M15	 gyrA96	 recA1	 relA1	 endA1	 thi-1	
hsdR17	
Taylor	et	al.,	1993	
E.	coli	BL21	 F	 –	 ompT	 gal	 dcm	 lon	 hsdSB(rB	 -	 mB	 -	 )	 λ(DE3	
[lacI	lacUV5-T7	gene	1	ind1	sam7	nin5])	
Studier	&	Moffatt,	1986	
S.	 aureus	SH1000	 8325-4	with	rsbU	mutation	repaired		 Horsburgh	et	al.,	2002	
S.	aureus	8325-4			 NTCC8325	cured	of	prophages		 Horsburgh	et	al.,	2001	
S.	 aureus	8325-4	ΔgapA	 NTCC8325	cured	of	prophages,	ΔgapA	 Purves	et	al.,	2010	
S.	 aureus	SH1000	ΔgapA	 8325-4	with	rsbU	mutation	repaired,	ΔgapA	 this	study			
Table	2.1.	Strains	used	in	this	study,	with	their	genotype	and	reference	of	origin.	
	
PCR	Number	 Program		 Description		1	 95	˚C,	10	mins;	(95	˚C,	30	s;	60	˚C,	30	s;	72	˚C,	5	mins)	x	30;	72	˚C	10	mins		
used	for	amplification	of	the	pLEICS03-GapA	plasmid	in	mutagenesis	
2	 95	˚C,	10	mins;	(95	˚C,	30	s;	60	˚C,	30	s;	72	˚C,	3	mins)	x	30;	72	˚C	10	mins		
used	for	amplification	of	the	gapA	gene	for	mutant	verification	and	sequencing	of	 mutated	 pLEICS03-GapA	 open	reading	frame	regions	3	 95	˚C,	10	mins;	(95	˚C,	30	s;	55	˚C,	30	s;	72	˚C,	5	mins)	x	30;	72	˚C	10	mins		
used	 for	 amplification	 of	 rsbU	 for	SH1000	strain	verification		
	
Table	2.2	PCR	reactions	listed	by	number	with	the	program	used	and	description	
of	the	purpose	of	each	reaction.	All	reactions	were	carried	out	using	a	C1000	Touch	Thermo	Cycler	from	Biorad.	 	
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Primer	name		 Sequence		 Application		gapA	F	 GGTAGAATTGGTCGTTTAGC	 confirm	ΔgapA	mutant	gapA	R	 GAAAGTTCAGCTAAGTATGC	 confirm	ΔgapA	mutant	QC	PL03-GapA	H178A	For	 GGTTTAATGACTACAATTGCTGCTTACACAGGTGATC											 quick-change	of	p-Leics-03	GapA	overexpression	vector		QC	PL03-GapA	H178A	Rev	 GATCACCTGTGTAAGCAGCAATTGTAGTCATTAAACC							 quick-change	of	p-Leics-03	GapA	overexpression	vector		QC	PL03-GapA	C151A	For	 GTTTCAGGTGCTTCAGCTACTACAAACTCATTAG								 quick-change	of	p-Leics-03	GapA	overexpression	vector		QC	PL03-GapA	C151A	Rev	 CTAATGAGTTTGTAGTAGCTGAAGCACCTGAAAC							 quick-change	of	p-Leics-03	GapA	overexpression	vector		QC	PL03-GapA	C96A	For	 CGATGTAGTATTAGAAGCTACTGGTTTCTACACTG							 quick-change	of	p-Leics-03	GapA	overexpression	vector		QC	PL03-GapA	C96A	Rev	 CAGTGTAGAAACCAGTAGCTTCTAATACTACATCG							 quick-change	of	p-Leics-03	GapA	overexpression	vector		pL-03	gapA	seq	for	 ATGGCAGTAAAAGTAGCAATTAAT	 sequencing	of	pLEICS03	gene	expression	region		pL-03	gapA	seq	rev	 TTATTTAGAAAGTTCAGCTAAGTA	 sequencing	of	pLEICS03	gene	expression	region		RsbU	Amp	For	 TCAAATTATTATATACCCATC	 amplifying	and	sequencing	
rsbU		RsbU	Amp	Rev	 CCTTGCTTAAGCATTTGC	 amplifying	and	sequencing	
rsbU			
Table	2.3	Primers	used	in	this	study,	with	sequence	and	application	shown.		 	
Plasmid		 Description		 Reference		pLEICS03-SaGapA	 pLEICS03	containing	gapA	open	reading	frame	for	protein	expression	 Purves	et	al.	,	2010	pLEICS03-
SaGapA(C151A)	 pLEICS03	containing	gapA(C151A)	open	reading	frame	for	protein	expression	 this	study		pLEICS03-
SaGapA(H178A)	 pLEICS03	containing	gapA(H178A)	open	reading	frame	for	protein	expression	 this	study		pLEICS03-
SaGapA(C96A)	 pLEICS03	containing	gapA(C96A)		open	reading	frame	for	protein	expression	 this	study			
Table	 2.4.	 Plasmids	 used	 in	 this	 study,	 with	 description	 of	 application	 and	
reference	of	origin	shown.		 	
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Chapter	3:	S.	aureus	GapA	binds	to	copper,	and	is	inhibited	by	copper	in	vivo.		
3.1	Introduction	to	Chapter	3	As	discussed	 in	 the	 introduction	 (section	1.4),	 copper	 is	 toxic	 to	S.	 aureus,	whilst	 also	being	 required	 in	 trace	 amounts	 for	 growth.	 In	 this	 chapter	 the	 range	 of	 copper	concentrations	 that	 inhibit	 growth	 of	 this	 species	 was	 investigated	 in	 a	 number	 of	different	growth	media	and	using	different	carbon	sources.			Preliminary	 data	 from	 the	 Waldron	 laboratory,	 using	 chromatography-based	metalloproteomics	approaches,	identified	several	candidate	proteins	as	being	associated	with	copper	within	S.	aureus	cells	exposed	to	high	copper	concentrations	during	growth.	One	 of	 these	 proteins	 was	 GapA.	 Herein,	 the	 correct	 identification	 of	 GapA	 was	confirmed	 by	 comparison	 of	 copper	 distribution	 in	 chromatographic	 fractions	 from	 a	ΔgapA	mutant	with	wild	type	S.	aureus.	Furthermore,	by	testing	the	effects	of	copper	on	the	activity	of	SaGapA,	we	demonstrate	that	copper	inhibits	its	activity	and	propose	that	this	inhibition	is	likely	mediated	by	direct	binding	of	copper	ions	to	the	enzyme.		Despite	there	being	no	known	copper	importers	in	S.	aureus,	copper	is	present	in	many	bacterial	 cells	 in	 higher	 concentrations	 than	 in	 the	 surrounding	media,	 implying	 that	copper	 does	 enter	 the	 cells	 by	 some	 active	 mechanism	 (Figure	 3.7)73.	 Such	 an	implication	 sits	 well	 with	 the	 existence	 of	 a	 S.	 aureus	 copper	 homeostasis	 system43,	conserved	in	many	staphylococcal	genomes,	with	the	function	of	exporting	copper	from	cells140.		Intracellular	 reducing	 conditions	 are	 expected	 to	 lead	 to	 the	 predominant	 form	 of	copper	in	the	cytosol	being	the	Cu(I)	ion,	which	binds	strongly	to	a	range	of	ligands	but	particularly	 to	cysteine	 thiolates,	exhibiting	some	of	 the	highest	affinities	 found	 in	any	biological	 metal-ligand	 interactions45,85.	 Within	 the	 cytoplasm,	 copper	 is	 expected	 to	bind	overwhelmingly	to	the	copper	homeostatic	proteins	(CopA,	CopZ	and	CsoR),	which	each	 demonstrate	 very	 high	 Cu(I)	 binding	 affinities	 and	 have	 evolved	 to	 suit	 this	function43.	However,	when	copper	first	enters	the	cell,	or	when	exogenous	copper	levels	(and	thus	rate	of	copper	influx)	is	overwhelming,	it	may	be	assumed	that	the	metal	does	not	 immediately	bind	 to	 the	usual	 binding	 ligands	 and	may	 in	 fact	 bind	 to	non-native	copper	proteins	before	being	passed	to	proteins	with	higher	affinities,	 thus	having	the	
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potential	 to	 damage	 non-native	 proteins	 and	 affect	 the	 processes	 in	 which	 they	 are	involved;	perceived	experimentally	as	toxicity.		A	 fully	 effective	 copper	 homeostatic	 system	 may	 be	 expected	 to	 keep	 copper	concentrations	within	 cells	 at	 a	 concentration	 that	 does	 not	 inhibit	 growth.	 A	 growth	defect	 would	 therefore	 suggest	 that	 this	 system	 is	 overwhelmed	 somewhat	 as	intracellular	copper	concentrations	increase;	when	a	certain	intracellular	concentration	is	reached	cells	fail	to	grow,	and	above	this	cell	death	may	occur.		As	copper	homeostasis	is	overwhelmed,	what	is	copper	doing	that	leads	to	the	observed	growth	defect?	Several	intracellular	targets	of	copper	toxicity	have	been	suggested,	the	main	 candidates	 being	 iron-sulphur	 (Fe-S)	 cluster	 containing	 proteins66	 (see	Introduction;	section	1.4.1).	The	indirect	effects	of	high	levels	of	copper	have	also	been	suggested	 as	 causative	 of	 copper	 toxicity,	 such	 as	 the	 catalysis	 of	 the	 Fenton	 reaction	within	cells,	leading	to	oxidatively	damaged	macromolecules,	but	this	has	been	disputed	by	others70,141.	It	may	well	be	that	more	than	one	process	is	responsible	for	toxicity,	and	these	may	even	differ	depending	on	the	environment	that	the	cells	are	in.		It	 is	 likely	 that	as	 the	 intracellular	copper	concentration	rises,	 the	damage	that	copper	causes	 within	 cells	 also	 increases.	 Adventitious	 binding	 of	 copper	 to	 incorrect	 metal	binding	 sites	 (and	 potentially	 displacement	 of	 the	 native	 metal	 ions	 from	metalloproteins)	 may	 lead	 to	 a	 damaging	 cascade	 of	 incorrect	 metal	 binding	 and	macromolecule	 oxidation	 that	 exacerbates	 toxicity	 and	 is	 an	 effect	 of	 the	 presence	 of	overwhelming	copper	levels.		Identification	of	such	non-native	copper	targets	within	cells	is	fraught	with	complexity,	not	least	as	it	is	difficult	to	isolate	proteins	in	the	same	state	as	one	would	expect	to	find	
in	 vivo.	 The	 reducing	 potential	 of	 the	 intracellular	 environment	 is	 different	 to	extracellular	conditions;	such	a	reducing	environment	 is	critical	 to	 the	maintenance	of	homeostasis	 of	 all	 biometals	 as	well	 as	many	other	 cell	 regulatory	processes,	 and	 cell	lysis	may	well	result	in	a	rapid	change	in	metal	occupancy	sites;	if	such	a	scenario	is	not	minimised	 or	 avoided	 experimentally	 it	 may	 lead	 to	 the	 artefactual	 identification	 of	proteins	 bound	 to	metals	 (false	 positives)	 or	 a	 lack	 of	 identification	 of	 protein-metal	complexes	that	do	occur	in	vivo	(false	negatives).	
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	In	 order	 to	 identify	 potential	 targets,	 our	 approach	 has	 been	 to	 grow	 cells	 in	 media	containing	 copper	 and	 to	 prepare	 their	 cytosolic	 extracts	 under	 rigorously	 anaerobic	conditions	 to	prevent	oxidation	of	metal	 ions	or	binding	protein	 residues,	and	 then	 to	minimally	 separate	 the	 extracts	 by	 native	 multi-dimensional	 chromatography	 (again	using	 anaerobic	 conditions).	 Chromatography	 fractions	 are	 then	 analysed	 for	 protein	and	 for	 metal	 concentration,	 and	 these	 two	 values	 then	 correlated	 to	 match	 the	abundance	of	individual	proteins	within	a	sample	to	the	abundance	of	metal	in	order	to	identify	 which	 proteins	 are	 associated	 with	 the	 copper87,142.	 In	 this	 manner	 one	particular	protein,	GapA,	was	identified	amongst	others	from	preliminary	data	gathered	prior	to	this	project.		
S.	 aureus	GapA	 (SaGapA)	 is	 thought	 to	 be	 primarily	 cytosolic	where	 it	 participates	 in	central	 carbon	 metabolism	 (the	 glycolytic	 pathway),	 but	 a	 proportion	 of	 it	 has	 been	shown	to	be	localised	to	cell	wall	fractions143.	How	it	gets	to	this	location	is	unclear	as	it	has	no	pre-sequence;	cell	autolysis	could	be	a	potential	route111.	The	only	other	previous	detailed	study	of	SaGapA	function	focused	on	the	enzyme	localised	to	the	cell	wall,	via	utilisation	of	a	whole	cell	GapA	activity	assay,	and	not	upon	the	intracellular	enzyme113.	Here,	we	focus	exclusively	on	SaGapA	within	the	cytoplasm	of	the	bacteria.	 	
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3.2	 The	 growth	 of	 S.	 aureus	 is	 inhibited	 in	 liquid	 media	 by	 copper	 in	 a	 dose-
dependent	manner	Initially	we	were	 interested	 in	determining	 the	 inhibitory	effect	of	 copper	on	S	aureus	cells	in	different	concentrations	and	in	different	media.	This	would	allow	for	selection	of	a	 suitable	 concentration	 of	 copper	 in	 which	 to	 grow	 cells	 for	 subsequent	metalloproteomics	 experiments.	 This	 concentration	 is	 important,	 as	 if	 too	 high	 a	concentration	 is	 used,	 leading	 to	 intense	 growth	 inhibition,	 the	 effects	 of	 copper	may	change	the	metabolism	of	the	cells	to	such	a	degree	that	our	observed	result	would	be	an	artefact	 of	 such	 conditions,	 due	 to	 changes	 in	 expression	 patterns	 or	 other	 effects.	Furthermore,	 it	was	 required	 that	 sufficient	 bacterial	 biomass	 could	 be	 acquired	with	which	to	perform	metalloproteomics	experiments,	requiring	significant	cell	growth,	and	therefore	too	great	an	inhibition	of	growth	by	copper	was	not	desired.		Figures	 3.1	 and	 3.2	 demonstrate	 growth	 inhibition	 over	 a	 wide	 range	 of	 copper	concentrations	(0	–	10,000	μM	CuSO4)	in	four	different	types	of	growth	media.	Growth	in	TSB,	a	complex,	rich	medium	which	contains	0.25%	(w/v)	glucose	as	primary	carbon	source,	 as	well	 as	 soytone	 (a	 lysate	 of	 soya)	 and	 abundant	 casamino	 acids,	 shows	 an	unexpected	phenotype	as	growth	appears	to	be	stimulated	by	the	addition	of	copper	up	to	1,000	μM	after	5	hours,	with	 this	difference	being	 less	pronounced	after	16	and	24	hours.	 Growth	 was	 observed	 in	 TSB	 medium	 supplemented	 with	 1,000	 µM,	 but	 no	growth	was	observed	in	TSB	medium	supplemented	with	10,000	µM	copper.	This	same	trend	 (i.e.	 growth	up	 to	1,000	µM,	but	no	growth	at	10,000	µM)	was	also	observed	 in	another	rich	medium,	LB	(which	contains	 tryptone	and	yeast	extract)	and	also	 in	TSM	(which	contains	a	high	level	of	the	carbon	source	succinate).	In	these	cases	however	the	addition	of	copper	at	concentrations	between	0	µM	and	1,000	µM	did	not	make	a	notable	difference	to	growth.			A	notable	exception	to	the	trends	observed	in	TSB,	LB	and	TSM	media	was	observed	in	the	TWM	medium,	which	 shows	no	growth	at	1,000	µM	or	10,000	µM,	with	no	major	differences	 in	 growth	 seen	 at	 concentrations	 below	 these.	 The	 major	 differences	between	TWM	and	TSM	is	that	TSM	contains	succinate	as	a	carbon	source	in	addition	to	the	amino	acids	added	to	it	as	part	of	a	casmino	acid	digest,	whilst	TWM	contains	amino	acids	 added	 individually	 (and	 at	 lower	 concentrations)	 with	 no	 additional	 carbon	
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source;	in	the	case	of	TWM,	cells	are	therefore	using	amino	acids	as	their	major	carbon	source.			TSM	minus	 succinate	was	 chosen,	 herein	 referred	 to	 as	TM,	 as	 a	 standard	medium	 in	which	 to	 grow	S.	 aureus	 due	 to	 it	 being	 a	minimal,	well-defined	medium	 in	which	we	could	 manipulate	 concentrations	 of	 metals	 and	 carbon	 sources	 and	 one	 in	 which	 S.	
aureus	shows	a	high	sensitivity	to	copper,	allowing	us	to	focus	on	relatively	fine	changes	in	 growth	 brought	 about	 by	 differing	 copper	 concentrations.	 The	 primary	 source	 of	amino	 acids	 in	 TM	 is	 a	 casamino	 acid	 digest	 (as	 in	 TSM),	 supplemented	 with	 added	cysteine	and	tryptophan.	This	addition	of	just	three	reagents	as	opposed	to	18	individual	amino	 acids	 (as	 in	 TWM)	 gave	 less	 room	 for	 error	 during	 preparation	 of	 the	 media	(several	of	the	individual	amino	acids	display	poor	solubility,	 leading	to	batch-to-batch	variability)	and	meant	that	this	medium	was	more	highly	standardised	between	batches.		 	
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Figure	 3.1.	 Copper	 inhibits	 the	 growth	 of	 S.	 aureus	 in	 a	 dose-	 and	 medium-
dependent	manner.	S.	aureus	was	inoculated	into	sterile	TSB	and	LB	containing	0,	10,	100,	1,000	and	10,000	μM	CuSO4	to	a	starting	OD595	of	0.05,	and	incubated	at	37°C	with	180	rpm	orbital	 shaking.	OD595	 readings	were	 taken	at	5,	16	and	24	hour	 time	points.	The	change	in	density	(ΔOD595)	readings	are	shown,	i.e.	with	the	OD595	at	0	hours	being	equivalent	to	0.	 	
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Figure	3.2.	Copper	inhibits	the	growth	of	S.	aureus	in	a	dose-	and	medium-
dependent	manner.	S.	aureus	was	inoculated	into	TWM	and	TSM	containing	0,	10,	100,	1,000	and	10,000	μM	copper	to	a	starting	OD595	of	0.05,	and	incubated	at	37°C	with	180	rpm	orbital	shaking.	OD595	readings	were	taken	at	5,	16	and	24	hour	time	points.	The	change	in	density	(ΔOD595)	readings	are	shown,	i.e.	with	the	OD595	at	0	hours	being	equivalent	to	0.	 	
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Growth	 inhibition	 of	 S.	 aureus	 by	 copper	 was	 also	 established	 at	 a	 lower	 range	 of	concentrations	 than	 used	 in	 Figures	 3.1	 and	 3.2	 in	 TM	 without	 the	 addition	 of	 an	additional	 carbon	 source	 (Figure	 3.3)	 and	 then	 with	 the	 addition	 of	 glucose	 and	succinate	to	the	media	(Figure	3.4).		It	was	observed	that	in	the	absence	of	an	added	carbon	source	(i.e.	utilising	amino	acids	from	casamino	acids	alone),	S.	aureus	 is	not	able	to	grow	to	as	high	a	density	as	in	the	presence	of	a	carbon	source.	Indeed,	even	in	the	presence	of	1	mM	copper,	S.	aureus	 is	able	 to	 grow	 significantly	 in	TM	containing	 glucose	or	 succinate,	whereas	when	 those	carbon	sources	are	omitted,	S.	aureus	fails	to	grow	in	this	medium	with	500	µM	added	copper.	The	fact	that	S.	aureus	does	not	grow	to	the	same	density	as	that	observed	in	the	presence	of	glucose	 is	consistent	with	the	fact	that	the	carbon	source	present	 in	TM	is	amino	acids,	which	are	 less	 rich	 in	energy	 than	glucose,	being	utilised	within	 the	TCA	cycle	 when	 the	 CCR	 is	 not	 occurring,	 as	 opposed	 to	 glucose,	 the	 initial	 metabolite	 of	glycolysis	 which	 allows	 energy	 generation	 via	 glycolysis	 as	 well	 as	 producing	 useful	metabolites	which	feeds	into	the	TCA	cycle	and	other	pathways	(see	introduction).			Figure	3.5	demonstrates	 some	of	 the	higher	 concentrations	of	 copper	 that	S.	aureus	 is	able	 to	 grow	 in	 when	 glucose	 is	 available.	 It	 appears	 that	 between	 0.5	 and	 2.5	 mM	copper,	 the	 effect	 of	 increasing	 copper	 upon	 growth	 is	minor	whilst	 remaining	 dose-dependent	 in	 TM	 containing	 glucose.	 At	 3	 mM	 copper,	 a	 large	 decrease	 in	 growth	compared	 to	 the	 2.5	 mM	 sample,	 as	 well	 as	 the	 control,	 can	 be	 observed.	 As	demonstrated	in	Figure	3.1	(top	panel),	cells	grown	in	10	mM	copper	do	not	grow,	even	in	 the	 presence	 of	 glucose	 and	 other	 complex	 media	 reagents	 (present	 in	 TSB).	 The	upper	limit	of	the	copper	concentration	in	which	S.	aureus	may	grow	in	the	presence	of	0.25	%	(w/v)	glucose	is	between	5	and	10	mM	copper	(data	not	shown).		It	was	 possible	 from	 these	 data	 that	 high	 levels	 of	 glucose	may	be	 acting	 as	 a	 copper	chelator,	 effectively	 reducing	 the	 copper	 concentration	 available	 to	 cells.	 As	 stated,	copper	 has	 non-specific	 high	 affinity	 for	 many	 varied	 ligands.	 To	 explore	 possible	chelation	of	copper	by	glucose	it	was	demonstrated	that	when	S.	aureus	was	grown	in	a	3	 mM	 inhibitory	 dose	 of	 copper,	 increasing	 the	 level	 of	 glucose	 present	 made	 little	difference	to	growth	(Figure	3.6).	If	the	effect	that	glucose	has	of	increasing	the	amount	of	copper	required	to	inhibit	the	growth	of	S.	aureus	was	caused	by	copper	chelation	by	
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glucose	 itself	 in	 the	medium,	 the	 expected	 result	would	 be	 that,	 as	 glucose	 increased,	copper	exerted	less	inhibition	upon	growth.	In	fact,	copper	in	the	presence	of	5	%	(w/v)	glucose	seems	to	have	a	greater	inhibitory	effect	than	lower	concentrations	of	glucose,	which	is	probably	due	to	the	osmotic	pressures	that	such	a	high	level	of	glucose	would	exert.		If	 glucose	 does	 not	 rescue	S.	 aureus	growth	 from	 copper	 inhibition	 by	 chelation,	 then	possibilities	remain	that	it	does	so	because	of	the	energy	it	provides	to	cells	or	through	alterations	to	cellular	metabolism	which	heighten	the	resistance	of	 the	cells	 to	copper.	The	 copper	 exporter	 in	 S.	 aureus	 (CopA)	 is	 an	 ATPase,	 therefore	 utilising	 energy	released	by	hydrolysis	of	ATP	 to	 transport	 copper	across	 the	cell	membrane,	with	 the	most	 efficient	 ATP	 generation	 occurring	 in	 the	 presence	 of	 glucose.	 This	 is	 the	 most	obvious	way	that	can	explain	the	ability	of	cells	to	survive	much	higher	concentrations	of	copper	in	the	presence	of	glucose	compared	to	in	its	absence.	More	energy	may	also	be	 useful	 for	 cells	 attempting	 to	 repair	 intracellular	 damage	 that	 copper	 has	 caused.	Another	 possibility	 is	 that	 the	 presence	 of	 glucose	 causes	 heightened	 expression	 of	proteins	which	 protect	 the	 cell	 from	 copper	 damage,	 for	 example	 through	 a	 chelating	mechanism.	 An	 example	 of	 such	 a	 protein	 to	 be	 highly	 expressed	 in	 the	 presence	 of	glucose	is	SaGapA.		 	
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Figure	3.3.	S.	aureus	grown	in	TM	without	the	addition	of	a	carbon	source	has	its	
growth	 completely	 inhibited	 in	 the	 presence	 of	 500	 µM	 copper.	 S.	 aureus	 was	inoculated	 to	 an	 initial	 OD595	 of	 0.05	 in	 TM	 medium	 containing	 varying	 copper	concentrations.	An	aliquot	(300	µl)	of	each	culture	was	grown	for	24	hours	in	an	orbital	shaking	plate	reader	(180	rpm)	at	37	˚C.	Each	data	point	represents	the	average	change	in	OD595	of	3	readings	from	3	individual	experiments,	error	bars	have	been	omitted	for	clarity.	Concentrations	of	copper	used	were;	0	µM,	closed	circles;	50	µM,	closed	squares;	100	 µM,	 closed	 triangles;	 250	 µM,	 open	 circles;	 300	 µM,	 open	 squares;	 400	 µM,	 open	triangles;	500	µM,	closed	inverted	triangles.		 	
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Figure	3.4.	S.	aureus	can	grow	in	at	least	1,000	µM	copper	in	TM	in	the	presence	of	
glucose	or	succinate.	S.	aureus	was	inoculated	to	an	initial	OD595	of	0.05	in	TM	medium	containing	varying	copper	concentrations.	Aliquots	(300	µl)	of	each	culture	were	grown	for	24	hours	in	an	orbital	shaking	plate	reader	(180	rpm)	at	37	˚C.	Panel	A	shows	cells	grown	in	TM	with	the	addition	of	1%	(w/v)	glucose,	whereas	Panel	B	shows	cells	grown	in	TM	with	the	addition	of	1%	(w/v)	succinate.	Each	data	point	represents	the	average	OD595	 of	 3	 readings	 from	 3	 individual	 experiments,	 error	 bars	 have	 been	 omitted	 for	clarity.	Concentrations	of	 copper	used	were;	0	µM,	 closed	circles;	10	µM,	open	circles;	100	µM.	closed	squares;	1000	µM,	open	squares.	 	
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Figure	 3.5.	 S.	 aureus	 is	 able	 to	 grow	 in	 the	 presence	 of	 3	 mM	 copper	 in	 the	
presence	of	0.25	%	(w/v)	glucose.	S.	aureus	was	inoculated	to	an	initial	OD595	of	0.05	in	 TM	 medium	 with	 added	 glucose	 (0.25	 %	 w/v)	 containing	 varying	 copper	concentrations.	Aliquots	(300	µl)	of	each	culture	were	grown	for	24	hours	in	an	orbital	shaking	 plate	 reader	 (180	 rpm)	 at	 37	 ˚C.	Concentrations	 of	 copper	 used	were;	 0	mM,	closed	circles;	0.5	mM,	open	circles;	1	mM,	closed	squares;	1.5	mM,	open	squares;	2	mM,	closed	triangles;	2.5	mM,	closed	circles;	and	3	mM,	open	triangles.	
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Figure	 3.6.	 Increasing	 the	 glucose	 concentration	 in	 TM	 does	 not	 increase	 the	
growth	of	S.	aureus	in	the	presence	of	3	mM	copper.	S.	aureus	was	inoculated	to	an	initial	OD595	of	0.05	in	TM	medium.	Aliquots	(300	µl)	of	each	culture	were	grown	for	24	hours	in	an	orbital	shaking	(180	rpm)	plate	reader	at	37	˚C.	Each	data	point	represents	the	 average	 change	 in	 OD595	 of	 3	 readings	 from	 3	 individual	 experiments,	 error	 bars	have	been	omitted	for	clarity.	Concentrations	of	glucose	used	were	(%	w/v);	0.25,	open	circles;	0.5,	closed	squares;	1,	open	squares;	5,	closed	triangles.	
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3.3	 S.	 aureus	 cells	 grown	 under	 elevated	 copper	 conditions	 increase	 their	
intracellular	levels	of	copper,	but	not	of	other	metals	As	we	were	interested	in	the	effects	of	copper	within	the	cytoplasm	of	S.	aureus	we	next	determined	 whether	 those	 cells	 accumulated	 cytoplasmic	 copper	 copper.	 Figure	 3.7	demonstrates	 that	 cells	 cultured	 in	 TM	 containing	 no	 added	 carbon	 source,	 with	 the	addition	 of	 0,	 10	 and	 100	 µM,	 accumulate	 copper	 with	 an	 increase	 in	 the	 amount	 of	cellular	copper	observed	in	all	of	these	conditions.		As	observed	in	Figure	3.3	of	S.	aureus	grown	in	TM	without	added	carbon,	the	OD595	of	S.	
aureus	 does	 not	 increase	 as	much	 as	 when	 100	 µM	 copper	 is	 added	 to	 the	media.	 It	should	be	noted	that	the	data	shown	in	Figure	3.7	has	not	been	adjusted	for	cell	count,	thus	the	apparent	reduction	 in	uptake	of	copper	as	copper	concentration	 in	the	media	rises	to	10	µM	from	100	µM	is	most	likely	a	product	of	a	lower	of	number	of	cells	within	the	sample.		From	these	results	we	can	also	observe	that	the	import	of	other	biometals	(manganese,	iron,	cobalt	and	zinc)	 is	not	affected	by	the	addition	of	copper	to	the	medium,	with	no	observed	 increase	 or	 decrease	 in	 any	 other	 metal	 recorded	 in	 this	 experiment.	 As	mentioned	in	the	introduction,	the	route	by	which	copper	enters	S.	aureus	cells	remains	unknown,	 and	 it	 remains	 possible	 that	 copper	 accesses	 cells	 by	 hijacking	 the	 known	importers	 of	 other	 transition	 metal,	 but	 such	 a	 scenario	 has	 yet	 to	 have	 been	demonstrated.	 The	 results	 here	 are	 as	 expected,	 a	 change	 in	 the	 presence	 of	 another	metal	due	to	the	addition	of	copper	was	not	hypothesised.			 	
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Figure	3.7.	Increased	copper	can	be	detected	by	ICP-MS	in	the	cytosolic	extracts	of	
cells	grown	in	copper.	S.	aureus	SH1000	was	grown	from	a	starting	OD595	of	0.05	in	TM	with	glucose	(0.25%	w/v)	with	shaking	(180	rpm)	at	37	˚C	for	6	hours.	CuSO4	was	added	to	the	media	at	concentrations	of	0	µM	(black	bars),	10	µM	(light	grey	bars)	and	100	µM	(dark	 grey	 bars).	 Cells	 were	 washed	 with	 and	 then	 without	 EDTA	 to	 remove	 excess	copper	and	then	lysed	using	a	bead	beater.	The	lysate	was	diluted	30	fold	in	2.5	%	nitric	acid	and	the	sample	tested	for	metal	content	by	ICP-MS.		 	
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3.4	 GapA	 co-migrates	 with	 copper	 in	 chromatographic	 fractions	 from	 copper-
treated	S.	aureus	cells	As	stated	in	the	introduction	to	this	chapter,	preliminary	data	obtained	in	the	Waldron	lab	 prior	 to	 the	 start	 of	 this	 project	 had	 suggested	 that	 the	 enzyme	 SaGapA	 might	associate	with	copper	in	cells	cultured	under	elevated	copper	conditions.	Data	from	one	example	 of	 such	 an	 experiment,	 conducted	 by	 Dr	 Emma	 Tarrant	 (Waldron	 Group,	Newcastle	University),	is	shown	in	Figure	3.8	and	Figure	3.9.		After	growing	SH1000	S.	aureus	cells	 in	elevated	copper	medium	(500	µM	in	TSB),	the	cell	 pellet	 was	 lysed	 and	 cytoplasmic	 extract	 was	 prepared	 and	 separated	 under	rigorously	 anaerobic	 conditions	 by	 multi-dimensional	 liquid	 chromatography.	 Two	rounds	of	chromatography	was	necessary	as	the	mixture	of	proteins	in	single	fractions	after	one	round	was	still	too	complex	for	effective	analysis.	Fractions	derived	from	the	chromatography	were	analysed	by	 ICP-MS,	as	well	as	being	resolved	by	SDS-PAGE	 for	protein	analysis.	This	allowed	allocation	of	one	of	the	copper	pools	identified	by	ICP-MS	to	protein	bands	resolved	by	SDS-PAGE.			Figure	3.8	shows	one	example	of	this	preliminary	data	whereby	GapA	was	identified	in	the	 same	 fractions	 as	 copper.	The	 corresponding	SDS-PAGE	gels	 for	 selected	 fractions	are	 also	 shown	 (Figure	 3.9).	 Bands	 upon	 the	 gel	 that	 were	 deemed	 to	 be	 of	 interest,	which	 peaked	 in	 the	 same	 chromatographic	 fractions	 as	 the	 copper,	 were	 identified	using	MALDI-TOF	analysis	of	a	slice	of	the	gel.	These	bands	were	selected	by	statistical	analysis	 of	 the	 ICP-MS	 data	 and	 densitometry	 analysis	 of	 SDS-PAGE	 gels,	 specifically	principal	component	analysis	and	correlation	analysis	(data	not	shown).			This	 experiment	 was	 performed	 several	 times,	 and	 GapA	 was	 identified	 in	 copper-containing	fractions	on	each	occasion	(data	not	shown).		 	
69	
	
	
Figure	 3.8.	 Metalloproteomics	 analysis	 of	 cytoplasmic	 extracts	 from	 S.	 aureus	
SH1000	 cells	 grown	 in	 50	 µM	 copper.	 Panels	 A	 and	 B:	 Protein	 concentration	 is	displayed	in	mAU	(left	Y-axis,	black	line),	copper	concentration	in	ppb	(right	y-axis,	grey	line)	and	elution	volume	in	ml	(x-axis).	Panel	A:	A	cytoplasmic	extract	of	SH1000,	grown	in	TSB	containing	50	µM	copper,	was	initially	applied	to	a	hydroxyapatite	column.	The	flow-through	from	this	column	contained	a	copper	peak	identified	by	ICP-MS	(data	not	shown).	This	 flow-through	material	was	 applied	 to	 an	 anion	 exchange	 (Q-HP)	 column	using	a	NaCl	gradient	(panel	A,	black	dashed	line,	0	–	1	M	NaCl),	the	analysis	of	which	is	shown	 in	 panel	 A.	 The	 fraction	 eluting	 at	 27	 ml	 from	 this	 separation	 contained	 a	relatively	 high	 amount	 of	 copper,	 and	 was	 subsequently	 applied	 to	 a	 size-exclusion	column	(Superdex	200	Increase	10/300	GL,	GE;	 flowrate,	1	ml	min-1;	buffer,	150	NaCl,	20	mM	Tris,	pH	7.5),	the	analysis	of	which	is	shown	in	panel	B.	Eluent	from	both	anion	exchange	 and	 size	 exclusiojn	 chromatography	 was	 then	 analysed	 by	 ICP-MS.	 Data	acquired	by	Dr	Emma	Tarrant	(Waldron	Group,	Newcastle	University).	 	
70	
	
	
	
	
Figure	3.9.	Oriole	stained	SDS-PAGE	gel	of	cell	lysates	after	separation	using	multi-
dimensional	 liquid	 chromatography.	 SDS-PAGE	 analysis	 of	 size	 exclusion	 fractions	from	Figure	3.8;	panel	B,	demonstrated	a	prominent	band,	identified	as	GapA,	eluting	in	the	fraction	corresponding	to	12-12.5	ml	 identified	by	MALDI-TOF	PMF,	where	copper	also	peaks.	SaGapA	 is	highlighted	 in	 red	 in	12-12.5	ml;	 it	 is	 by	 far	 the	most	 abundant	protein	in	this	fraction.	Data	acquired	by	Dr	Emma	Tarrant	(Waldron	Group,	Newcastle	University).	
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3.5	Confirmation	of	 a	ΔgapA	mutant	of	S.	 aureus	and	 its	 successful	 transduction	
into	SH1000	from	8325-4	As	preliminary	data	showed	that	SaGapA	was	potentially	bound	to	copper	after	 it	was	extracted	 from	 cells	 grown	 in	 elevated	 copper	 conditions,	 a	 ΔgapA	mutant	 of	 SH1000	was	 costructed	 in	 order	 to	 confirm	 this	 identification	 and	 to	 compare	 the	 effects	 of	copper	on	WT	S.	aureus	with	those	upon	a	ΔgapA	mutant	in	vivo.		
	We	obtained	a	S.	aureus	8325-4	ΔgapA	mutant	from	the	University	of	Leicester	(a	kind	gift	 from	Dr	 Julie	Morrissey).	Before	undertaking	experimental	work	with	 this	mutant,	we	 confirmed	 the	 existence	 of	 the	 correct	 mutation	 (data	 not	 shown)	 using	 PCR	amplification	of	 the	gene	 in	 the	WT	and	 in	 the	mutant,	 the	 latter	of	which	contains	an	inserted	tetracycline	resistance	cassette	(Figure	3.10).		As	discussed	in	the	introduction,	S.	aureus	8325-4	has	a	mutation	in	the	rsbU	gene	which	prevents	 it	 from	 being	 able	 to	 cope	 effectively	 with	 oxidative	 stress.	 As	 this	 project	utilises	copper	which	is	purported	in	some	cases	to	lead	to	a	rise	in	oxidative	stress,	 it	was	important	to	work	with	a	strain	that	was	able	to	cope	with	this	stress	in	a	manner	resembling	a	WT	strain.	Therefore,	after	confirming	the	correct	mutation	in	8325-4,	we	transduced	 the	 ΔgapA	 mutation	 from	 8325-4	 (transduction	 was	 performed	 by	 A.	Barwinska-Sendra,	 Waldron	 group)	 into	 SH1000,	 which	 has	 had	 its	 rsbU	 mutation	corrected24,	utilising	a	standard	φ11	phage	transduction	technique	(see	methods).			The	 mutation	 of	 rsbU	 in	 8325-4	 is	 an	 11	 base	 pair	 deletion	 within	 the	 gene.	 It	 is	therefore	difficult	 to	see	 the	difference	 in	size	between	amplicons	generated	 from	this	gene	 in	 SH1000	 versus	 8325-4	 when	 visualised	 on	 an	 agarose	 gel.	 We	 therefore	designed	 a	 DNA	 digest	 using	 the	 enzyme	 ApoI	 which	 cuts	 differentially	 within	 these	amplicons	due	 to	 the	11	base	pair	 difference,	with	 a	 site	present	 in	 the	mutated	 rsbU	gene	but	not	in	the	repaired	gene	of	SH1000.	A	digest	of	the	amplicons	generated	from	the	two	strains	separated	by	agarose	gel	electrophoresis	demonstrated	that	our	SH1000	ΔgapA	mutant	strain	was	indeed	within	an	SH1000	genetic	background	with	regard	to	
rsbU	 two	 bands	 appeared	 in	 the	 case	 of	mutant	 gene	 and	 only	 one	 in	 the	 case	 of	 the	WT(data	not	shown).			 	
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Figure	 3.10.	 DNA	 gel	 demonstrating	 the	 presence	 of	 a	 tetracycline	 resistance	
cassette	within	the	gapA	gene	of	the	SH1000	ΔgapA	strain.	Left)	agarose	gel	showing	PCR	 products	 amplified	 from	 genomic	 DNA	 from	 SH1000	 WT	 (lane	 1)	 and	 SH1000	ΔgapA	(lane	2)	using	primers	flanking	the	gapA	gene.	The	larger	product	produced	using	the	mutant	DNA	is	diagnostic	of	the	presence	of	a	tetracycline	resistance	cassette	within	the	gene,	removing	its	functionality.	Lanes	3	and	4	are	positive	controls	(amplification	of	a	 region	 of	 genomic	DNA	upstream	of	 the	 copZ	 gene)	 and	 lanes	 5	 and	 6	 are	 negative	controls	 (no	 template	 DNA	 present)	 using	 identical	 template	 DNA	 as	 in	 1	 and	 2	respectively.	 Right)	 schematic	 diagram	 of	 tetracycline	 resistance	 cassette	 insertional	inactivation	of	gapA,	demonstrating	the	position	of	 the	cassette	and	primers	used.	The	precise	 size	 of	 the	 SH1000	WT	product	 is	 1053	 bp	 and	 of	 the	 SH1000	ΔgapA	mutant	product	is	2189	bp.	Primers	were	designed	by	researchers	at		the	University	of	Leicester	(Morrissey	group).		 	
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3.6	 Phenotypic	 analysis	 of	 SH1000	 ΔgapA	 confirms	 inability	 to	 grow	 in	 the	
presence	of	glucose	After	 successful	 transduction	 of	 the	 ΔgapA	mutation	 into	 SH1000,	 we	 confirmed	 the	same	growth	phenotype	for	SH1000	ΔgapA	in	TM	as	has	been	shown	for	8325-4	ΔgapA	(Figure	3.11),	i.e.	that	the	WT	will	grow	in	glucose,	but	the	SH1000	ΔgapA	will	not.	The	phenotype	 shown	by	 the	ΔgapA	mutant	 in	glucose	 is	due	 to	 the	mechanism	of	 carbon	catabolite	 repression	 (CCR)	 via	 the	 CrpA	 protein.	 CCR	 is	 a	mechanism	 that	 represses	expression	 of	 genes	 required	 for	 S.	 aureus	 to	 grow	 in	 the	 absence	 of	 glycolytic	conditions144,145,	 which	 is	 discussed	 at	 length	 in	 the	 introduction	 to	 this	 work.	When	glucose	or	other	specific	metabolites	(such	as	lactose)	are	present,	the	enzymes	required	for	growth	under	other	carbon	source	limited	conditions	are	not	required;	expression	of	their	 genes	 is	 therefore	 repressed	 in	 order	 to	 save	 energy	 and	 nutrients.	 In	 glucose	replete	 conditions,	 GapA	 is	 utilised	 as	 part	 of	 the	 glycolysis	 pathway	 and	 is	 therefore	required	for	cells	to	grow	under	these	conditions.		In	a	ΔgapA	mutant,	glycolysis	does	not	function.	Therefore	the	ΔgapA	mutant	will	fail	to	grow	in	the	presence	of	glucose,	even	if	there	are	other	carbon	sources	available.	This	is	because	catabolite	repression	continues	to	function	in	the	mutant,	meaning	that	cells	are	effectively	 forcing	 themselves	 to	utilise	 the	 glycolysis	pathway	despite	 its	malfunction	due	to	the	absence	of	the	GapA	enzyme.		When	 glucose	 is	 not	 present,	 as	 in	 TM	 alone	 and	 TM	 with	 the	 addition	 of	 pyruvate,	catabolite	 repression	 does	 not	 occur	 and	 cells	 are	 able	 to	 utilise	 secondary	 carbon	sources	such	as	those	shown	in	Figure	3.11;	pyruvate	and	amino	acids.			 	
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Figure	3.11.	SH1000	WT	grows	in	glucose	whereas	a	SH1000	ΔgapA	mutant	does	
not.	Starter	cultures	of	S.	aureus	SH1000	WT	(A)	and	SH1000	ΔgapA	(B)	cells	grown	in	TM	 were	 diluted	 100-fold	 into	 TM	 containing	 various	 carbon	 sources	 (1	 %	 glucose,	triangles;	 5	 mM	 pyruvate,	 circles;	 no	 added	 carbon	 source,	 squares).	 Change	 in	 OD	(ΔOD595)	was	measured	every	hour	 for	14	hours.	Data	 shown	are	 an	average	of	 three	independent	data	sets,	each	performed	in	triplicate,	error	bars	have	been	removed	for	clarity.	 This	 growth	 assay	 was	 performed	 in	 a	 CoStar®	 96	 well,	 flat-bottomed	 plate,	shaking	(180	rpm)	at	37°C.	Data	shown	is	representative	of	3	independent	experiments.		 	
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3.7	SH1000	ΔgapA	shows	the	same	growth	phenotype	in	copper	as	the	WT	It	was	thought	that	if	copper	was	binding	to	SaGapA	then	the	enzyme	may	be	providing	some	 protective	 effect	 to	 the	 cell,	 effectively	 acting	 as	 a	 copper	 sink,	 even	 if	 just	 a	fraction	of	the	total	amount	of	SaGapA	present	was	doing	this.		If	this	was	the	case	then	one	would	hypothesise	a	decreased	resistance	to	growth	in	copper	in	a	ΔgapA	mutant.			To	 investigate	 this,	 the	 SH1000	 WT	 and	 SH1000	 ΔgapA	mutant	 were	 grown	 in	 TM	without	 any	 added	 carbon	 source,	 containing	 varying	 concentrations	 of	 copper.	Contrary	to	the	hypothesised	outcome	of	this	experiment,	no	significant	difference	was	seen	between	growth	of	the	WT	versus	the	mutant	(Figure	3.12)	under	these	conditions.			Both	 strains	 showed	 no	 growth	 in	 500	 µM	 copper,	 as	 seen	 previously	 (Figure	 3.3).	Whilst	the	strains	showed	similar	growth	in	all	other	concentrations	of	copper	used.		 	
3.8	SH1000	ΔgapA	shows	poorer	growth	in	succinate	than	the	WT	in	the	absence	
of	copper	Due	to	the	inability	of	S.	aureus	to	grow	in	glucose,	and	no	difference	in	the	growth	of	the	SH1000	ΔgapA	mutant	 compared	 to	 the	WT	 in	 copper,	 the	 growth	 of	 the	 two	 strains	were	 compared	 in	 TM	 with	 the	 addition	 of	 succinate.	 Under	 such	 conditions	 the	glycolytic	function	of	S.	aureus	should	not	be	required	and	therefore	it	was	hypothesised	that	the	two	mutants	would	grow	identically	without	the	addition	of	copper.		In	 fact,	 the	 ΔgapA	mutant	 grew	 much	 less	 in	 succinate	 than	 the	 WT.	 This	 result	 is	difficult	to	explain,	but	it	may	be	that	some	of	the	hypothesised	regulatory	functions	of	
SaGapA	have	 a	 role	 to	 play	 in	 the	metabolism	of	 glucose.	 In	 addition,	 the	 presence	 of	glucose	 in	the	media	did	not	have	a	significant	effect	upon	the	growth	of	either	strain,	relative	to	their	controls	(Figure	3.13).	 	
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Figure	3.12.	Growth	analysis	of	 SH1000	WT	versus	SH1000	ΔgapA.	 Cultures	 (300	µl)	 of	 SH1000	WT	 (Panel	A)	 and	SH1000	ΔgapA	were	 grown	 from	a	 starting	OD595	 of	0.05	 in	 TM	 (without	 an	 additional	 carbon	 source)	 at	 37	 ˚C	 shaking	 (180	 rpm)	 in	 an	orbital	 plate	 reader.	 Concentrations	 of	 copper	 used	 in	 the	 media	 were;	 0	 µM,	 black	circles;	 50	 µM,	white	 circles;	 100	 µM,	 black	 squares;	 250	 µM,	white	 squares;	 500	 µM,	triangles.			 	
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Figure	3.13.	Growth	analysis	of	SH1000	WT	versus	SH1000	ΔgapA	after	16	hours	
in	TM	containing	succinate.	Cultures	(300	µl)	of	SH1000	WT	and	SH1000	ΔgapA	were	grown	from	a	starting	OD595	of	0.05	in	TM	with	the	addition	of	succinate	(1	%	w/v)	as	a	carbon	source	at	37	˚C	shaking	in	an	orbital	plate	reader.	Data	shown	is	the	OD595	after	16	hours	of	growth.	Strains	were	grown	without	the	addition	of	copper	(WT	control	and	ΔgapA	control),	with	the	addition	of	10	µM	copper	(WT	10	µM	CU	and	ΔgapA	10	µM	Cu)	and	with	the	addition	of	100	µM	copper	(WT	100	µM	CU	and	ΔgapA	100	µM	Cu)			 	
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3.9	An	assay	to	measure	the	enzymatic	activity	of	GapA	in	S.	aureus	As	 explored	 in	 the	 introduction,	 GapA	 is	 an	 enzyme	 that	 catalyses	 the	 conversion	 of	glyceraldehyde	3-phosphate	into	1,3-bisphosphoglycerate,	and	as	part	of	this	reaction	it	utilises	NAD+	as	a	cofactor	which	 it	converts	to	NADH.	 	NADH	absorbs	strongly	at	340	nm	whereas	NAD+	does	not.	We	are	therefore	able	to	measure	the	activity	of	the	enzyme	
in	 vitro	 by	 observing	 the	 change	 in	 absorbance	 of	 the	 reaction	 at	 340	 nm	 using	 an	enzyme	 specific	 assay.	 This	 assay	 has	 been	 used	 successfully	 by	 others	 in	 previous	studies	concentrating	on	GapA	in	S.	aureus113.			Throughout	this	work,	we	have	used	an	enzyme	assay	to	observe	the	activity	of	GapA	in	cells	and	in	purified	SaGapA	preparations,	and	to	determine	the	effects	of	adding	copper	and	other	metals	and	reagents	on	the	enzyme	activity.			We	have	taken	two	approaches	when	performing	this	assay	in	vivo.	Firstly	to	grow	cells	within	 a	medium	 containing	 copper,	 followed	 by	 cell	 lysis	 and	 preparation	 of	 soluble	extracts	 to	 assay	GapA	 activity;	 or	 secondly,	 to	 grow	 cells	 in	 a	medium	 containing	 no	added	metal,	 then,	after	preparation	of	the	soluble	extract,	 to	add	the	desired	metal	to	the	lysate	prior	to	assaying	for	enzyme	activity.		The	 former	 experimental	 approach	 requires	 uptake	 of	 the	 metal	 by	 cells,	 and/or	changes	to	metabolism	caused	by	the	metal,	and	any	inhibition	would	then	be	the	result	of	intracellular	metal	upon	GapA.	The	latter	removes	the	cell	wall	and	membrane	prior	to	 metal	 addition	 and	 therefore	 effectively	 increases	 the	 concentration	 of	 metal	treatment	to	which	GapA	relative	to	the	first	approach.	It	also	demonstrates	the	effects	of	a	given	treatment	upon	GapA	within	the	complex	cytoplasmic	milieu	of	proteins	and	other	macromolecules	that	are	present	in	a	lysate,	but	effects	would	not	be	the	result	of	a	regulatory	change	as	cells	are	killed	via	lysis	before	the	metal	is	added.		During	this	study	this	assay	has	been	performed	using	two	types	of	spectrophotometer.	Firstly,	 using	 a	 plate-reader	 based	 spectrophotometer	 (Biotek)	 that	 takes	 a	 reading	every	 10	 seconds	 of	 a	 number	 of	 samples	 simultaneously.	 This	 allows	 numerous	samples	 to	 be	 analysed	 under	 precisely	 the	 same	 conditions.	 The	 plate	 reader	spectrophotometer	 also	 allows	 for	 various	 path	 lengths	 to	 be	 used,	 which	 affects	 the	conversion	of	absorbance	readings	into	concentrations	of	reagents	(NADH	in	this	case)	
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using	 the	 Beer-Lambert	 law	 (A	 =	 εCl).	 Typically	 a	 reaction	 set	 up	within	 a	multi-well	plate	 for	 analysis	 in	 the	 plate-reader	 spectrophotometer	 has	 a	 volume	 of	 200	 µl.	Secondly,	 a	 cuvette	 based	 spectrophotometer	 (Perkin	 Elmer)	 	 has	 been	 used,	 which	analyses	 one	 sample	 at	 a	 time,	 but	 is	 much	 more	 sensitive	 than	 the	 plate	 reader	spectrophotometer	and	is	able	to	take	readings	every	two	seconds.	Reactions	set	up	for	analysis	in	this	spectrophotometer	are	performed	in	a	quartz	cuvette	(Hellma)	that	has	a	precise	path	length	of	1	cm.	Both	of	these	spectrophotometers	have	the	disadvantage	of	having	a	time	lag	between	the	initiation	of	the	reaction	and	the	initial	reading	at	340	nm,	which	 means	 that	 the	 very	 start	 of	 the	 reaction	 cannot	 be	 measured.	 The	 nature	 of	taking	the	absorbance	over	a	time	period	allows	the	measurement	of	a	rate	of	activity.		Because	 of	 the	 nature	 of	 the	 plate	 reader	 spectrophotometer	 having	 a	 variable	 path-length	depending	on	the	volume	of	the	reaction	analysed,	 it	was	necessary	to	compare	their	 outputs.	 This	 allowed	 a	 correction	 factor	 to	 be	 calculated	 to	 adjust	 all	 activity	assays	 according	 to	 a	 path-length	 of	 1	 cm	 (equivalent	 to	 the	 Perkin	 Elmer	spectrophotometer).	We	observed	that	a	reaction	volume	of	300	µl	 in	the	plate	reader	spectrophotometer	 gave	 very	 similar	 reading	 to	 those	 observed	 in	 the	 Perkin	 Elmer	spectrophotometer.	Results	are	shown	in	Figure	3.14.		 	
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Figure	 3.14.	 NADH	absorbance	 at	 340	nm	measured	 in	 different	 volumes	 in	 the	
plate-reader	 spectrophotometer	 and	 in	 the	 Perkin	 Elmer	 spectrophotometer.	NADH	at	 various	 concentrations	 in	buffer	 (150	mM	NaCl,	 40	mM	HEPES,	 pH	7.5)	was	analysed	 in	 volumes	 of	 100	 µl	 (triangles),	 200	 µl	 (inverted	 triangles),	 and	 300	 µl	(circles)	and	in	the	Perkin	Elmer	plate	reader	(squares).		 	
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3.10	S.	aureus	ΔgapA	mutant	lysates	lack	GAPDH	activity	using	an	enzyme-specific	
activity	assay	Initially,	using	the	assay	described	above,	we	assayed	the	activity	of	GapA	present	 in	a	SH1000	WT	lysate	compared	to	a	SH1000	ΔgapA	mutant	lysate	without	any	added	metal	(Figure	3.15).	This	confirmed	that	GapA	 is	specifically	required	 in	order	 to	observe	an	increase	in	absorbance	at	340	nm	under	the	conditions	of	the	reaction,	and	verified	that	the	ΔgapA	mutant	constructed	(Figure	3.10)	was	not	producing	an	active	GapA	enzyme.	Further	 to	 this,	 control	 reactions	 lacking	 the	 substrate	 (G3P),	 cofactor	 (NAD+)	 and	protein	 have	 been	 performed,	 showing	 that	 these	 are	 all	 required	 for	 activity	 to	 be	observed	in	the	WT	lysates	as	would	be	expected	from	the	chemistry	of	the	reaction	that	GapA	catalyses	(Figure	3.16).			Notably,	GapB,	the	GapA	orthologue	in	S.	aureus	which	is	present	in	the	SH1000	ΔgapA	mutant	lysate	does	not	produce	an	increase	in	A340	as	measured	by	this	assay.	This	is	again	consistent	with	data	shown	by	Purves	et	al.	who	demonstrated	that	GapB	did	not	show	NAD+	dependent	activity113.			Regarding	 the	 data	 shown	 in	 Figure	 3.15,	 if	 the	 increase	 in	 absorbance	 at	 340	 nm	between	10	and	20	seconds	is	calculated,	we	can	present	this	increase	in	A340	as	a	rate	of	reaction	over	this	discrete	period	of	time.	This	allows	for	a	different	presentation	of	the	data	 that	gives	a	 snapshot	of	 the	 reaction	 rate	and	allows	 for	 the	comparison	of	a	number	 of	 samples.	 We	 can	 convert	 the	 change	 in	 absorbance	 at	 340	 nm	 into	 a	concentration	 of	 NADH	 produced	 using	 the	 Beer-Lambert	 law,	 and	 the	 published	extinction	 coefficient	 (ε)	 of	 NADH	 at	 340	 nm	 of	 6,220	M-1	 cm-1,	 allowing	 the	 enzyme	activity	 to	 be	 expressed	 as	 the	 amount	 of	 NADH	 produced	 per	 unit	 time,	 per	 unit	concentration	of	protein	in	the	sample.	Thus,	using	the	data	shown	in	Figure	3.15	we	can	subsequently	produce	Figure	3.17.		Analysis	of	 this	data	shows	that	 the	WT	lysate	produced	26.81	nmoles	NADH	minute-1	mg	protein-1	in	the	given	time	period,	much	more	than	the	ΔgapA	lysate	which	shows	a	value	that	is	close	to	zero	(1.61	nmoles	NADH	minute-1	mg	protein-1).	The	small	amount	of	 activity	 observed	 in	 the	 SH1000	ΔgapA	 lysate	 is	within	 the	 noise	 generated	 in	 this	assay,	as	defined	by	the	rise	in	A340	shown	in	control	assays	that	demonstrate	that	even	when	protein,	cofactor	or	substrate	are	present	there	is	still	a	rise	in	absorbance	(Figure	
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3.16).	GapA	activity	assays	will	be	shown	in	the	format	shown	in	Figure	3.17	from	herein	unless	otherwise	stated.		 	
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Figure	 3.15.	 SaGapA	 activity	 is	 detectable	 in	 a	 SH1000	WT	 lysate,	 but	 not	 in	 a	
SH1000	ΔgapA	mutant	lysate.	A	lysate	from	WT	SH1000	cells	results	in	an	increase	in	absorbance	 at	 340	 nm,	 whilst	 a	 ΔgapA	 SH1000	 lysate	 shows	 very	 little	 increase.	 An	aliquot	(15	µl)	of	SH1000	lysate	from	SH1000	WT	cells	(closed	circles)	or	SH1000	ΔgapA	cells	 (open	 circles)	 adjusted	 for	 equal	 protein	 concentration	 was	 added	 to	 185	 µl	 of	reaction	buffer	and	the	absorbance	of	NADH	(at	340	nm)	was	monitored	over	time	in	a	plate	reader.	The	reaction	was	performed	at	room	temperature.		 	
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Figure	 3.16.	 Added	 substrate	 (G3P),	 cofactor	 (NAD+)	 and	 enzyme	 (GapA)	 are	 all	
required	for	a	significant	rise	in	A340	to	occur.	Reactions	contain	(see	methods	for	concentrations):	 +SaGapA,	 recombinant	 SaGapA,	 NAD+	 and	 G3P;	 -SaGapA,	 NAD+	 and	G3P;	 -NAD+,	 recombinant	 SaGapA	 and	 G3P;	 -G3P,	 SaGapA	 and	 NAD+;	 -G3P	 –	 NAD+,	
SaGapA;	+BCS	-SaGapA,	NAD+,	G3P	and	BCS.	Each	reaction	containing	SaGapA	contained	5	 µM	 enzyme	 and	 all	 reactions	 contained	 50	 mM	 sodium	 phosphate.	 This	 data	 was	previously	 used	 in	 a	 non-publicly	 accessible	 Newcastle	 University-submitted	dissertation	written	by	the	author	(Jack	Stevenson).	
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Figure	 3.17.	 A	 lysate	 from	WT	 SH1000	 shows	 SaGapA	 activity,	 whilst	 a	 SH1000	
ΔgapA	mutant	lysate	shows	negligible	activity.	15	µl	of	SH1000	lysate	from	SH1000	WT	cells	or	SH1000	ΔgapA	cells	adjusted	for	protein	concentration	was	added	to	185	µl	of	 reaction	 buffer.	 Data	 here	 is	 adapted	 from	 that	 shown	 in	 Figure	 3.15	 using	 data	between	10	and	20	seconds..	
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3.11	SaGapA	activity	is	inhibited	in	cells	grown	in	media	containing	high	copper		It	was	of	interest	to	examine	how	extracellular	copper	within	the	growth	medium	would	affect	 the	activity	of	SaGapA	within	cytoplasmic	extracts	and	how	this	 correlated	with	growth	phenotypes.	The	results	of	such	an	experiment	can	be	observed	in	Figure	3.18.		Here,	S.	 aureus	was	 grown	 in	TM	with	0.25	%	glucose	 (w/v)	 for	 4	 hours	 before	 lysis,	extract	preparation	and	assaying	of	GapA	activity	(Figure	3.18).		Cells	were	washed	thoroughly	in	a	buffer	containing	5	mM	EDTA	(which	is	in	excess	to	the	highest	copper	concentration	used	in	this	experiment)	three	times	before	lysis	was	performed.	This	was	 to	prevent	 any	 residual	 copper	 in	 the	 extracellular	 fraction	 from	mixing	with	the	intracellular	fraction	upon	lysis.	Such	a	situation	could	have	resulted	in	a	greater	concentration	of	copper	binding	to	cytoplasmic	proteins	and	exaggerated	any	inhibitory	effects.	Thorough	washing	aimed	to	prevent	this.		 	Growth	data	(though	acquired	from	separate	cultures)	for	some	of	the	concentrations	of	copper	used	here	can	be	seen,	in	the	same	medium,	in	Figure	3.3	(Panel	A)	(100	µM)	and	in	 Figure	 3.4.	We	 can	 see	 that	 there	 is	 inhibition	 of	 growth	 upon	 addition	 of	 500	 µM	copper	to	the	medium	but	that	cells	can	cope	with	higher	concentrations	of	copper	than	this.	Ideally,	a	GapA	assay	of	activity	of	cells	in	these	higher	concentrations	would	have	been	 performed	 but	 in	 the	 interest	 of	 timely	 submission	 of	 this	 work	 this	 was	 not	possible.	 The	 data	 point	 for	 the	 assay	 performed	 from	 lysates	 produced	 from	 cells	grown	in	400	µM	copper	shows	what	appears	to	be	inhibition	of	activity	(the	difference	between	the	control	and	this	value	is	however	statistically	insignificant,	P	=	0.1633).	One	might	 assume	 that	 increasing	 concentrations	 would	 increase	 this	 effect.	 Presumably	even	at	higher	concentrations	of	copper,	SaGapA	is	not	saturated	with	copper	as	within	glucose,	as	we	have	observed,	cells	lacking	SaGapA	activity	will	not	grow.	
	Little	 inhibition	 of	 SaGapA	 under	 elevated	 copper	 growth	 conditions	 does	 not	 rule	
SaGapA	out	of	involvement	in	copper	toxicity.	It	may	be	that	copper	is	binding	to	SaGapA	as	levels	of	intracellular	Cu(I)	increase	above	a	certain	threshold,	but	that	the	cell	is	able	to	compensate	for	this	by,	for	example,	increasing	expression	of	SaGapA.	If	this	was	the	case,	 the	 enzyme	would	 essentially	 be	 acting	 as	 a	 copper	 sink,	 and	would	 in	 essence	
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function	 as	 part	 of	 the	 copper	 homeostasis	 system	 by	 preventing	 damage	 to	 other	proteins	and	keeping	cells	in	a	viable	state.			 	
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Figure	 3.18.	 SaGapA	 is	 not	 significantly	 inhibited	 in	 cell	 lysates	 produced	 from	
cells	grown	in	concentrations	of	copper	up	to	400	µM.	Cells	were	grown		in	TM	with	glucose	(0.25%	w/v)	at	37	˚C	for	4	hours	 in	an	orbital	shaker	(180	rpm),	before	being	thoroughly	washed	 (3	 x)	 in	 5	mM	EDTA	 and	 lysed.	 Lysates	were	 assayed	 for	 SaGapA	activity	 using	 a	 plate	 reader	 spectrophotometer	 (Biotek)	 using	 the	 standard	 method	(see	materials	and	methods).	Each	lysate	was	adjusted	to	a	concentration	of	50	µg	ml-1	before	 15	 µl	 was	 added	 to	 a	 96	 well	 plate.	 Reaction	 buffer	 (185	 µl)	 was	 added	immediately	prior	to	observation	of	the	reaction	at	A340.	Data	shown	is	the	production	of	NADH	per	minute	per	mg	of	added	protein	between	10	and	20	seconds	of	the	reaction.				 	
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3.12	 The	 copper	 peak	 associated	with	 GapA	 in	 chromatographic	 fractions	 from	
copper-treated	WT	S.	aureus	cells	is	absent	in	a	S.	aureus	ΔgapA	mutant	Preliminary	data	that	identified	SaGapA	in	SH1000	as	a	potential	target	of	toxicity	was	performed	in	TSB	with	the	addition	of	50	µM	copper.	The	fact	that	copper,	as	measured	by	ICP-MS,	was	isolated	in	the	same	fraction	as	SaGapA	implied	that	SaGapA	is	binding	to	copper.		Having	constructed	a	SH1000	ΔgapA	mutant,	and	having	verified	its	growth	phenotype	in	the	presence	of	glucose	as	well	as	showing	that	lysates	of	the	mutant	demonstrate	no	detectable	SaGapA	activity,	we	repeated	the	metalloproteomics	experiments	that	led	to	our	preliminary	data	in	this	strain.		As	 the	 SH1000	 ΔgapA	mutant	 does	 not	 grow	 well	 in	 TSB	 or	 in	 a	 glucose	 containing	media,	we	performed	 this	 analysis	 in	TM	medium	without	 the	 addition	of	 any	 carbon	source.	We	performed	the	analysis	in	parallel	with	both	the	SH1000	WT	and	the	SH1000	ΔgapA	mutant,	 cultured	and	prepared	 simultaneously	 so	 that	 any	 changes	 in	metal	 or	protein	 profiles	 could	 not	 be	 attributed	 to	 differences	 in	 media	 composition	 or	variations	in	growth	conditions.		These	 metalloproteomics	 experiments	 utilise	 two	 dimensions	 of	 chromatography.	Initially	the	soluble	lysates	were	prepared	in	an	anaerobic	glovebox	and	then	separated	by	anion	exchange	chromatography	using	a	1	ml	HiTrap	Q	HP	anion-exchange	column	(GE	 Healthcare).	 Here	 the	 column	 was	 loaded	 with	 the	 soluble	 lysate,	 washed	 and	subsequently	a	set	of	buffers	(pH	7.5)	containing	different	concentrations	of	NaCl	were	applied	to	the	column	in	a	stepwise	fashion,	eluting	a	profile	of	different	proteins	with	each	 different	 concentration	 of	 NaCl	 applied	 according	 to	 the	 affinity	 of	 the	 different	proteins	for	the	charged	column,	independent	of	pH.	Each	1	ml	fraction	was	analysed	for	its	 copper	 content	by	 ICP-MS	as	well	 as	 its	protein	 content	by	Bradford	assay	 (Figure	3.19).		As	 observed	 in	 Figure	 3.19,	 there	 was	 little	 difference	 in	 the	 protein	 or	 copper	distribution	 detected	 in	 WT	 versus	 ΔgapA	 mutant	 fractions	 eluted	 from	 the	 initial	chromatographic	separation.	This	pattern	is	reflected	in	SDS-PAGE	analysis	of	the	same	anion	exchange	elution	samples	(Figure	3.20).	This	presented	a	difficulty	in	identifying	
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which	of	these	fractions	of	the	WT	extract	contained	SaGapA,	in	order	for	this	fraction	to	be	 further	 separated.	Previous	 separations	utilised	 in	preliminary	work	used	different	chromatographic	 columns	 which	 means	 that	 these	 cannot	 easily	 be	 used	 to	 cross	reference	the	location	of	the	protein.	Notably,	the	SDS-PAGE	gels	shown	in	Figure	3.20	show	 minimal	 differences,	 confirming	 that	 chromatography	 of	 the	 two	 extracts	 was	identical,	 and	 that	 no	 major	 changes	 in	 protein	 expression	 was	 observed	 between	strains.		To	 identify	which	 fraction	 SaGapA	was	 in	we	 utilised	 the	 specific	 GapA	 activity	 assay	described	previously.	The	results	of	this	assay	are	shown	in	Figure	3.21			As	we	had	treated	the	cells	with	copper,	we	added	50	µM	BCS	to	aliquots	of	the	fractions	to	be	tested	in	order	to	check	whether	any	inhibition	of	SaGapA	had	occurred,	keeping	some	aside	for	further	analysis.	BCS	is	a	Cu(I)	specific	chelator	with	a	very	high	affinity	for	 Cu(I),	 as	 described	 previously,	 and	 would	 be	 expected	 to	 remove	 at	 least	 a	proportion	of	copper	that	may	be	bound	to	SaGapA	and	inhibiting	the	enzyme.			An	increase	in	specific	SaGapA	activity	is	seen	when	BCS	is	added	to	the	reaction.	This	suggests	 strongly	 that	 the	SaGapA	 in	 these	 fractions	had	some	copper	bound	and	 that	removal	of	this	by	the	addition	of	BCS	has	increased	the	activity	of	the	enzyme	(Figure	3.21).		We	observed	that	fractions	300	(2),	400	(1)	and	400	(2)	showed	activity,	with	400	(1)	showing	the	greatest	value	of	143.14	nmoles	NADH	min-1	mg	protein-1	in	the	untreated	fractions	and	310.93	nmoles	NADH	min-1	mg	protein-1	in	the	fractions	treated	with	BCS,	representing	a	2-fold	 increase.	We	did	not	 test	 fractions	100	 (1),	100	 (2),	1000	(1)	or	1000	 (2)	 as	 these	 fractions	 contained	 relatively	 low	 levels	 of	 protein	 (Figure	 3.19).	Corresponding	 fractions	 from	 the	 SH1000	 ΔgapA	 separation	 showed	 no	 activity,	confirming	the	absence	of	SaGapA	in	the	mutant.		Based	 on	 our	 findings	 from	 these	 activity	 assays,	 fraction	 400	 (1)	 was	 selected	 for	further	purification	by	size	exclusion.	An	aliquot	(500	µl)	of	400	(1)	was	injected	onto	a	size	exclusion	column	(Superdex	200	 Increase	10/300,	GE	Healthcare).	Fractions	(500	µl)	 were	 collected,	 and	 analysed	 for	 copper	 content	 by	 ICP-MS,	 with	 protein	
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concentration	 determined	 by	 UV/visible	 spectrophotometry	 at	 280	 nm.	 The	 resulting	chromatogram	is	shown	in	Figure	3.22.		Here	 we	 can	 clearly	 see	 the	 convergence	 in	 protein	 concentration	 and	 copper	concentration	across	fractions	in	both	the	SH1000	WT	and	the	SH1000	ΔgapA	mutant.	However	there	are	notable	exceptions	to	this	trend,	with	the	two	most	obvious	copper	peaks	in	the	WT	elution	not	appearing	in	the	ΔgapA	mutant	fractions,	at	12.5	ml	and	19	ml.		A	number	of	 the	collected	 fractions	were	 run	on	SDS-PAGE	 in	order	 to	observe	which	proteins	were	present	within	them	which	are	shown	in	Figure	3.23.	Samples	on	the	gels	shown	correspond	to	the	volume	eluted	between	approximately	10.5	ml	and	15	ml	from	size-exclusion	chromatography	(see	Figure	3.22).	The	fractions	eluted	from	12	-	13.5	ml	are	highlighted	as	these	areas	of	the	SDS-PAGE	gel	clearly	show	the	disappearance	of	a	band	in	the	SH1000	ΔgapA	mutant	fractions	which	corresponds	to	SaGapA,	eluting	in	the	expected	fractions,	and	being	of	the	correct	size	on	the	gel	itself.	The	fraction	eluting	at	13	ml	demonstrates	 the	appearance	of	 a	 triplet	of	bands	 in	 the	SH1000	WT	 fractions,	which	is	observed	as	only	a	doublet	of	protein	bands	in	the	SH1000	ΔgapA	mutant.			The	observation	of	the	disappearance	of	a	copper	peak	as	measured	by	ICP-MS	in	these	fractions	 from	 the	 SH1000	 ΔgapA	mutant,	 corresponding	 with	 the	 disappearance	 of	
SaGapA	 on	 the	 SDS-PAGE	 gel	 within	 these	 same	 fractions,	 when	 compared	 to	 the	presence	of	a	copper	peak	and	SaGapA	on	the	SDS-PAGE	gel	 in	the	equivalent	SH1000	WT	 fractions	 indicates	 strongly	 that	 SaGapA	was	 indeed	 bound	 to	 copper	 in	 the	WT	fractions.			To	 further	 investigate	 the	 impact	 that	 copper	may	have	had	on	 the	activity	of	SaGapA	within	 these	 fractions,	 fractions	 of	 the	 SH1000	 WT,	 collected	 after	 size	 exclusion	chromatography,	 were	 assayed	 for	 GapA	 activity.	 As	 previously,	 we	 also	 assayed	aliquots	of	 the	 fractions	after	 treatment	with	50	µM	of	 the	Cu(I)	specific	chelator	BCS.	Aliquots	of	 the	SH1000	ΔgapA	mutant	 fractions	were	also	tested	for	GapA	activity	and	showed	none	as	expected	(data	not	shown).		
92	
	
As	in	fractions	collected	after	the	anion	exchange	chromatography	step,	it	was	observed	that	 activity	 increases	 after	 the	 addition	of	BCS.	The	highest	 activity	was	 found	 in	 the	fraction	eluting	at	12.5	ml	in	both	untreated	and	treated	fractions	with	values	of	86.84	and	144.74	nmoles	NADH	min-1	mg	protein-1	respectively.		 	
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Figure	3.19.	The	differences	between	profiles	of	copper	and	protein	distribution	
after	 anion	 exchange	 chromatography	 of	 WT	 and	 ΔgapA	 soluble	 extracts	 are	
minimal.	Panel	A:	SH1000	WT	lysate.	Panel	B:	SH1000	ΔgapA	lysate.	Cells	were	grown	in	 TM	 +	 50	 µM	 CuSO4	 for	 6	 hours	 shaking	 (180	 rpm)	 at	 37	 ˚C.	 Cells	were	 harvested,	washed	 (x	 3)	 with	 EDTA	 (5	mM)	 and	 then	 lysed	 by	 freeze	 grinding	 under	 anaerobic	conditions.	 Soluble	 extract	 was	 separated	 by	 centrifugation	 followed	 by	ultracentrifugation	 before	 the	 lysate	was	 applied	 to	 an	 anion	 exchange	 column,	 again	under	anaerobic	conditions	(1	ml	Q-HP	column,	GE;	buffer,	40	mM	Hepes,	pH	7.5	with	varying	NaCl	concentrations	 (100,	200,	300,	400,	600	and	1000	mM);	 flowrate,	0.5	ml	min-1).	 Each	 fraction	 (X	 axis)	 is	 labelled	 according	 to	 the	 NaCl	 concentration	 used	 to	elute	 it	 (mM)	 and	 which	millilitre	 of	 eluent	 volume	 it	 represents;	 i.e.	 the	 first	 (1)	 or	second	 (2)	millilitre.	 Each	 fraction	was	 analysed	 by	 ICP-MS	 for	 copper	 content	 (left	 Y	axis,	black	line)	and	protein	concentration	by	Bradford	assay	(right	Y	axis,	grey	line)	 	
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Figure	3.20.	SDS-PAGE	analysis	of	fractions	from	anion-exchange	chromatography	
of	 copper	 treated	 SH1000	WT	and	SH1000	ΔgapA	 cell	 lysates.	Aliquots	 (30	 µl)	 of	each	 anion	 exchange	 fraction	 from	WT	 and	 ΔgapA	 extracts	were	 loaded	 onto	 a	 12	%	acrylamide	 SDS-PAGE	 gel,	 which	 was	 stained	 with	 Coomassie	 blue.	 Left	 panel;	 WT	fractions	200	mM	(2)	to	600	mM	(1).	Middle	panel;	ΔgapA	fractions	200	mM	(2)	t0	600	mM	 (1).	 Fractions	 not	 shown	 contained	 low	 protein	 levels.	 Protein	 MW	 ladder	 (size	shown	 in	kDa)	has	been	digitally	positioned	closer	 to	 the	200	mM	(2)	 fraction	 in	both	main	panels	for	ease	of	analysis.	Right	panel;	aligned	ladder	and	lanes	containing	400	(1)	fractions	from	both	the	WT	and	mutant	analysis	for	ease	of	comparison.		
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Figure	 3.21.	 SaGapA	 activity	 of	 WT	 fractions	 collected	 from	 anion-exchange	
chromatography	rises	after	treatment	with	BCS.	Panel	A;	The	activity	of	WT	fractions	is	shown.	Activities	are,	in	nmoles	NADH	minute-1	mg	protein-1;	300	(2),	72.70;	400	(1)	143.14;	400	 (2),	 37.68.	Panel	B;	 the	 activity	of	WT	 fractions	 is	 shown	upon	 treatment	with	50	µM	BCS.	Activities	are,	in	nmoles	NADH	minute-1	mg	protein-1;	300	(2),	132.85;	400	 (1)	 310.93;	 400	 (2),	 8.61.	 Fractions	 not	 shown	 gave	 negligible	 activity.	 Fractions	from	 the	 separation	of	 lysates	 from	 the	SH1000	ΔgapA	mutant	are	not	 shown	as	 they	showed	 no	 activity,	 as	 expected.
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Figure	3.22.	The	copper	peak	associated	with	GapA	in	the	SH1000	WT	during	size-
exclusion	 chromatography	 is	 absent	 in	 the	 SH1000	 ΔgapA	mutant.	 Fraction	 ‘400	(1)’,	 shown	 in	 Figure	 3.19,	 was	 applied	 to	 a	 size-exclusion	 column	 (Superdex	 200	10/300	GL,	GE;	buffer,	150	mM	NaCl,	40	mM	Hepes,	pH	7.5;	flowrate	1	ml	min-1	)	for	this	analysis.	Upper	panel:	SH1000	WT.	Lower	Panel:	SH1000	ΔgapA.	In	both	panels	protein	concentration	is	displayed	in	mAU	(left	Y-axis,	solid	 line),	copper	concentration	 in	ppb	(right	y-axis,	dashed	line)	and	elution	volume	in	ml	(x-axis).			 	
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Figure	3.23.	SDS-PAGE	gels	of	fractions	from	SEC	analysis	of	SH1000	lysates	show	
that	GapA	is	absent	in	the	fractions	from	the	SH1000	ΔgapA	mutant.	40	µl	of	each	fraction	 was	 loaded	 onto	 a	 15	 %	 (w/v)	 acrylamide	 gel	 (see	 methods).	 The	 gel	 was	stained	using	Oriole	staining	agent	for	superior	staining	sensitivity	due	to	the	relatively	low	concentrations	of	protein	within	the	fraction.	The	images	were	acquired	under	a	UV	light.	 Top	 panel:	 SH1000	WT.	 Bottom	 Panel:	 SH1000	 ΔgapA.	 In	 both	 panels	 fractions	eluting	at	12,	12.5	and	13	ml	have	been	highlighted	(red	oval)	as	the	difference	between	the	WT	and	mutant	is	most	obvious	in	these.			 	
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Figure	 3.24.	 GapA	 activity	 of	 WT	 fractions	 collected	 from	 size-exclusion	
chromatography	 rises	 after	 treatment	 with	 BCS.	 Panel	 A;	 The	 enzyme	 activity	present	 in	 fractions	 is	 shown	 without	 treatment	 with	 BCS.	 Activities	 are	 (in	 nmoles	NADH	minute-1	mg	protein-1):	fraction	12,	58.29;	fraction	12.5,	86.84;	fraction	13,	48.93;	fraction	13.5,	12.66.	Panel	B;	the	activity	in	the	fractions	is	shown	after	treatment	with	50	µM	BCS.	Activities	are	(in	nmoles	NADH	minute-1	mg	protein-1):	fraction	11.5,	27.05;	fraction	 12,	 116.58;	 fraction	 12.5,	 114.74;	 fraction	 13,	 97.85;	 fraction	 13.5,	 25.33.	Fractions	 not	 shown	 gave	 negligible	 activity.	 Fractions	 from	 the	 separation	 of	 lysates	from	the	SH1000	ΔgapA	mutant	are	not	shown	as	they	showed	no	activity,	as	expected.	
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3.13	GapA	activity	is	inhibited	in	cell	lysates	to	which	copper	is	added	As	well	as	observing	possible	inhibition	of	SaGapA	in	lysates	from	cells	grown	in	copper	(Figure	3.18),	we	also	observed	reduced	activity	in	lysates	to	which	copper	was	added	after	 lysis.	 Whilst	 this	 method	 does	 not	 imitate	 the	 conditions	 in	 vivo	 it	 is	 further	evidence	 that	within	 the	 complex	milieu	 of	 proteins	 present	within	 a	 lysate	 copper	 is	able	to	inhibit	the	activity	of	SaGapA.		In	this	case	50	µM	Cu(II)	was	added	to	the	lysate,	we	chose	not	to	use	Cu(I)	as	the	lysate	in	 this	 case	was	 prepared	 in	 aerobic	 conditions.	 Indeed	 it	may	 be	 the	 case	 that	 some	Cu(II)	is	converted	to	Cu(I)	by	reducing	agents	within	the	lysate.	The	fact	that	activity	is	seen	 in	 the	control	 lysate	 is	 indicative	 that	 the	entire	population	of	SaGapA	cannot	be	oxidised	as	it	has	been	shown	that	oxidised	SaGapA	is	inactive115.		
3.14	Other	metals	also	inhibit	the	activity	of	GapA	within	cell	lysates	It	 was	 of	 interest	 to	 examine	 whether	 this	 effect	 was	 limited	 to	 copper	 or	 was	 also	exhibited	by	other	bio-metals.	Cobalt,	nickel,	zinc	and	silver	(not	a	bio-metal,	but	with	similar	 chemistry	 to	 copper)	 were	 added	 to	 a	 cytoplasmic	 extract	 of	 S.	 aureus	 at	 a	concentration	 of	 50	 µM.	 It	 was	 found	 that	 cobalt,	 nickel	 do	 not	 significantly	 inhibit	
SaGapA	 activity	 (p	 >	 0.05,	 unpaired	 t-test),	whereas	 silver	 (p	 =	 0.0119)	 and	 zinc	 (p	 =	0.0274)	do.	Silver	had	a	similar	effect	to	copper	as	expected,	whereas	zinc	inhibited	the	enzyme	 significantly	 but	 not	 to	 the	 extent	 of	 silver	 or	 copper.	 Such	 a	 result	would	 be	expected	 on	 reflection	 upon	 on	 the	 Irving-Williams	 series	 of	 the	 relative	 stabilities	 of	divalent	 metal	 iron	 complexes,	 which	 attributes	 stability	 such	 that	 copper	 forms	 the	most	stable	complexes,	followed	by	(of	those	metals	used	here),	zinc,	nickel	and	cobalt.			 	
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Figure	3.25.	Cu(II)	completely	inhibits	the	activity	of	SaGapA	within	a	cytoplasmic	
extract	of	SH1000.	Protein	lysate	extract	(15	µg)	of	SaGapA	was	used	with	50	µM	Cu(II)	added	 and	 incubated	 with	 the	 protein	 for	 approximately	 10	 minutes	 at	 room	temperature.	The	control	reaction	gave	a	mean	value	of	661.54	nmoles	NADH	minute-1	mg	 protein-1,	 the	 copper	 treated	 lysate	 gave	 no	 activity	 (p	 =	 0.0125).	 The	 reaction	 is	based	 on	 the	 activity	 between	 10	 and	 20	 seconds	 performed	 in	 a	 plate	 reader	spectrophotometer.		 	
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Fig	 3.26.	 Cobalt	 and	 nickel	 do	 not	 inhibit	 the	 activity	 of	 SaGapA	 within	 a	
cytoplasmic	 extract	 of	 SH1000,	whereas	 zinc	 and	 silver	 do.	Protein	 lysate	 extract	(15	µg)	of	WT	S.	aureus	was	used	with	50	µM	of	each	metal	added	and	incubated	with	the	protein	 for	 approximately	10	minutes	 at	 room	 temperature.	Mean	 reaction	values	were	(in	nmoles	NADH	minute-1	mg	protein-1);	control,	661.54;	+Co,	730.09;	+Ni,	401.04;	+Zn,	 119.97.	 The	 silver	 treated	 sample	 gave	 no	 activity.	 The	 reaction	 is	 based	 on	 the	activity	between	10	and	20	seconds	performed	in	a	plate	reader	spectrophotometer.		 	
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3.15	Chapter	3	Conclusions		
	
• The	growth	of	S.	aureus	is	inhibited	in	liquid	media	by	high	concentrations	copper.	
• Levels	 of	 copper	 inhibition	of	S.	 aureus	 growth	 are	 variable	 and	dependent	 on	 the	type	(complexity)	of	media	used	for	growth.	
• S.	aureus	is	particularly	sensitive	to	copper	in	TM,	with	complete	inhibition	of	growth	occurring	at	500	µM	CuSO4.	
• The	presence	of	a	 carbon	source	 (in	addition	 to	amino	acids,	present	 in	all	media)	increases	the	concentration	of	copper	in	which	S.	aureus	can	grow.	
• S.	aureus	grows	to	a	higher	OD595	in	glucose	than	in	succinate.	
• Different	amounts	of	glucose	above	0.25	%	do	not	increase	the	growth	of	S.	aureus	in	copper,	ruling	out	glucose	complexing	effects/	
• Preliminary	 data	 identified	 SaGapA	 as	 a	 potential	 copper	 binding	 cytoplasmic	protein	in	S.	aureus.	
• A	S.	aureus	SH1000	ΔgapA	mutant	shows	the	same	glucose	growth	phenotype	to	that	of	an	8325-4	ΔgapA	mutant,	previously	described.	
• The	growth	phenotype	in	copper	of	a	S.	aureus	SH1000	ΔgapA	mutant	does	not	differ	from	the	WT.	
• A	SH1000	ΔgapA	mutant	grows	poorly	in	succinate	compared	to	the	WT,	but	copper	does	not	affect	growth	of	the	ΔgapA	mutant	relative	to	the	WT	when	growing	with	succinate	as	the	main	carbon	source.	
• Copper	in	the	media	does	not	affect	the	activity	of	SaGapA	detectable	within	those	cells	up	to	a	concentration	of	400	µM	CuSO4.	
• A	SH1000	ΔgapA	mutant	lysate	cultured	in	copper	is	missing	the	copper	pool	present	in	the	WT	in	the	same	fraction	as	SaGapA,	confirming	that	SaGapA	binds	copper.	
• Treatment	of	cell	lysates	prepared	from	WT	S.	aureus	cells	grown	in	copper	with	the	copper	chelator	BCS	results	in	an	increase	in	activity.	
• SH1000	lysates	treated	with	copper	in	vitro	show	no	SaGapA	activity.	
• SH1000	lysates	treated	with	nickel	and	cobalt	show	no	significant	reduction	in	
SaGapA	activity	compared	to	the	WT,	whereas	zinc	shows	significant	inhibition	whilst	silver	shows	full	inhibition.		 	
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Chapter	4:	Copper	binding	to	S.	aureus	GapA	in	vitro		
4.1	Introduction	to	Chapter	4	Having	explored	the	effects	of	copper	on	S.	aureus	in	vivo	and	having	identified	a	protein	that	 copper	 may	 bind	 to	 within	 the	 cytoplasm,	 SaGapA,	 further	 investigation	 was	performed	 involving	 the	potential	 interaction	of	 this	protein	with	copper	 in	vitro.	This	chapter	 will	 thus	 explore	 in	 vitro	 binding	 of	 copper	 to	 recombinant	 S	 aureus	 GapA	(rSaGapA).		As	 seen	 in	Chapter	3,	 it	 is	 clear	 that	 fractions	 containing	SaGapA	 from	copper	 treated	lysates	 from	SH1000	WT	S.	 aureus	 cells	 contain	 copper,	 and	 that	when	 the	 identically	prepared	 cell	 lysates	 were	 anal	 ysed	 from	 the	 SH1000	 ΔgapA	mutant,	 copper	 is	 not	present.	We	hypothesised	 that	 the	 result	 observed	 in	 the	WT	 is	 due	 to	 the	binding	of	copper	 to	 SaGapA	 in	 vivo,	 hence	 when	 there	 is	 no	 SaGapA	 present	 there	 is	 no	accompanying	copper	pool.		There	are	other	possibilities	that	could	explain	this	result.	It	could	be	that	treatment	of	a	SH1000	ΔgapA	mutant	with	copper	results	in	a	shift	in	copper	distribution	within	cells	to	other	proteins,	i.e.	through	re-distribution	of	copper	at	the	protein	level.	Alternatively,	it	may	be	 that	 the	 background	 expression	 of	 genes	 in	 a	 SH1000	ΔgapA	mutant	 varies	from	the	SH1000	WT,	again	resulting	in	a	shift	in	copper	distribution	but	this	time	due	to	genetic	regulation.	Or	indeed	the	result	of	copper	treatment	in	the	ΔgapA	mutant	may	be	a	hybrid	of	 these	 two	events.	The	 fact	 that	protein	distribution,	 as	 seen	 in	 the	gels	seen	in	Figure	3.23,	between	fractions	from	the	SH1000	WT	versus	the	SH1000	ΔgapA	mutant	remains	remarkably	consistent	provides	some	evidence	that	expression	profiles	have	 not	 changed	 markedly,	 but	 such	 an	 observation	 cannot	 rule	 out	 more	 subtle	changes	to	protein	abundances	which	may	affect	copper	distribution.		In	this	chapter,	the	ability	of	rSaGapA	to	bind	to	copper	in	vitro	is	demonstrated,	thereby	strengthening	the	hypothesis	that	binding	is	in	fact	occurring	in	vivo.		
	Identification	 of	 SaGapA	 in	 Chapter	 3	 as	 a	 potential	 copper	 toxicity	 target	 led	 to	investigation	 of	 the	 published	 crystal	 structure	 of	 the	 protein	 in	 S.	 aureus114	 as	 well	investigation	 of	 current	 knowledge	 of	 its	 function	 in	 bacteria	 (and	 more	 broadly	 in	
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eukaryotes)	 where	 it	 is	 widely	 conserved	 at	 structural	 and	 sequence	 levels	 (see	introduction).	In	this	chapter	we	have	delved	into	the	nature	of	the	structural	properties	of	SaGapA	that	make	it	a	potential	copper	binding	target.		As	mentioned	 in	 the	 introduction,	SaGapA	 contains	 a	 cysteine	 residue	 and	 a	 histidine	residue	within	its	active	site	that	are	both	essential	to	the	activity	of	the	protein114.	This	is	 significant	 because	 both	 cysteine	 and	 histidine	 resides	 are	 often	 involved	 in	 native	copper	 co-ordinating	 sites	 throughout	 nature	 due	 to	 their	 inherent	 abilities	 to	 co-ordinate	copper	with	high	affinity.		The	structures	of	cysteine,	histidine	and	methionine	(another	typical	copper	ligand)	can	be	 seen	 in	Figures	4.2,	4.3	and	4.4	 respectively.	As	observed,	 cysteine	 contains	a	 thiol	group	as	the	terminal	structure	of	its	R	group.	This	is	the	ligand	that	makes	cysteine	so	amenable	 to	 binding	 copper,	 especially	 as	 the	 thiophilic	 ion	 Cu(I).	 Other	 well-known	copper	binding	compounds	such	as	glutathione	and	bacillithiol	 also	 contain	 functional	thiol	groups.	The	thiol	group	can	become	deprotonated,	giving	rise	to	the	thiolate	anion	which	 can	 co-ordinate	 positively	 charged	 metal	 cations	 with	 extremely	 low	 stability	constants146.			The	thiol	group	is	thus	able	to	undergo	metallation	and	in	the	process	becomes	a	metal-thiolate.	 A	 metal	 co-ordination	 centre	 usually	 contains	 a	 number	 of	 co-ordinating	residues	that	may	be	composed	of	multiple	cysteine	residues	as	well	as	other	residues	that	may	have	individually	weaker	bonds	with	the	metal	centre,	but	act	to	stabilise	the	position	 of	 the	 bound	metal	 ion;	 however	 not	 all	metal	 co-ordination	 centres	 contain	cysteine.	Of	 the	cupric	and	cuprous	 ions,	cysteine	has	a	preference	 for	cuprous	(Cu(I))	ions,	 making	 cysteine	 a	 significant	 ligand	 in	 anaerobic	 environments,	 such	 as	 the	cytoplasm	of	cells,	in	the	binding	of	Cu(I).			As	 well	 as	 having	 the	 potential	 to	 become	 metallated,	 the	 thiol	 group	 of	 cysteine	residues	 is	 also	 vulnerable	 to	 oxidation	 reactions	 that	 can	 damage	 their	 function	 in	enzymes.	 Damage	 to	 such	 groups	 is	 countered	 by	 the	 evolved	 antioxidant	 pathways	within	 cells	which	 allow	 continued	 function,	 by	 protecting	 proteins’	 cysteine	 residues	from	 oxidation	 in	 a	 buffering	 capacity,	 by	 detoxifying	 the	 reactive	 oxygen	 species	themselves	or	the	harmful	reagents	that	generate	the	reactive	species	in	the	first	place,	
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through	repair	of	the	proteins	and	other	macromolecules	damaged	by	oxidation	through	reduction,	or	through	de	novo	synthesis	if	damage	to	them	is	irreversible.		Histidine	(Figure	4.3)	contains	a	functional	imidazole	group,	and	it	is	this	group	which	is	able	to	interact	with	copper	ions.	Specifically,	the	N1	nitrogen	atom	of	the	imidazole	ring	is	able	to	donate	electrons	to	a	copper	ion	from	its	lone	pair.	In	contrast	with	cysteine,	histidine	is	not	readily	oxidised.	Histidine	readily	binds	to	both	the	Cu(I)	and	the	Cu(II)	ion.	Methionine	 is	another	common	copper	binding	 ligand	within	metalloproteins	(see	Figure	4.4).	When	methionine	is	utilised	for	copper	binding	within	metalloenzymes	it	is	often	found	in	environments	that	are	more	likely	to	experience	aerobic	conditions,	and	where	the	lack	of	potential	residue	oxidation	would	be	advantageous.		Examples	 of	 native	 copper	 binding	 proteins	 include	 those	 that	 use	 both	 histidine	 and	cysteine	 in	 their	copper	co-ordination	centres.	Two	such	examples	are	umecyanin	and	plastocyanin,	of	which	plastocyanin	also	incorporates	a	methionine	residue147.	There	are	few	examples	of	enzymes	which	utilise	just	two	residues	to	co-ordinate	copper	in	which	one	 is	 histidine.	 However,	 Cu(I)	 binding	 sites	 utilising	 dual	 thiol	 sidechains	 from	cysteine	 residues	 are	 relatively	 common	 and	 include	 the	 copper	 metallochaperones	CopZ	 and	 Atx1.	 In	 some	 instances	 amino	 acids	 apart	 from	 cysteine,	 histidine	 or	methionine	 are	 utilised	 in	 copper	 binding	 centres;	 again	 umecyanin	 is	 an	 example,	which	also	employs	a	glutamate	residue147.		Common	to	all	copper	complexes	 is	 the	nature	by	which	copper	 is	bound	to	 its	 ligand.	Copper	 is	 held	 in	 place	 through	 multiple	 coordinative	 bonds	 (also	 known	 as	 dative	covalent	bonds	or	dipolar	bonds).	Such	bonds	are	defined	by	their	formation	by	a	pair	of	electrons	that	are	donated	from	one	of	atoms	 involved	 in	the	bond,	as	opposed	to	one	electron	 originating	 from	 each	 atom	 in	 a	 standard	 covalent	 bond.	 This	 requires	 the	donor	 atom	 of	 the	 ligand	 to	 have	 a	 lone	 pair	 of	 electrons	 that	 can	 be	 donated	 to	 the	copper	centre	and	it	why	nitrogen	in	histidine	and	sulphur	in	methionine	and	cysteine	are	often	involved	in	metal	chelation148.	An	example	of	such	a	co-ordination	complex	is	shown	in	Figure	4.6.	Another	example	is	demonstrated	in	Figure	4.1,	the	2:1	complex	of	copper	and	bathocuproine	disulphonate	(BCS),	a	reagent	that	has	been	used	extensively	throughout	this	work.		
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Figure	 4.1.	 The	 copper	 (I)	 -	 BCS	 complex.	 Two	molecules	 of	 BCS	 form	 co-ordinate	bonds	with	a	central	Cu(I)	ion.	These	four	bonds	(dashed	lines)	are	formed	from	the	lone	pairs	of	electrons	that	exist	on	each	of	the	nitrogen	atoms	involved;	two	from	each	BCS	molecule.	The	sulphonate	groups	have	been	removed	from	this	structure,	as	they	would	dissociate	from	the	central	structure	of	each	BCS	molecule	in	solution.			 	
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Figure	 4.2.	 The	 amino	 acid	 cysteine.	 The	 thiol	 group	 of	 cysteine	makes	 it	 an	 ideal	ligand	in	the	co-ordination	of	copper,	especially	Cu(I).	Many	native	copper	enzymes	use	cysteine	residues	 in	 their	active	sites,	whilst	many	non-copper	enzymes	also	use	 it	 for	catalysis,	such	as	SaGapA.			
			
Figure	 4.3.	 The	 amino	 acid	 histidine.	 The	 imidazole	 ring	 can	 coordinate	 copper.	Histidine	is	often	found	in	copper	binding	sites,	of	both	Cu(I)	and	Cu(II)	sites,	as	well	as	non-copper	binding	active	sites.			
			
Figure	4.4.	The	amino	acid	methionine.	The	S-methyl	thioester	group	of	methionine	is	the	main	copper	binding	component	of	this	residue.	Methionine	is	not	often	found	as	a	catalytic	 residue,	 but	 the	 sulphur	 centre	 of	 its	 sidechain	 can	 contribute	 to	 copper	binding,	especially	in	aerobic	compartments.	 	
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Mukherjee	 et	 al.	 showed	 that	 Cys151	 and	His178	 are	 both	 essential	 to	 the	 activity	 of	GapA114.	These	two	residues	are	both	positioned	in	the	active	site	of	the	protein	and	play	a	 role	 binding	 the	 enzyme	 substrate,	 glyceraldehyde	 3-phosphate.	 They	 align	 the	substrate	which	in	turn	allows	NAD+	to	interact	with	it.	NAD+	binds	to	the	Rossmann	fold	of	the	protein,	a	conserved	region	amongst	dinucleotide-cofactor	utilising	enzymes149.			The	active	site	within	the	crystal	structure	of	S.	aureus	GapA	was	examined	closely	using	published	 data	 gathered	 by	Mukherjee	 et	 al.114	 in	 order	 to	 ascertain	 a	more	 detailed	view	of	how	copper	may	bind	to	the	enzyme.	The	N1	of	the	His178	imidazole	ring	and	the	sulphur	of	the	Cys151	residues	are	approximately	3.5	Å	apart	making	it	feasible	that	these	 residues	 could	 together	 coordinate	a	Cu(I)	 ion.	Other	 residues	around	 these	are	not	typical	copper	binding	residues,	but	several	of	them	may	contribute	to	coordination	alongside	 the	 cysteine	 and/or	 histidine	 residues.	 There	 is	 only	 one	 other	 cysteine	residue	(Cys96)	within	the	structure	of	the	monomer	and	the	potential	of	this	to	form	a	disulphide	 bridge	 or	 copper	 coordination	 site	 with	 Cys151	 was	 thought	 of	 as	 a	possibility,	 although	 such	 a	 bridge	 has	 not	 previously	 been	 described.	 However,	 the	distance	 between	 the	 two	 sulphur	 residues	 is	 12.7	 Å.	 A	 typical	 disulphide	 bond	 is	approximately	 2	Å,	making	 it	 extremely	 unlikely	 that	 these	would	 interact,	 unless	 the	protein	was	substantially	denatured.	The	crystal	structure	also	shows	the	thiol	group	of	Cys96	 pointing	 towards	 the	 centre	 of	 the	 protein	 and	 surrounded	 by	 hydrophobic	residues,	making	the	residue	even	less	likely	to	interact	with	Cys151	or	any	copper	that	came	within	proximity	of	the	residue.		Notably,	one	study	conducted	by	Matsumara	et	al.	has	shown	copper	bound	to	the	active	site	of	crystallised	GAPDH	from	Synechococcus	elongatus,	SeGAPDH150.	Here,	copper	(in	the	 form	 of	 CuSO4)	 was	 incorporated	 into	 the	 crystallisation	 conditions	 in	 which	
SeGAPDH	was	being	co-crystallised	with	another	protein,	CP12,	due	to	previous	studies	having	 shown	 that	 copper	may	 be	 bound	 to	 CP12,	which	 is	 utilised	 in	 photosynthetic	organisms	 to	 regulate	 GAPDH	 activity.	 In	 the	 crystal	 structure,	 copper	 was	 found	 to	interact	 with	 four	 residues,	 three	 from	 GAPDH	 itself	 (Cys155,	 His182	 and	 Thr156	equivalent	 to	Cys151,	His	178	and	Thr152	 in	SaGapA)	and	one	 from	CP12	 (Asp76)150.	However,	it	is	likely	that	this	binding	through	four	residues	is	mainly	attributable	to	the	presence	 of	 copper	 in	 its	 oxidised,	 Cu(II)	 ionic	 form.	 In	 the	 case	 of	 Cu(I)	 binding	 to	
SaGapA	 it	may	 be	 that	 no	 further	 residues	 are	 needed,	 as	 Cu(I)	 can	 form	 stable	 two-
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coordinate	 sites.	 Alternatively,	 another	 residue	may	 take	 the	 place	 of	 the	Asp76,	 or	 it	may	be	the	case	that	an	interaction	with	the	substrate	or	NAD+	cofactor	holds	the	copper	in	place,	with	 that	molecule	 effectively	 replacing	 the	 function	of	CP12	with	 regards	 to	copper	co-ordination	in	SeGAPDH.	Notably,	the	Thr156	that	is	adjacent	to	the	Cys155	in	
S.	 elongatus	 is	 conserved	 in	 terms	of	 its	 position	 adjacent	 to	 the	Cys151	within	 the	S.	
aureus	GapA114.	 Indeed	each	residue	of	SeGAPDH	involved	 in	copper	binding	 is	shifted	by	 four	 residues	 within	 the	 primary	 structure	 of	 SaGapA,	 with	 them	 being	 equally	spaced	when	comparing	the	two	sequences	to	each	other.		Any	 stable	 interaction	 of	 copper	with	 either	 of	 the	 catalytic	 residues	 of	 these	 enzyme	(Cys151	 or	 His178)	 would	 presumably	 inhibit	 the	 activity	 of	 the	 protein,	 either	 by	prevent	it	from	binding	or	releasing	its	substrate.			Interestingly	Matsumara	et	al.150	had	not	expected	the	copper	ions	within	the	structure	to	be	located	in	the	described	position	at	the	active	site,	but	hypothesised	that	it	would	be	more	 intimately	 bound	 to	 CP12	 as	 this	 protein	 had	 already	been	 found	 to	 interact	with	 copper	 independently	 of	 SeGAPDH151.	 The	 interaction	 of	 CP12	with	 copper	 is	 of	relatively	 low	 affinity	 and	 contrary	 to	most	 copper	 binding	 proteins	 does	 not	 involve	cysteine,	 histidine	 or	 methionine	 residues,	 despite	 the	 presence	 of	 the	 former	 two	within	 its	 sequence.	 Binding	 of	 copper	 to	 CP12	 has	 been	 ascribed	 to	 glutamic	 acid	residues,	which	is	rarely	seen	in	copper	proteins	without	the	involvement	of	at	least	one	of	the	conventional	copper	binding	residues.			The	fact	that	the	crystallised	GAPDH/CP12	complex	from	S.	elongatus	contained	copper	at	the	GAPDH	active	site,	at	least	under	the	conditions	used	for	crystallisation,	led	us	to	test	 whether	 copper	 could	 bind	 to	 this	 site	 in	 SaGapA.	 In	 the	 case	 of	 Synechococcus	
elongatus,	 the	 question	 arises	 as	 to	whether	 copper	 binding	 is	 artefactual.	 The	 initial	binding	 of	 copper	 was	 observed	 when	 copper	 was	 present	 in	 a	 solution	 containing	purified	 CP12152,	 and	 has	 been	 ascribed	 to	 glutamic	 acid	 residues	 by	 further	 study,	including	 crystallisation	 of	 CP12.	 No	 in	 vivo	 studies	 have	 gone	 on	 to	 attempt	 to	demonstrate	that	copper	binds	to	CP12	within	living	cells,	and	indeed	the	relatively	low	affinity	glutamic	acid	binding	site	would	suggest	that	this	is	not	the	case	as	the	copper	homeostasis	systems	of	organisms	expressing	CP12,	as	well	as	native	copper	proteins,	would	almost	certainly	prevent	such	an	interaction.		
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	Furthermore,	these	investigations	of	CP12	and	copper	has	been	performed	with	Cu(II),	whereas	 Cu(I)	 is	 thought	 to	 be	 the	 prevalent	 ion	 in	 the	 cytosol	 in	 vivo	 as	 discussed.	Nonetheless,	co-crystallisation	of	CP12	and	GAPDH	with	copper	bound	to	the	active	site	of	 the	 GAPDH	 component	 overwhelmingly	 pointed	 to	 copper	 binding	 to	 this	 site	 if	indeed	such	binding	was	to	occur	in	vivo,	 for	which	we	have	presented	evidence	in	the	previous	chapter.		On	 the	 basis	 of	 the	 above	 information,	 we	 hypothesised	 that	 rSaGapA	would	 bind	 to	copper	 in	vitro,	and	that	this	binding	would	most	 likely	 involve	Cys151	and/or	His178	due	to	their	aforementioned	propensity	to	bind	copper	above	other	amino	acid	residues,	as	 well	 as	 their	 location	 in	 the	 accessible	 active	 site	 of	 SaGapA.	 Furthermore,	 we	hypothesised	that	binding	of	Cu(I)	to	these	residues	would	lead	to	inhibition	of	enzyme	activity	by	precluding	access	of	the	substrate	to	these	essential	catalytic	residues.		 	
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Figure	 4.5.	 The	 crystal	 structure	 of	 the	 tetramer	 of	 SeGAPDH.	 Shown	 in	 cartoon	representation,	coloured	blue	to	green	from	N	to	C	termini,	with	the	active	site	copper	binding	residues	as	sticks	highlighted	in	yellow	(C155,	T156,	H182)	and	bound	copper	represented	 as	 orange	 spheres.	 Data	 from	 PDB	 file	 (3b1j)	 collected	 by	Matsumara	 et	
al.150	and	image	created	using	PyMol	software	by	Anna	Barwinska-Sendra.		
	
Figure	4.6.	Amino	acid	alignment	of	glyceraldehyde	3-phosphate	dehydrogenase	
from	S.	elongatus	(Query)	compared	with	that	of	S.	aureus	(Sbjct).		C155,	T156	and	H182	 of	 S.	 elongatus	 GAPDH	 are	 all	 conserved	 within	 the	 sequence	 of	 SaGapA	(highlighted	in	red	boxes).		 	
Chain	A Chain	C 
Chain	D Chain	B 
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Figure	 4.7.	 The	 structure	 of	 the	 SeGAPDH	 monomer	 with	 copper	 bound.	 Left:	
SeGAPDH	cartoon	representation	of	a	single	monomer	(Chain	A)	coloured	blue	to	green	from	N	to	C	termini,	with	the	copper	binding	residues	highlighted	in	yellow	(C155,	T156,	H182)	 and	 bound	 copper	 represented	 as	 an	 orange	 sphere.	 Right:	 SeGAPDH	 surface	representation	of	monomer	 (chain	A)	with	 the	 copper	binding	 residues	highlighted	 in	yellow	(C155,	T156,	H182)	and	bound	copper	represented	as	an	orange	sphere,	NAD+	shown	 as	 blue	 sticks.	 Below:	 magnification	 of	 left	 image	 displaying	 copper	 (orange	sphere)	bound	to	residues	highlighted	in	yellow	(C155,	T156,	H182).	Data	from	PDB	file	(3b1j)	 collected	 by	 Matsumara	 et	 al.150	 and	 images	 created	 using	 PyMol	 software	 by	Anna	Barwinska-Sendra.		 	
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4.2	Purification	of	recombinant	S.	aureus	GapA	In	order	to	study	the	effects	of	copper	binding	to	the	SaGapA	protein	in	vitro	it	was	first	necessary	 to	 purify	 recombinant	 SaGapA.	 We	 obtained	 a	 plasmid	 vector,	 pLEICS-03	containing	 the	gapA	gene,	 from	 the	University	 of	 Leicester	 (another	 kind	 gift	 from	Dr	Julie	Morrissey).	This	plasmid	was	stored	in	E.	coli	DH5α	cells	prior	to	being	isolated	by	use	of	a	plasmid	mini-prep	kit	and	transformed	into	BL21	cells,	in	which	the	protein	was	expressed.	 Expression	 of	 the	 gapA	 gene	 was	 induced	 by	 addition	 of	 IPTG	 to	 BL21	cultures.		Initially,	tests	for	optimal	expression	of	GapA	were	performed.	Cultures	were	grown	to	OD595	~0.6	before	the	addition	of	0.1	mM	or	1	mM	IPTG.	Aliquots	of	cells	were	collected	at	2,	4	and	6	hours	after	the	addition	of	IPTG	and	soluble	extracts	were	analysed	by	SDS-PAGE	 to	determine	which	 time-point	and	concentration	of	 IPTG	was	optimal	 for	gapA	expression.	The	results	are	shown	in	Figure	4.8.	It	was	decided	to	use	a	concentration	of	1	mM	IPTG	for	6	hours	as	this	was	the	condition	which	resulted	in	the	highest	level	of	
SaGapA.		The	plasmid	linked	the	gapA	gene	to	a	hexa-histidine	tag	which	allowed	for	purification	of	 the	protein	using	nickel-affinity	chromatography.	The	tag	was	subsequently	cleaved	using	Tobacco	Etch	Virus	(TEV)	protease	which	was	then	removed	via	a	second	round	of	nickel-affinity	chromatography.	The	tag	was	clearly	required	to	be	removed	due	to	the	propensity	 of	 histidine	 to	 bind	 metals,	 including	 copper.	 The	 TEV	 protease	 could	 be	removed	 in	 this	 way	 as	 it	 was	 also	 tagged	 with	 a	 hexa-histidine	 motif.	 Further	purification	of	SaGapA	was	achieved	using	size-exclusion	chromatography.	A	final	step	of	anion-exchange	chromatography,	under	anaerobic	conditions,	allowed	for	removal	of	reducing	 agents	 (DTT,	 TCEP)	 under	 conditions	 where	 SaGapA	 would	 remain	 in	 a	reduced	state	(see	Materials	and	Methods	for	a	comprehensive	protocol).	An	SDS-PAGE	gel	of	the	purification	can	be	seen	in	Figure	4.9.	The	final	steps	of	the	purification	were	applied	in	order	to	ensure	the	high	purity	of	the	protein	as	well	as	to	remove	reducing	agents.	Subsequent	copper	binding	experiments	used	to	examine	copper	binding	would	be	easily	affected	by	the	presence	of	such	contaminants.		 	
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Figure	4.8.	Expression	test	of	rSaGapA	in	BL21	cells.	Expression	testing	of	SaGapA	in	
E.	coli	BL21	cells	reveals	6	hours	of	growth	after	the	additon	of	IPTG	at	an	OD595	of	0.6	provides	the	greatest	yield	of	rSaGapA.	BL21	cell	lysate	(20	µl)	was	added	to	lanes	2-7.	Lane	1	contains	a	protein	marker	 ladder,	with	sizes	given	 in	kDa.	Lanes	2-7	contained	lysates	from	cultures	treated	with	0.1	or	1	mM	IPTG	and	having	been	cultured	for	2,	4	or	6	hours	after	its	addition	as	follows;	lane	2:	0.1	mM,	2	hours;	lane	3:	1	mM,	2	hours;	lane	4:	 0.1	mM,	 4	 hours;	 lane	 5:	 1	mM,	 4	 hours;	 lane	 6:	 0.1	mM,	 6	 hours;	 lane	 7:	 1	mM,	 6	hours.			 	
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Figure	4.9.	SDS-PAGE	gel	showing	the	purification	steps	of	rSaGapA	through	four	
steps	of	chromatography.	Samples	2-8	were	matched	for	protein	concentration	to	20	µg	protein	ml-1	by	Bradford	assay.	Sample	9	was	loaded	at	approximately	40	µg	protein	ml-1.	 Lanes	 1	 and	 10	 contain	 protein	 MW	 marker	 ladders.	 Samples	 were;	 lane	 2:	insoluble	 lysate;	 lane	 3:	 soluble	 lysate;	 lane	 4:	 initial	 nickel-affinity	 chromatography	rSaGapA	step	product;	lane	5:	initial	nickel-affinity	chromatography	flow-through;	lane	6:	secondary	nickel-affinity	chromatography	rSaGapA	purification	step	product;	lane	7:	secondary	 nickel-affinity	 chromatography	 flow-through;	 lane	 8:	 size-exclusion	chromatography	 rSaGapA	 elution;	 lane	 9:	 anion-exchange	 chromatography	 rSaGapA	elution.	 The	 gel	 demonstrates	 the	 increasing	 purity	 of	 rSaGapA	 throughout	 the	purification.	
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4.3	Purified	rSaGapA	contains	one	accessible	reduced	thiol		After	 purification	 of	 rSaGapA	 it	 was	 necessary	 to	 test	 if	 its	 thiol	 groups	 were	 fully	reduced.	This	was	achieved	using	a	DTNB	(5,5’-dithiobis-(2-nitrobenzoic	acid))	reagent	based	 assay.	 DTNB	 contains	 a	 disulphide	 bridge	 which	 reacts	 with	 reduced	 thiols,	liberating	 an	 anion	 which	 absorbs	 light	 strongly	 at	 412	 nm.	 The	 absorbance	 at	 this	wavelength	is	thus	directly	proportional	to	the	level	of	accessible	reduced	thiols	within	a	given	solution.		The	difficulty	of	measuring	the	level	of	reduced	thiols	in	a	solution	of	purified	rSaGapA	is	caused	 by	 the	 accessibility,	 or	 lack	 thereof,	 of	 the	 reduced	 thiol	 groups	 to	 the	 DTNB	molecules	 in	 solution.	This	 is	due	 to	 the	 shape	of	 the	active	 site	 and	 the	possibility	of	other	molecules	blocking	the	reaction,	such	as	G3P	or	NAD+	for	example,	which,	despite	not	being	present	in	buffers	during	the	purification,	will	have	been	present	in	the	BL21	cells	 during	 expression	prior	 to	 cell	 lysis,	 and	may	 therefore	 remain	within	 the	 active	site	of	the	protein	upon	purification,	blocking	access	of	the	DTNB	molecule.	On	the	other	hand,	one	of	the	cysteine	residues	is	expected	to	be	relatively	buried	within	the	folded	protein,	based	on	the	crystal	structure114.		Our	approach	to	solving	this	issue	was	to	attempt	to	unfold	the	protein	using	guanidine	or	 urea	 under	 anaerobic	 conditions	 to	 allow	 full	 access	 to	 all	 reduced	 thiols.	 Before	attempting	 this	 it	 was	 necessary	 to	 evaluate	 the	 ability	 of	 these	 reagents	 to	 unfold	rSaGapA.	To	do	this	we	used	fluorescence	spectroscopy,	with	an	excitation	wavelength	of	280	nm	and	a	detection	wavelength	range	of	300	nm	to	450	nm.	If	the	protein	under	investigation	 is	 unfolded	 in	 the	 presence	 of	 either	 chaotropic	 agent,	 a	 shift	 in	 the	emission	maximum	is	observed	as	well	as	an	increase	in	overall	intensity	of	the	emission	(a	 greater	 maximal	 value);	 this	 is	 caused	 by	 the	 unfolding	 of	 the	 protein	 revealing	tryptophan	residues	that	may	have	been	previously	buried	within	the	structure,	or	not	as	fluorescent	due	to	a	quenching	of	their	fluorescence	by	the	surrounding	environment.	Dissolution	of	rSaGapA	in	6	M	guanidine	resulted	in	a	blue	shift	as	well	as	an	increase	in	intensity,	 whereas	 use	 of	 8	 M	 urea	 resulted	 in	 a	 blue	 shift	 but	 with	 a	 decrease	 in	intensity	(both	denaturation	using	guanidine	and	urea	were	carried	out	at	pH	7.5;	data	not	 shown).	 The	 greater	 increase	 in	maximum	 intensity	 observed	 through	use	 of	 6	M	guanidine	 led	us	 to	 choose	 this	as	 the	denaturant	 in	order	 to	allow	 the	DTNB	reagent	access	to	reduced	thiol	groups.	
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	Figure	 4.10	 shows	 the	 results	 from	 an	 example	 of	 a	 DTNB	 assay	 performed	 on	 one	purification	of	rSaGapA	in	order	to	evaluate	the	oxidation	state	of	 its	thiols.	The	DTNB	assay,	along	with	absorbance	of	the	sample	at	280	nm,	is	an	additional	method	by	which	to	 evaluate	 protein	 concentration,	 assuming	 that	 all	 thiols	 are	 reduced	 and	 that	 the	number	 of	 cysteine	 residues	 within	 the	 protein	 is	 known.	 S.	 aureus	GapA	monomers	have	 two	 cysteine	 residues	 that	 do	 not	 form	 a	 disulphide	 bridge,	 Cys151	 and	 Cys96.	According	 to	 the	 crystal	 structure	 published	 by	Mukherjee	 et	 al.114	 the	 thiol	 group	 of	Cys96	 likely	 points	 inwards	 towards	 the	 centre	 of	 the	 protein,	 and	 is	 therefore	presumably	 inaccessible	 to	 DTNB	 under	 native	 conditions.	 Therefore	 under	 native	conditions	one	would	expect	the	absorbance	from	the	DTNB	reaction	with	one	of	these	thiols	 to	 produce	 a	 1:1	 ratio	 with	 protein	 concentration	 as	 recorded	 by	 A280.	 When	rSaGapA	has	been	denatured,	and	remains	under	reducing	conditions	DTNB	should	have	access	 to	all	reduced	thiols	 therefore	altering	the	ratio	 to	2:1,	as	 found	 in	 the	example	shown	in	Figure	4.10.		Variability	 was	 observed	 in	 this	 DTNB-determined	 value	 for	 accessible	 thiol	 groups	between	protein	preparations	in	the	absence	of	guanidine.	One	factor	in	this	variability	could	 be	 discrepancies	 between	 the	 protein	 concentration	 as	 assessed	 by	 alternative	methods	 (such	 as	 A280	 and	 Bradford)	 and	 the	 DTNB	 assay	 itself.	 However,	 the	 DTNB	assay	 gave	 an	 approximate	 ratio	 of	 1	 reduced	 thiol	 group	 to	 each	 rSaGapA	monomer	(within	 an	 error	 of	 15	 %)	 without	 the	 presence	 of	 guanidine,	 indicating	 that	 the	accessible	thiol	of	Cys151	was	reduced	in	the	cases	where	subsequently	used	for	copper	binding	(data	not	shown).	 	
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Figure	4.10.	DTNB	assay	demonstrating	reduced	status	of	purified	rSaGapA.	After	the	purification	of	rSaGapA,	a	sample	was	dissolved	in	6	M	guanidine	under	anaerobic	conditions	before	a	UV/visible	spectrum	was	taken	using	a	spectrophotometer	(Perkin	Elmer).	DTNB	reagent	was	then	added	to	the	sample	in	order	to	quantify	the	number	of	free	thiols	within	solution.	The	concentration	of	protein	attained	here	by	A280	was	12.46	µM	(using	an	ε	value	of	22,920	M-1	cm-1,	acquired	using	ExPasy	ProtParam	open	source	software,	for	rSaGapA	at	280	nm)	and	the	concentration	of	thiols	observed	through	use	of	DTNB	was	25.38	µM	(using	an	ε	value	of	14,150	M-1	cm-1	at	412	nm).	As	there	are	two	cysteine	residues	within	rSaGapA	the	expected	value	 for	 the	DTNB	reaction	was	 twice	that	of	the	value	acquired	via	A280.		 	
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4.4	rSaGapA	binds	one	equivalent	of	Cu(I)	in	vitro	After	purification	of	 rSaGapA	we	wanted	 to	assess	 its	capability	 to	bind	copper.	There	are	 a	 number	 of	 methods	 by	 which	 to	 investigate	 this,	 each	 contributing	 a	 piece	 of	evidence	in	support	of	the	hypothesis	that	this	protein	does	indeed	bind	to	copper.			Central	 to	 potential	 copper	 binding	 is	 the	 hypothetical	 binding	 site,	 which	 has	 been	predicted	to	involve	the	Cys151	residue	of	SaGapA.	When	Cu(I)	binds	to	the	thiol	group	of	a	cysteine	residue,	the	bond	formed	is	not	ionic	or	covalent	in	nature,	but	co-ordinate	(hence	 the	 term	 co-ordinate	 metal	 complex),	 and	 can	 usually	 be	 detected	spectroscopically.	In	the	case	of	Cu(I)	and	a	thiol	ligand,	the	formation	of	a	complex	gives	rise	 to	 ligand-to-metal	 change	 transfer	 (LMCT)	 absorption	 bands	 in	 the	 UV/visible	spectrum.	 In	 this	 case,	 we	 hypothesise	 that	 such	 a	 coordination	would	 consist	 of	 the	Cu(I)	and	Cys151	and	the	co-ordination	bond	between	them.	This	bond	can	absorb	UV	light	energy,	giving	rise	to	the	transfer	of	charge	(electrons)	from	the	ligand,	in	this	case	the	thiol	of	Cys151,	to	the	Cu(I)	ion.			LMCT	 complexes	 exhibit	 specific	 absorbance	 characteristics	 that	 differ	 from	 the	absorbance	 of	 the	 ligand	 or	 metal	 ion	 alone,	 generally	 increasing	 their	 absorbance	across	a	defined	 range	of	 their	 spectrum,	 relative	 to	 the	 spectrum	of	 the	 ligand	alone.	The	 absorbance	 in	 the	 diagnostic	 region	 will	 continue	 to	 increase	 until	 the	 ligand	 is	saturated.	 This	 feature	 can	 therefore	 be	 detected	 spectroscopically.	 The	 discrete	changes	 in	absorbance	can	occur	at	a	 range	of	different	wavelengths,	dependent	upon	the	nature	of	the	bond	formed,	which	is	inherent	to	the	nature	of	the	ligand,	metal	and	the	environment	 in	which	they	exist.	 In	the	case	of	LMCT	complexes	of	Cu(I)	and	thiol	groups	(such	as	cysteine	residues),	changes	in	absorbance	usually	occur	in	the	region	of	250	–	300	nm,	but	are	not	limited	to	this	region153.			In	order	to	visualise	the	spectra	of	Cu(I)	in	a	complex	with	rSaGapA	it	was	required	to	titrate	 Cu(I)	 into	 a	 solution	 of	 recombinant	 rSaGapA	 of	 known	 concentration.	 Under	oxidising	conditions	Cu(I)	is	not	stable	and	rapidly	oxidises	to	Cu(II).	A	solution	of	Cu(I)	was	 therefore	 prepared	 under	 anaerobic	 conditions	 using	 an	 acetonitrile	 solution,	forming	tetrakis	(acetonitrile)	copper(I)	hexafluorophosphate,	which	is	a	tetrahedral	co-ordination	 complex	 of	 Cu(I)	with	 acetonitrile.	 The	 acetonitrile	 ligands	 form	a	 four	 co-ordinate	complex	with	a	Cu(I)	ion	that	prevents	its	oxidation,	but	the	weak	interaction	of	
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the	 ligands	with	 the	metal	allows	 the	Cu(I)	 to	 interact	with	other	 ligands	present	 that	have	 a	 stronger	propensity	 to	 bond	with	 it.	Once	 the	 solution	has	been	prepared	 it	 is	subsequently	 kept	 under	 rigorous	 under	 anaerobic	 conditions	 to	 further	 prevent	 any	oxidation	 of	 Cu(I).	 The	 Cu(I)	within	 the	 solution	must	 then	 be	 quantified	 precisely	 as	only	 this	 would	 allow	 precise	 interpretation	 of	 any	 interaction	 with	 rSaGapA	spectroscopically.	 This	 experiment	 involves	 the	 aforementioned	 BCS	 copper	 chelator	which	forms	a	strong	two	co-ordinate	complex	with	Cu(I)	that	absorbs	strongly	at	483	nm.			Titration	of	Cu(I)	 into	BCS	results	 in	absorbance	spectra	with	a	 local	maximum	at	483	nm	 that	 increases	 in	 absorbance	 value	 proportionally	 to	 the	 concentration	 of	 Cu(I)	added.	 Subsequently	 the	 concentration	of	 the	 [Cu(I)(BCS)2]	 complex	 can	be	 calculated	using	 the	Beer-Lambert	 law	and	 the	published	extinction	coefficient	of	 the	complex	at	this	 wavelength	 (13,300	 M-1	 cm-1)136.	 An	 example	 of	 such	 a	 titration	 can	 be	 seen	 in	Figure	4.11.	Each	time	a	new	stock	solution	of	Cu(I)	was	prepared,	i.e.	each	new	day	that	a	 Cu(I)	 titration	 experiment	 was	 performed,	 this	 quantification	 experiment	 was	performed.	Figures	4.11	and	4.12	are	an	example	of	one	such	quantification.		After	quantification	of	Cu(I)	within	a	stock	with	BCS,	 total	copper	(i.e.	 the	sum	of	both	Cu(I)	and	Cu(II)	within	solution)	was	quantified	using	atomic	absorption	spectroscopy	(AAS),	whereby	a	diluted	sample	of	the	copper	stock	is	analysed	spectroscopically	after	being	 atomised	 within	 an	 acetylene	 flame.	 This	 gives	 further	 verification	 of	 the	 total	copper	within	the	stock	and	theoretically	allows	for	the	calculation	of	the	ratio	of	Cu(I)	to	 Cu(II)	 in	 the	 stock	 by	 subtraction	 of	 the	 former	 concentration	 from	 the	 total	 as	determined	by	AAS.	After	AAS	quantification	of	copper,	the	stock	of	Cu(I)	made	was	only	used	in	titrations	if	 the	quantification	using	BCS	matched	that	given	within	an	error	of	10%	(data	not	shown).		We	 initially	 titrated	2	 µl	 aliquots	 of	 a	 Cu(I)	 stock	 solution	 into	1	ml	 of	 a	 25	µM	GapA	solution.	Each	2	µl	addition	increased	the	concentration	of	Cu(I)	within	the	solution	by	approximately	 2	 µM.	 After	 each	 addition	 an	 absorbance	 spectra	 was	 immediately	recorded.	We	continued	to	add	Cu(I)	until	approximately	1.25	mole	equivalents	of	Cu(I),	relative	to	the	amount	of	GapA,	had	been	added.	The	data	are	shown	in	Figure	4.13.		
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As	observed	 in	Figures	4.13,	4.14	and	4.15,	each	Cu(I)	addition	 leads	to	an	 increase	 in	absorbance	 at	 various	wavelengths.	 Upon	 the	 addition	 of	 1	mole	 equivalent	 of	 GapA,	there	is	a	sudden	increase	in	absorbance	relative	to	the	previous	additions	of	Cu(I).	After	this,	there	is	only	a	slight	increase	in	absorbance	from	subsequent	Cu(I)	additions,	much	smaller	changes	than	previous	to	the	addition	of	one	equivalent	of	Cu(I).	We	can	observe	this	change	more	clearly	by	plotting	 the	change	 in	absorbance	against	added	Cu(I)	 for	specific	wavelengths	as	shown	in	Figure	4.16.		The	 increase	 in	absorbance	observed	here	can	be	explained	by	 the	binding	of	Cu(I)	 to	the	 thiol	group	of	a	 cysteine	 residue;	most	 likely	 the	Cys151	residue	as	 this	 is	 solvent	accessible	in	the	crystal	structure.	As	demonstrated	in	the	previously	published	crystal	structure	 of	 GapA,	 the	 functional	 group	 of	 Cys96	 is	 buried	 within	 the	 centre	 of	 the	protein	and	not	solvent	accessible.	The	change	in	gradient	in	the	change	in	absorbance	beyond	1	 equivalent	of	 Cu(I)	 indicates	 saturation	of	 the	 cysteine	 residue	with	 copper.	Further	 spectral	 changes	were	 nonetheless	 observed	 beyond	 1	 equivalent,	 suggesting	that	perhaps	copper	may	have	bound	to	another	site	with	a	cysteine	residue	(perhaps	Cys96)	 or	 that	 addition	 of	 further	 copper	 is	 able	 to	 alter	 the	 initial	 complex	 and	 thus	alter	 its	 absorbance.	 It	 should	 be	 noted	 that	 protein	 precipitation	was	 observed	 after	additions	of	high	concentrations	of	Cu(I).	The	most	likely	explanation	is	that	Cu(I)	binds	to	a	 cysteine	 residue,	most	 likely	Cys151,	at	a	 ratio	of	1:1,	but	 that	 some	non-specific,	adventitious	binding	does	occur	on	saturation	of	the	preferred	specific	site.	If	a	second	cysteine	 site	 was	 available	 to	 Cu(I)	 after	 saturation	 of	 the	 first,	 one	 would	 expect	 a	consistent	continued	increase	in	absorbance	with	further	additions	of	Cu(I).		The	 relatively	 large	 increase	 in	 absorbance	 upon	 reaching	 one	 equivalent	 of	 Cu(I)	compared	 to	 previous	 additions	 may	 be	 demonstrative	 of	 a	 change	 in	 conformation	and/or	 oligomerisation	 of	 the	 protein	 when	 saturated	 with	 Cu(I).	 Other	 data	 (not	shown)	 corroborates	 this	 hypothesis	 and	 suggest	 the	 formation	 of	 a	 higher	 order	complex,	 i.e.	 higher	molecular	weight	 than	 the	 tetramer,	which	 is	 thought	 to	 occur	 in	
vivo	and	which	we	purify	 in	 the	absence	of	copper,	as	observed	through	calibration	of	the	chromatographic	columns	used	during	purification	of	rSaGapA.		A	 difficulty	 of	 these	 titration	 experiments	 is	 the	 predisposition	 of	 purified	proteins	 to	precipitate	with	the	addition	of	sub-	or	super-stoichiometric	concentrations	of	copper.	
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This	is	due	to	the	added	copper	drawing	the	solubilised	enzyme	molecules	together	as	it	tries	to	form	stable	complexes;	the	excess	of	potential	binding	sites	results	in	an	initial	weak	 attraction	 of	 Cu(I)	 to	 multiple	 potential	 binding	 sites,	 pulling	 separate	 enzyme	units	 into	 close	 proximity,	 under	 which	 conditions	 the	 likelihood	 of	 aggregation	 is	increased.	 	 This	 has	 made	 it	 difficult	 to	 attain	 consistent	 replication	 of	 these	 results.	Even	with	 the	presence	of	 increases	 in	 absorbance,	 if	 precipitation	 is	 thought	 to	have	occurred	it	is	difficult	to	interpret	spectra.	Precipitation	can	be	easily	detected	by	large	increases	in	absorbance	in	the	wavelength	range	of	600	–	800	nm.		Having	 observed	 the	 saturation	 of	 GapA	 with	 Cu(I)	 when	 loading	 with	 super-stoichiometric	 concentrations,	 but	 being	 prevented	 from	 further	 characterisation	spectroscopically	due	to	protein	precipitation,	we	decided	to	attempt	to	further	confirm	copper	 binding	 using	 chromatography.	 In	 this	 case	 we	 added	 both	 sub-	 and	 super-stoichiometric	concentrations	of	copper.		This	 method	 allowed	 further	 examination	 of	 the	 stoichiometry	 of	 binding	 and	eliminated	some	of	the	complexities	of	analysis	of	LMCT	spectra.	We	applied	SaGapA	to	a	 size-exclusion	 chromatography	 column,	 using	 samples	 of	 SaGapA	 before	 and	 after	treatment	 with	 Cu(I).	 Subsequent	 analysis	 of	 eluted	 fractions	 by	 Bradford	 assay	 (for	protein	content)	and	by	ICP-MS	(for	copper)	allowed	us	to	ascertain	the	ratio	of	protein	and	copper	within	collected	fractions.		To	 prevent	 adventitious	 copper,	 bound	 to	 the	 column	 from	 previous	 analyses,	 from	affecting	the	result	we	cleaned	the	column	using	a	known	high-affinity	copper	binding	protein,	recombinant	SaCopZ.	The	SaCopZ	was	purified	by	Dr	Gus	Pelicioli-Riboldi	(data	not	shown),	with	500	µl	of	a	50	µM	solution	of	the	protein	being	applied	as	a	wash	step.	Previous	 to	 SaCopZ	 application	 the	 column	 was	 washed	 with	 EDTA	 to	 remove	 any	residual	 Cu(II).	 Subsequent	 to	washing	 the	 column	 in	 this	manner,	 untreated	 SaGapA	eluted	from	size	exclusion	with	no	copper	bound,	as	expected	(Figure	4.17).		After	 this,	 we	 treated	 GapA	 with	 a	 sub-stoichiometric	 concentration	 (0.9	 mole	equivalents)	of	Cu(I)	and	incubated	the	sample	at	4	˚C	for	36	hours	in	order	to	allow	the	mixture	 to	 reach	 equilibrium;	 we	 incubated	 at	 4	 ˚C	 to	 further	 minimise	 the	 risk	 of	precipitation.	 This	 sample	 was	 then	 applied	 to	 the	 column,	 subsequent	 to	 the	 non-
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treated	 sample,	 and	 fractions	 tested	 for	 protein	 and	metal	 content.	We	 repeated	 this	once	more	with	a	sample	that	had	been	loaded	with	approximately	1.5	mole	equivalents	of	Cu(I).	The	results	from	each	of	these	analyses	are	shown	in	Figure	4.18.		The	 results	 seen	 in	 Figure	 4.18	 further	 confirm	 our	 hypothesis	 that	 SaGapA	 binds	 to	Cu(I)	in	vitro.	The	enzyme	has	predominantly	eluted	at	the	same	volume	as	it	did	in	the	absence	of	added	copper,	demonstrating	that	the	tetramer	is	still	 the	main	form	of	the	protein	 and	 indicating	 that	 copper	 does	 not	 disrupt	 tetramerisation.	 Such	 disruption	would	 not	 be	 expected	 if	 copper	 bound	 to	 the	 active	 site	 of	 the	 protein,	which	 is	 not	located	close	to	the	interface(s)	between	monomers.			Most	notable	is	the	apparent	stoichiometry	of	copper	binding	to	the	protein.	In	the	case	of	 adding	 a	 sub-stoichiometric	 amount	 of	 copper	 (0.9	 mole	 equivalents)	 we	 see	 this	reflected	 in	 our	 results,	 with	 sub-stoichiometric	 levels	 of	 copper	 present	 in	 fractions	containing	 SaGapA.	 In	 terms	 of	 the	 elution	 volume	 from	 12	 to	 13.5	ml	 the	 respective	levels	of	protein	and	copper	were	(to	2	decimal	places);	12	ml,	0.77	µM	protein	and	0.57	µM	copper	(0.74	mole	equivalents);	12.5	ml,	1.03	µM	and	0.91	µM	(0.88	M	equivalents);	13	 ml,	 0.56	 µM	 and	 0.40	 µM	 (0.71	 M	 equivalents).	 The	 small	 discrepancies	 between	measured	 copper	 and	 protein	 are	 likely	 a	 reflection	 of	 the	 error	 associated	 with	measurement	 of	 metal	 (by	 ICP-MS)	 and,	 most	 importantly,	 of	 protein	 (by	 Bradford	assay).		In	 the	 case	 of	 the	 addition	 of	 super-stoichiometric	 addition	 of	 copper	 to	 SaGapA	 (1.5	mole	equivalents)	we	see	a	change	compared	 to	 the	sub-stoichiometric	additions	with	values	of	protein	and	copper	concentrations	respectively	in	the	fractions	detailed	above	being;	12	ml,	0.84	µM	and	0.82	µM	(0.97	M	equivalents);	12.5	ml,	1.03	µM	and	1.12	µM	(1.08	M	 equivalents);	 13	ml,	 0.57	 µM	 and	 0.91	 µM	 (1.59	M	 equivalents).	 This	 is	 very	close	to	1	mole	equivalent,	with	the	discrepancy	most	likely	due	to	error	associated	with	the	 Bradford	 quantification	 of	 the	 protein.	 However,	 the	 presence	 of	 a	 second,	 lower	affinity	binding	site,	cannot	be	ruled	out.		 	
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Figure	4.11.	Measurement	of	Cu(I)	stock	concentration	using	BCS.	Main	panel;	 full	UV/visible	 spectra	 during	 the	 titration	 of	 Cu(I)	 into	 a	 solution	 of	 the	 copper	 chelator	BCS,	and	inset:	expanded	view	of	the	region	in	which	the	[Cu(I)(BCS)2]	complex	absorbs.	.	 The	 spectrum	which	 shows	 no	maximum	at	 483	 nm	 is	 BCS	with	 no	 added	 Cu(I).	 As	Cu(I)	 is	 titrated	 into	BCS,	 absorbance	 increases	 in	 the	 region	of	 360	 –	 600	nm	with	 a	maxima	at	483	nm.	When	BCS	has	been	saturated	with	Cu(I),	the	absorbance	ceases	to	increase.	 The	 increase	 in	 absorbance	 at	 483	 nm	 per	 addition	 of	 Cu(I)	 can	 be	 used	 to	calculate	the	concentration	of	Cu(I)	 in	solution	before	the	solution	 is	used	for	titration	into	rSaGapA.	In	this	example,	a	value	of	2	µM	Cu(I)	per	addition	was	sought,	and	a	BCS	concentration	of	15	µM	was	prepared.	The	values	given	by	the	titration	itself	were;	Cu(I)	per	injection,	2.07	µM;	BCS,	14.50	µM.		 	
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Figure	4.12.	Quantitation	of	Cu(I)	present	in	an	anaerobic	Cu(I)	stock	solution.	The	addition	 of	 Cu(I)	 to	 BCS	 increases	 the	 concentration	 of	 the	 [Cu(I)(BCS)2]	 complex	 in	solution.		In	this	example	the	same	data	is	shown	as	in	Figure	4.9,	but	data	values	only	for	change	in	absorbance	at	483	nm	are	shown;	a	value	of	2	µM	Cu(I)	per	addition	was	sought,	 and	 a	 BCS	 concentration	 of	 15	 µM	 was	 prepared.	 The	 values	 given	 by	 the	titration	itself	were;	Cu(I)	per	injection,	2.07	µM;	BCS,	14.50	µM.	
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Figure	 4.13.	 Spectroscopic	 titration	 of	 Cu(I)	 into	 recombinant	 SaGapA.	 The	concentration	 of	 SaGapA	 was	 24.39	 µM	 as	 measured	 by	 absorbance	 at	 280	 nm	 (ε	 =	22,920).	Each	addition	of	Cu(I)	added	to	the	concentration	of	Cu(I)	within	the	solution	by	approximately	1.95	µM.	As	more	copper	 is	added,	 so	 the	absorbance	of	 the	sample	generally	 increases	 (as	 indicated	 by	 the	 arrow	 on	 the	 figure).	 There	 are	 particular	wavelengths	where	the	absorbance	increases	more	than	at	others	(see	Figure	4.14).		 	
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Figure	 4.14.	 Expanded	 view	 of	 absorbance	 changes	 in	 rSaGapA	 during	 titration	
with	Cu(I).	Titration	of	Cu(I)	into	recombinant	SaGapA	(as	in	Figure	4.11),	shown	as	an	expanded	view	over	a	shorter	range	of	wavelengths	for	clarity.	The	legend	indicates	the	number	of	additions	of	 copper,	with	each	being	an	addition	of	approximately	1.95	µM	Cu(I)	 (as	described	above).	The	wavelengths	 that	 appear	 to	 show	 the	 greatest	 change	when	 copper	 is	 added	 are	 between	 245	 and	 260	 nm.	 The	 12th	 addition	 appears	 to	provoke	a	greater	increase	in	absorbance	than	previous	to	it,	and	subsequent	additions	give	 relatively	 decreased	 increases	 in	 absorbance.	 12	 additions	 is	 equal	 to	approximately	1	mole	equivalent	of	the	protein	concentration	(23.4	µM	Cu(I),	24.39	µM	
SaGapA).						 	
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Figure	 4.15.	 Difference	 spectra	 of	 rSaGapA	 titrated	 with	 Cu(I).	 Note	 that	 ‘0’	additions	of	Cu(I)	is	equivalent	to	the	baseline,	i.e.	the	spectrum	of	protein	alone,	so	has	not	been	included	here.	Again	each	addition	as	shown	on	the	legend	is	equivalent	of	the	addition	 of	 1.95	 µM	 Cu(I).	 The	 maximum	 at	 241	 nm	 shows	 the	 greatest	 change	 in	absorbance,	and	is	accompanied	by	local	maxima	at	290	and	410	nm.	Those	at	241	and	290	nm	are	in	the	typical	region	expected	to	show	an	absorbance	increase	when	a	LMCT	occurs	between	a	Cu(I)	ion	and	a	thiol	group.		
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Figure	4.16.	Change	in	the	absorbance	of	SaGapA	at	particular	wavelengths	upon	
the	addition	of	Cu(I).	Wavelengths	correspond	to	those	emphasised	in	Figure	4.13	and	are	 represented	 as	 follows;	 242	 nm,	 navy	 circles;	 290	 nm,	 sky	 blue	 squares;	 410	 nm,	blue	 triangles.	 The	 concentration	 of	 SaGapA	 was	 24.39	 µM	 which	 corresponds	approximately	to	the	concentration	of	Cu(I)	at	which	the	 largest	change	in	absorbance	occurs	at	all	3	wavelengths.	After	this	there	is	a	decrease	in	the	change	occurring	at	all	three	wavelengths	represented	here.	Absorbance	at	241	nm	continues	to	increase	but	in	a	reduced	manner,	whereas	hardly	any	increase	at	all	is	observed	at	290	or	410	nm.	The	observation	at	242	nm	could	be	indicative	of	further	interaction	of	Cu(I)	with	cysteine.		 	
130	
	
		
Figure	4.17.	Analytical	SEC	of	rSaGapA	not	loaded	with	copper.	17.78	µM	rSaGapA	as	measured	by	A280	was	loaded	onto	an	analytical	size	exclusion	column	(Superdex	200	10/300	GL,	GE;	buffer,	150	mM	NaCl,	40	mM	Hepes,	pH	7.5;	flowrate,	1	ml	min-1)	having	not	been	treated	with	copper.	Elution	volume	shown	here	demonstrates	the	fractions	in	which	rSaGapA	elutes	from	this	column,	the	peak	value	as	measured	by	Bradford	assay	in	the	fraction	eluting	at	12.5	ml	is	1.33	µM	(blue	squares).	Copper	as	analysed	by	ICP-MS	is	shown	(orange	triangles).	All	copper	values	are	extremely	close	to	0.	
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Figure	 4.18.	 Analytical	 SEC	 of	 rSaGapA	 loaded	 with	 Cu(I).	 Top	 panel;	 17.50	 µM	rSaGapA	 as	 measured	 by	 A280	 was	 loaded	 onto	 an	 analytical	 size	 exclusion	 column	(Superdex	200	10/300	GL,	GE;	buffer,	150	mM	NaCl,	40	mM	Hepes,	pH	7.5;	flowrate,	1	ml	min-1)	 after	 having	 been	 loaded	with	 15.47	 µM	 Cu(I)	 or	 approximately	 0.91	mole	equivalents.	Bottom	panel;	17.72	µM	rSaGapA	as	measured	by	A280	was	loaded	onto	an	analytical	size	exclusion	column	(Superdex	200	10/300	GL,	GE)	after	having	been	loaded	with	 25.13	 µM	 Cu(I)	 or	 approximately	 1.47	 mole	 equivalents.	 Details	 of	 the	concentrations	 of	 protein	 (blue	 squares)	 and	 copper	 as	 analysed	 by	 ICP-MS	 (orange	triangles)	in	volumes	containing	rSaGapA	are	given	in	the	main	text.	
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4.5	rSaGapA	binds	Cu(I)	with	high	affinity	We	have	established	that	copper	binds	to	GapA	in	vivo	and	in	vitro	and	we	were	further	interested	 in	 investigating	 the	affinity	with	which	GapA	binds	 this	metal.	The	 fact	 that	binding	has	been	observed	 in	vivo	suggests	a	relatively	 tight	affinity,	as	within	the	cell	GapA	 is	 having	 to	 compete	 with	 a	 range	 of	 ligands	 for	 Cu(I),	 not	 least	 the	 copper	homeostasis	proteins	CopZ,	CopA	and	CsoR	which	themselves	have	high	affinity45,58,154.		The	Cu(I)	 specific	 chelator	BCS	has	already	been	mentioned	 for	 its	 capacity	 to	bind	 to	that	 ion	 with	 high	 affinity.	 The	 calculated	 affinity	 for	 Cu(I)	 has	 been	 stated	 as	 an	association	constant	by	Xiao	et	al.136.	and	is	approximately	one	order	of	magnitude	lower	than	the	same	value	stated	for	the	CsoR	copper	sensor	of	Bacillus	subtilis	155,	which	binds	copper	with	one	of	tightest	affinities	observed	in	any	protein.	If	GapA	could	demonstrate	an	 ability	 to	 compete	 with	 BCS	 for	 Cu(I),	 it	 would	 be	 evident	 that	 the	 interaction	between	GapA	and	copper	was	biologically	relevant.		Here,	 we	 titrated	 Cu(I)	 into	 a	 solution	 of	 BCS,	 as	 described	 above	 during	 Cu(I)	quantification.	 We	 then	 repeated	 the	 same	 experiment	 in	 the	 presence	 of	 GapA.	 The	absorbance	maximum	of	the	[Cu(I)(BCS)2]	complex	at	483	nm	can	then	be	observed.	The	increase	 in	 absorbance	 at	 483	 nm	 was	 reduced	 in	 the	 presence	 of	 GapA,	 indicating	competition	between	GapA	and	BCS	for	Cu(I),	and	verifying	that	GapA	binds	copper	with	relatively	high	affinity	(Figure	4.20).			Whilst	GapA	competes	with	BCS	it	does	not	compete	sufficiently	to	prevent	Cu(I)	from	binding	to	BCS	until	 it	has	been	saturated.	This	demonstrates	 that	 the	affinity	of	GapA	for	Cu(I)	may	be	at	a	similar	order	of	magnitude	to	BCS,	and	is	not	orders	of	magnitude	greater	than	that	of	BCS.	A	copper	binding	protein	such	as	Bacillus	subtilis	CsoR,	with	an	affinity	greater	than	BCS	has	been	shown	to	be	completely	saturated	with	Cu(I)	before	the	metal	binds	to	BCS	at	all155.		 	
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Figure	4.19.	Uv/vis	spectra	during	titration	of	Cu(I)	into	a	solution	of	BCS	and	BCS	
with	 rSaGapA.	 Top	 panel:	 Cu(I)	 was	 titrated	 into	 a	 solution	 of	 16.66	 µM	 BCS.	 Each	addition	of	Cu(I)	added	1.79	µM	to	the	total	copper	concentration.	Bottom	panel:	Cu(I)	was	 titrated	 into	 a	 solution	 of	 16.66	 µM	 BCS	 also	 containing	 5.9	 µM	 SaGapA.	 Each	addition	of	 Cu(I)	 added	1.79	µM	 to	 the	 total	 copper	 concentration.	 In	both	panels	 the	lowest	absorbance	spectra	is	the	buffer	(i.e.	not	containing	BCS	or	protein).	Spectra	were	obtained	after	each	subsequent	addition	of	Cu(I).	With	each	addition	of	Cu(I)	 the	 local	maximum	 at	 483	 nm	 increases	 its	 absorbance	 proportional	 to	 the	 binding	 of	 Cu(I)	 to	BCS	 and	 the	 formation	 of	 the	 [Cu(I)(BCS)2]	 complex	which	 absorbs	 at	 483	 nm.	When	
SaGapA	 is	 present	 alongside	 BCS	 the	 equivalent	 increase	 in	 A483	 requires	 a	 greater	added	concentration	of	Cu(I),	indicating	that	SaGapA	has	competed	for	binding	of	Cu(I)	with	BCS.	In	both	cases	spectra	are	displayed	for	10	Cu(I)	additions.		 	
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Figure	 4.20.	 Formation	 of	 the	 [Cu(I)(BCS)2]	 complex	 by	 titration	 of	 Cu(I)	 into	 a	
solution	of	BCS	and	BCS	with	rSaGapA.	The	total	formation	of	[Cu(I)(BCS)2]	complex	requires	the	addition	of	a	greater	concentration	of	Cu(I)	in	the	presence	of	SaGapA	(blue	circles)	 than	 in	 its	 absence	 (golden	 squares).	The	data	 shown	 is	 the	 conversion	of	 the	absorbance	 at	 483	 nm	 shown	 in	 Figure	 4.17	 to	 the	 concentration	 of	 [Cu(I)(BCS)2]	complex	 using	 the	 published	 extinction	 coefficient	 for	 the	 complex,	 ε	 =13,300136.	 The	concentration	 of	 complex	 increases	 as	 Cu(I)	 is	 added	 to	 the	 different	 solutions	 at	different	 rates,	 with	 the	 presence	 of	 SaGapA	 increasing	 the	 concentration	 of	 Cu(I)	required	 to	 bind	 all	 available	 BCS	 from	 12.	 35	 µM	 to	 14.09	 µM.	 This	 indicates	 that	
SaGapA	is	competing	with	BCS,	a	high	affinity	ligand,	for	Cu(I).		 	
135	
	
4.6	Cu(I)	binding	to	rSaGapA	reversibly	inhibits	enzyme	activity	in	vitro	Evidence	has	been	provided	that	demonstrates	copper	binding	to	rSaGapA	in	vitro.	It	has	been	 further	shown	here	 that	copper	 inhibits	 the	activity	of	 the	enzyme	(Figure	4.21).	The	rSaGapA,	without	treatment	with	copper,	gave	a	mean	value	for	activity	of	939.61	nmoles	 NADH	 s-1	 mg	 protein-1.	 In	 the	 same	 units,	 rSaGapA	 treated	 with	 one	 mole	equivalent	of	Cu(I)	gave	370	and	with	 two	equivalents	gave	285	equivalent	 to	a	61	%	and	 70	 %	 decrease	 in	 activity	 respectively.	 When	 rSaGapA	 treated	 with	 two	 mole	equivalents	 of	 copper	 is	 then	 treated	 with	 BCS	 activity	 recovers	 to	 903	 which	 is	 an	inhibition	 of	 only	 3.8	%.	 	 Therefore,	 Cu(I)	 strongly	 inhibits	 the	 enzyme’s	 activity,	 and	this	 can	 be	 reversed	 through	 treatment	 of	 the	 inhibited	 enzyme	 with	 the	 copper	chelator,	demonstrating	that	copper-mediated	enzyme	inhibition	is	reversible.		These	 experiments	 were	 performed	 under	 rigorous	 anaerobic	 conditions,	 preventing	redox	cycling	by	Cu(I)	from	oxidising	the	enzyme.	Therefore,	enzyme	inhibition	can	only	have	been	caused	by	binding	in	vitro	of	the	rSaGapA	to	Cu(I),	as	opposed	to	oxidation	via	Fenton	chemistry	catalysed	by	the	presence	of	copper.				We	used	silver	as	well	as	copper	in	this	experiment	for	several	reasons;	firstly,	as	silver	shares	similar	chemistry	with	copper	and	is	not	able	to	redox	cycle,	similar	inhibition	of	the	 enzyme	 by	 silver	 would	 suggest	 a	 similar	 mechanism	 of	 inhibition	 by	 copper.	Secondly,	silver	is	not	known	to	be	chelated	by	BCS,	thus	using	silver	with	BCS	and	not	observing	an	alleviation	of	inhibition	is	indicative	that	the	formation	of	the	BCS	copper	complex	 is	 what	 is	 causing	 alleviation	 of	 inhibition	 in	 this	 case,	 and	 not	 any	 other	property	of	BCS	affecting	absorbance	or	the	enzyme	itself.		Figure	 4.21	 demonstrates	 that	 rSaGapA	 with	 1	 equivalent	 of	 added	 silver	 produced	199.68	 nmoles	 NADH	 second-1	 mg	 protein-1	 and	 with	 2	 equivalents,	 150.68	 nmoles	NADH	 second-1	 mg	 protein-1-.	 When	 BCS	 is	 added	 in	 the	 presence	 of	 2	 equivalent	 of	silver,	 activity	 is	not	 rescued	as	much	as	 in	 the	 case	of	 copper,	 the	 reaction	produced	333.98	nmoles	NADH	second-1	mg	protein-1.			 	
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Figure	4.21.	Copper	and	silver	inhibit	the	activity	of	rSaGapA.	The	action	of	copper	
can	 be	 reversed	 through	 the	 addition	 of	 BCS.	 Activity	 was	 assayed	 by	spectrophotometric	 observation	 of	 the	 absorbance	 of	 the	 reaction	 at	 340	 nm,	 which	increases	due	to	the	formation	of	NADH	by	rSaGapA.	In	each	reaction	5	µM	rSaGapA	was	used.	Where	one	or	two	mole	equivalent	of	copper	or	silver	was	used	then	5	µM	or	10	µM	 respectively	 of	 the	 respective	 metal	 was	 added.	 BCS	 was	 used	 at	 a	 final	concentration	of	50	µM.	Mean	values	recorded	in	nmoles	NADH	second-1	mg	protein-1;	apoprotein,	939.61;	Cu(I)	–	1	equivalent,	370.27;	Cu(I)	–	2	equivalents,	284.82;	Cu(I)	–	2	equivalents	+	BCS,	903.16;	Ag	–	1	equivalent,	199.68;	Ag	–	2	equivalents,	150.68;	Ag	–	2	equivalents	+	BCS,	333.98.			 	
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4.7	Mutagenesis	of	rSaGapA	residues	Cys151,	Cys96	and	His178	Analysis	 of	 SaGapA	 has	 shown	 clearly	 that	 GapA	 binds	 to	 copper.	 Inactivation	 of	 the	enzyme’s	 activity,	 alongside	 crystal	 structures	 of	 the	 homologous	 enzyme	 from	 S.	
elongatus,	suggest	 co-ordination	residues	within	 the	active	 site	of	 the	enzyme,	namely	Cys151	and	His178.	Furthermore,	Mukherjee	et	al.	showed	that	single	point	mutants	of	Cys151	and	His178	had	no	 activity,	 supporting	our	hypothesis	 that	 if	 copper	binds	 to	these	residues	it	is	likely	to	interfere	with	catalysis.		In	 order	 to	 analyse	 the	 involvement	 of	 these	 residues	 in	 copper	 binding	 we	 created	point	 mutants	 of	 the	 essential	 catalytic	 residues	 of	 recombinant	 SaGapA.	 This	 was	achieved	 using	 a	 standard	 site-directed	 mutagenesis	 method	 (see	 Materials	 and	Methods)	 to	 produce	 two	 site-directed	 mutants	 of	 the	 SaGapA	 expression	 vector,	pLEICS-03-SaGapA,	 which	 was	 originally	 acquired	 from	 the	 Morrissey	 group	 at	 the	University	 of	 Leicester.	 Both	 Cys151	 (TGT)	 and	 His178	 (CAC)	 codons	 of	 the	 ORF	 of	
SaGapA	within	the	vector	were	changed	to	alanine	codons	(GCT),	resulting	in	two	novel	plasmids	 pLEICS03-SaGapA(C151A)	 and	 pLEICS03-SaGapA(H178A).	We	 chose	 alanine	because	of	its	non-polar	and	non-reactive	nature,	and	its	disinclination	to	interact	with	copper.		Because	 of	 the	 nature	 of	 cysteine	 residues’	 tendency	 to	 interact	 with	 Cu(I),	 we	 also	decided	to	construct	the	vector	pLEICS03-SaGapA(C96A),	despite	Cys96	of	SaGapA	not	being	involved	in	the	active	site	of	the	enzyme.	This	was	done	using	the	same	method	as	used	 in	 construction	 of	 the	 construction	 of	 pLEICS03-SaGapA(C151A)/pLEICS03-SaGapA(H178A).		Once	the	mutated	vectors	had	been	constructed	we	were	able	to	use	a	restriction	digest	to	confirm	the	presence	of	the	correct	mutation	in	the	case	of	pLEICS03-SaGapA(C151A)	and	pLEICS03-SaGapA(C96A).	In	these	cases	the	codon	changes	resulted	in	the	removal	of	 a	 restriction	site	of	 the	 restriction	enzyme	RsaI.	We	amplified	 the	gapA	ORF	on	 the	vector	 and	 then	 digested	 this	with	RsaI.	 For	 pLEICS03-SaGapA(H178A)	 no	 restriction	site	was	removed,	thus	we	relied	only	on	sequencing	for	the	verification	of	the	correct	point	 mutation;	 sequencing	 was	 also	 carried	 out	 for	 the	 two	 cysteine	 point	 mutant	vectors,	which	alongside	the	restriction	digest	demonstrated	that	the	mutation	protocol	had	been	successful.	
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	Figure	 4.22	 shows	 the	 restriction	 digest	 of	 the	 amplified	 gapA	 ORF	 from	 pLEICS03-
SaGapA,	 pLEICS03-SaGapA(C151A),	 pLEICS03-SaGapA(C96A)	 and	 pLEICS03-
SaGapA(H178A).	The	digest	of	the	non-mutated	amplicon	gives	three	fragments,	whilst	the	 digest	 of	 both	 cysteine	mutated	 amplicons	 give	 two	 fragments.	 The	 digest	 of	 the	histidine	mutated	amplicon	gives	the	same	digest	pattern	as	the	non-mutated	amplicon.			 	
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Figure	 4.22.	 Diagnostic	 DNA	 agarose	 electrophoresis	 gel	 of	 the	 point	 mutant	
vectors	of	pLEICS-03-SaGapA.	Stained	agarose	gel	showing	the	sizes	of	DNA	fragments	after	 treatment	 of	 amplicons	 from	 pLEICS03-SaGapA	 and	 its	 site-directed	 mutant	derivatives	with	the	restriction	enzyme	RsaI.	Number	labels	represent	fragment	sizes	in	base	pairs.	Lanes	 (from	 left	 to	right)	contain:	Lane	1:	DNA	mass-ruler	 ladder	 (ladder),	fragment	 sizes	 shown	 in	 bps;	 Lane	 2:	 RsaI	 treated	 amplicon	 from	 pLEICS03-SaGapA	(WT),	expected	size	557,	289	and	165	bp;	Lane	3:	RsaI	treated	amplicon	from	pLEICS03-
SaGapA(C151A),	 expected	 sizes	 722	 and	 289	 bp;	 Lane	 4:	RsaI	 treated	 amplicon	 from	pLEICS03-SaGapA(C96A),	expected	sizes	557	and	454	bp;	Lane	5:	RsaI	treated	amplicon	from	pLEICS03-SaGapA(H178A),	expected	sizes	557,	289	and	165	bps.					 	
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4.8	Purification	of	SaGapA(C151A),	SaGapA(C96A)	and	SaGapA(H178A)	The	three	point	mutants	of	rSaGapA	were	purified	using	the	same	method	used	for	the	WT	 rSaGapA	 (see	 above).	 SDS-PAGE	 gels	 shown	 in	 Figure	 4.23	 demonstrate	 that	 the	three	proteins	were	expressed	well	in	BL21	cells	and	that	in	each	case	the	monomer	was	of	the	expected	size.		The	 gels	 shown	 in	 Figure	 4.23	 are	 from	 the	 second	 round	 of	 nickel	 affinity	chromatography,	after	cleavage	of	the	his-tag	from	the	protein.	These	fractions	contain	a	number	 of	 contaminating	 proteins,	 although	 the	 abundance	 of	 these	 compared	 to	rSaGapA	is	minor.	After	this	stage	of	chromatography,	further	size	exclusion	and	anion-exchange	 rounds	 of	 chromatography	 were	 performed	 (as	 with	 WT	 rSaGapA)	 which	ensured	the	removal	of	contaminants	and	reductants	(data	not	shown).		Fractions	shown	below	are	all	equivalent	from	this	step	of	purification.	There	is	clearly	less	rSaGapA	C96A	and	rSaGapA	H178A	than	rSaGapA	C151A.	It	 is	not	quite	clear	why	this	 would	 be	 the	 case,	 as	 all	 the	 mutants	 were	 expressed	 in	 the	 same	 way.	 One	possibility	is	that	the	former	two	mutant	proteins	are	slightly	less	stable	than	the	latter	which	leads	to	a	lower	amount	of	expression.		Further	 to	 this,	 it	 was	 found	 that	 upon	 flash	 freezing	 of	 the	 rSaGapA	 C96A	 after	 the	second	round	of	nickel	affinity	chromatography	and	subsequent	thawing	in	preparation	for	size	exclusion	chromatography,	the	sample	was	prone	to	high	levels	of	precipitation.	The	purification	was	repeated	and	the	protein	diluted	in	an	attempt	to	prevent	this,	but	precipitation	continued	 to	occur,	which	made	potential	 experiments	upon	 this	protein	impossible	to	undertake	in	the	interests	of	timely	submission	of	this	work.		 	
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Figure	 4.23.	 SDS-PAGE	 gels	 of	 partially	 purified	 rSaGapA(C151A),	
rSaGapA(H178A)	 and	 rSaGapA(C96A).	 Panel	 A;	 rSaGapA(C151A);	 Panel	 B;	rSaGapA(H178A)	and	Panel	C;	rSaGapA(C96A).	In	each	case	20	µl	of	fractions	collected	after	 the	 initial	 stage	 of	 Ni-NTA	 chromatography	 containing	 recombinant	 protein	 (as	assessed	by	the	UV-Vis	trace	data	produced	by	AKTA	FPLC	equipment,	not	shown)	was	loaded	onto	a	12	%	acrylamide	SDS-PAGE	gel	before	electrophoresis	(180	V,	60	mins).	 	
142	
	
4.9	Cu(I)	binds	rSaGapA	through	co-ordination	by	Cys151		As	 observed	 previously	 recombinant	 SaGapA	 loaded	 with	 copper	 binds	 1	 mole	equivalent	 of	 copper.	 Examination	 the	 involvement	 of	 Cys151	 and	 His182	 in	 copper	binding	 through	utilisation	of	 the	point	mutants	of	 the	 recombinant	enzyme	was	 then	undertaken.	To	 this	end	both	mutants	were	applied,	after	copper	 loading,	 to	 the	same	size-exclusion	column	as	used	for	analysis	of	WT	rSaGapA.		As	 previously,	 spectra	 of	 the	 recombinant	mutated	 enzymes	were	 taken	 as	 they	were	loaded	with	 copper.	 In	 this	 case	 sub-stoichiometric	 amounts	of	 copper	were	 added	 to	the	recombinant	protein	and	spectra	taken	upon	each	injection	of	Cu(I)	taken	to	observe	the	change	in	absorbance	as	levels	of	Cu(I)	were	increased	incrementally.		Here,	 the	 raw	 spectra	 have	 not	 been	 shown	 upon	 the	 addition	 of	 copper	 as	 clear	interpretation	requires	the	observation	of	changes	at	particular	wavelengths,	as	seen	in	Figure	4.16.	 In	 this	 figure	 the	 increase	 in	absorbance	at	242	nm	 is	observed	upon	 the	addition	of	copper.	The	wavelength	242	was	chosen	due	to	this	being	the	wavelength	at	which	the	greatest	increase	in	absorbance	was	seen	in	WT	rSaGapA	(Figure	4.16).		In	Figure	4.24	 the	 concentrations	of	protein	used	were	different	between	WT	and	 the	two	mutants.	The	data	recorded	for	Δ242	has	therefore	been	normalised,	using	protein	concentration	 value	 of	 10	 µM,	 to	 take	 account	 of	 this.	 The	 concentration	 of	rSaGapA(C151)	was	10.33	µM,	of	 rSaGapA(H178A)	was	12.55	µM	and	of	 the	 rSaGapA	WT	was	24.39	µM	(the	data	shown	here	for	the	rSaGapA	WT	is	the	same	as	that	shown	in	Figure	4.14	but	normalised	as	stated).	Absorbance	at	242	nm	increases	as	copper	is	added	 in	 the	 case	 of	 rSaGapA	 WT	 and	 rSaGapA(H178A),	 but	 not	 in	 the	 case	 of	rSaGapA(C151).	This	result	shows	what	was	expected;	a	rise	in	absorbance	at	242	nm,	caused	by	an	LMCT	that	occurs	between	Cu(I)	and	the	Cys151	residue	which	is	present	in	 the	 rSaGapA	WT	and	 the	 rSaGapA(H178A).	When	 this	 residue	 is	not	present	 (as	 in	rSaGapA(C151))	 the	 LMCT	 does	 not	 occur,	 and	 an	 increase	 in	 absorbance	 is	 not	observed.	 This	 supports	 the	 hypothesis	 that	 Cu(I)	 binds	 to	 rSaGapA	 via	 its	 Cys151	residue.	 Inset	 within	 Figure	 4.24	 is	 the	 non-normalised	 data	 for	 rSaGapA(C151)	 and	rSaGapA(H178A)	 enzymes,	 showing	 the	 same	 result	 as	 observed	 for	 the	 normalised	data.		
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Subsequent	 to	 loading	 with	 copper,	 samples	 of	 rSaGapA(C151)	 and	 rSaGapA(H178)	were	investigated	further	by	analytical	size	exclusion	chromatography.	The	two	mutated	recombinant	 enzymes,	 rSaGapA(C151)	 and	 rSaGapA(H178A)	 were	 loaded	 onto	 the	analytical	column	with	and	without	the	addition	of	copper.	The	data	for	the	absorbance	of	the	protein	at	242	nm	for	the	same	samples	analysed	by	SEC	is	shown	in	Figure	4.24.	Fractions	collected	from	analytical	SEC	were	analysed	for	metal	content	by	ICP-MS	and	for	protein	concentration	by	Bradford	assay.		Figure	4.25	demonstrates	data	gathered	from	fractions	produced	from	analytical	SEC	of	rSaGapA(H178A).	The	top	panel	shows	the	data	from	the	sample	analysed	after	copper	loading,	copper	is	present	in	the	same	volume	in	which	the	protein	elutes.	The	bottom	panel	 shows	data	 from	the	sample	analysed	without	being	 loaded	with	copper,	 in	 this	case,	 no	 copper	 is	 present	 in	 the	 volume	 in	which	 rSaGapA(H178)	 elutes.	 These	 data	demonstrate	that	the	rSaGapA(H178)	enzyme	is	binding	to	Cu(I),	as	also	demonstrated	by	increased	absorbance	at	242	nm	due	to	a	LMCT	observed	in	Figure	4.24.			Figure	4.26	demonstrates	data	gathered	from	fractions	produced	from	analytical	SEC	of	rSaGapA(C151A).	The	top	panel	shows	the	data	from	the	sample	analysed	after	copper	loading,	and	the	bottom	panel	the	data	from	the	sample	analysed	without	coper	loading.	In	both	cases	no	copper	is	observed	in	volumes	where	rSaGapA(C151)	elutes				 	
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Figure	 4.24.	 Titration	 of	 Cu(I)	 into	 rSaGapA(C151A)	 and	 rSaGapA(H178A).	Main	
panel:	Data	showing	the	change	in	absorbance	at	242	nm	from	the	titration	of	Cu(I)	into	the	 rSaGapA	 (WT)	 (pink),	 rSaGapA(C151A)	 (blue)	 and	 rSaGapA(H178A)	 (red)	normalised	to	a	protein	concentration	of	10	µM	rSaGapA.	Data	for	rSaGapA	(WT)	is	as	shown	 in	 Figure	 4.14	 at	 242	 (normalised	 as	 stated).	 In	 the	 case	 of	 rSaGapA(C151A),	10.33	 µM	 rSaGapA(C151A)	 was	 titrated	 with	 Cu(I)	 with	 each	 addition	 adding	approximately	 1.75	 µM	 Cu(I).	 In	 the	 case	 of	 rSaGapA(H178A),	 12.56	 µM	rSaGapA(H178A)	was	titrated	with	Cu(I)	with	each	addition	adding	approximately	1.91	µM	 Cu(I).	 Inset;	 the	 non-normalised	 data	 as	 in	 the	 main	 panel	 for	 rSaGapA(C151A)	(blue)	and	rSaGapA(H178A)	(red).		
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Figure	4.25.	Analytical	SEC	of	Cu(I)	loaded	and	non-loaded	rSaGapA(H178A).	[Cu]	shown	by	orange	 line,	 [GapA]	shown	in	blue.	Top	panel;	 rSaGapA(H178A)	was	titrated	with	copper	as	described	 in	Figure	4.22,	12.56	µM	rSaGapA(H178A)	was	 titrated	with	approximately	 9.55	 µM	Cu(I)	 (0.76	mole	 equivalents).	 An	 aliquot	 (0.5	ml)	 of	 this	was	loaded	on	a	size	exclusion	column	(Superdex	200	10/300	GL,	GE;	buffer,	150	mM	NaCl,	40	mM	Hepes,	pH	7.5;	 flowrate,	1	ml	min-1).	SaGapA(H178A)	binds	copper	at	a	similar	stoichiometry	to	the	WT.	Bottom	panel;	0.5	ml	rSaGapA(H178A)	not	titrated	with	Cu(I)	was	loaded	onto	the	same	column	using	the	same	buffer	and	flowrate.	When	Cu(I)	was	not	titrated	onto	rSaGapA(H178A),	the	eluent	fractions	containing	that	protein	did	not	contain	 copper.	 Copper	 concentrations	 were	 measured	 using	 ICP-MS	 and	 protein	concentrations	using	the	Bradford	assay.	 	
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Figure	4.26.	Analytical	 SEC	of	 Cu(I)	 loaded	and	non-loaded	SaGapA(C151A).	 [Cu]	shown	by	orange	 line,	 [protein]	shown	in	blue.	Top	panel;	SaGapA(C151A)was	titrated	with	 copper	 as	 described	 in	 Figure	 4.22,	 10.33	 µM	 SaGapA(C151A)	was	 titrated	with	approximately	7	µM	Cu(I)	 (0.68	mole	equivalents).	0.5	ml	of	 this	was	 loaded	on	a	size	exclusion	column	(Superdex	200	10/300	GL,	GE;	buffer,	150	mM	NaCl,	40	mM	Hepes,	pH	7.5;	 flowrate,	 1	ml	min-1).	 SaGapA(C151A)	 loaded	with	 Cu(I)	 has	 bound	 none	 of	 that	Cu(I).	Bottom	panel;	0.5	ml	SaGapA(C151A)	not	titrated	with	Cu(I)	was	loaded	onto	the	same	 column	 using	 the	 same	 buffer	 and	 flowrate.	 When	 Cu(I)	 was	 not	 titrated	 onto	
SaGapA(C151A)	the	eluent	volume	containing	that	protein	did	not	contain	copper	either.	Copper	concentrations	were	measured	using	 ICP-MS	and	protein	concentrations	using	the	Bradford	assay.	 	
147	
	
4.10	SaGapA(C151A)	shows	no	activity	as	expected	Mukherjee	 et	 al.114	 have	 previously	 shown	 that	 a	 Cys151	 mutant	 of	 recombinant	rSaGapA	has	no	activity.	Here,	it	was	desired	that	the	rSaGapA	mutant	created	in	our	lab	be	tested	for	its	activity.	We	did	not	test	the	activity	of	the	recombinant	protein	directly,	but	 of	 a	 lysate	 of	BL21	 cells	 that	 had	been	 expressing	 the	protein,	 and	 compared	 this	with	the	activity	of	a	lysate	that	had	been	producing	the	WT	recombinant	protein	and	a	lysate	that	had	not	been	induced	for	expression	from	pLEICS03-SaGapA,		The	 results	 are	 shown	 in	Figure	4.27.	The	 lysate	expressing	 the	WT	enzyme	gives	 the	highest	activity	(105	nmoles	NADH	min-1	mg	protein-1)	the	lysate	of	cells	expressing	the	mutant	enzyme	(rSaGapA(C151A)	showed	a	similar	activity	(22.50	nmoles	NADH	min-1	mg	protein-1)	to	the	 lysate	from	the	non-induced	cells	(16.814	nmoles	NADH	min-1	mg	protein-1).	The	activities	demonstrated	by	the	 lysates	 from	these	 latter	samples	can	be	accounted	 for	 by	 the	 activity	 of	 the	 endogenous	 GAPDH	 of	 the	 BL21	 cells.	 It	 was	concluded	that	rSaGapA(C151A)	showed	no	activity.					 	
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Figure	4.27.	BL21	 cell	 lysate	 activity	 assay	of	 cells	 expressing	SaGapA	 (WT)	and	
SaGapA(C151A).	 Activity	 was	 assayed	 by	 spectrophotometric	 observation	 of	 the	absorbance	of	the	reaction	at	340	nm,	which	increases	due	to	the	formation	of	NADH	by	rSaGapA.	The	assay	was	performed	 in	 the	plate	 reader	 spectrophotometer	 (Biotek)	 in	this	 case.	 Lysates	 from	 BL21	 cells	 (15	 µl)	 induced	 to	 express;	 SaGapA	 (WT)	 (WT	induced),	SaGapA(C151A),	and	non-induced	cells	were	pipetted	into	a	96	well	plate.	All	samples	 were	 at	 a	 protein	 concentration	 of	 50	 µg	ml-1.	 Reaction	 buffer	 (185	 µl)	 was	added	(see	methods)	immediately	before	initiation	of	observation	at	340	nm.	The	lysate	expressing	 the	 WT	 enzyme	 shows	 the	 highest	 activity	 (105	 nmoles	 NADH	 min-1	 mg	protein-1)	 the	 lysate	expressing	the	mutant	showed	similar	activity	to	the	non-induced	lysate.	 The	 activities	 of	 both	 of	 these	 can	 be	 accounted	 for	 by	 the	 activity	 of	 the	endogenous	 GAPDH	 of	 the	 BL21	 cells.	 Error	 bars	 could	 not	 be	 added	 as	 only	 one	iteration	of	this	experiment	was	performed.	
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4.11	Nickel,	cobalt,	and	zinc	do	not	inhibit	SaGapA	to	the	same	extent	as	copper	or	
silver		We	 have	 been	 investigating	 the	 nature	 of	 the	 interaction	 of	 copper	with	 SaGapA	 and	have	provided	evidence	for	the	proposed	mechanism	of	copper	binding	and	inhibition	of	the	enzyme.	Data	has	also	shown	that	silver	inhibits	the	protein	to	a	similar	extent	and	we	 hypothesise	 that	 silver	 achieves	 this	 in	 a	 similar	way	 to	 copper	 due	 to	 its	 related	chemistry.		It	was	of	interest	whether	other	metals	also	inhibited	SaGapA	in	vitro	and	if	so,	did	they	do	 this	 at	 similar	 levels	 of	 stoichiometry	 as	 copper	 and	 silver.	We	decided	 to	 test	 the	activity	 of	 recombinant	 SaGapA	 after	 treatment	 with	 nickel,	 cobalt	 and	 zinc.	 These	metals	 are	 all	 biologically	 essential	metals	 that	 cells	 require	 and	may	 encounter	 on	 a	regular	basis	in	their	environment.		Inhibition	 of	 the	 enzyme	 by	 iron	 was	 also	 of	 interest,	 but	 due	 to	 the	 experimental	complexities	 of	 preparing,	 quantifying	 and	 maintaining	 solutions	 of	 the	 different	oxidation	states	of	iron,	as	well	as	the	potential	involvement	of	oxidation	via	the	Fenton	reaction	(see	introduction),	it	was	decided	to	omit	the	investigation	of	iron.		Results,	shown	in	Figure	4.28,	demonstrate	the	much	lower	 levels	of	 inhibition	caused	by	 these	 metals	 than	 by	 either	 silver	 or	 copper.	 The	 concentration	 of	 recombinant	
SaGapA	used	was	100	nM,	and	4	mole	equivalents	of	metal	were	added	to	protein.	In	the	cases	 of	 nickel,	 this	 resulted	 in	 an	 insignificant	 change	 in	 enzyme	 activity	 (p	 >	 0.05)	Cobalt	significantly	inhibited	activity	(P	=	0.0035).	In	the	case	of	zinc,	4	mole	equivalents	did	 result	 in	 a	 significant	decrease	 in	 activity	 (P	<	0.0001).	We	decided	 to	use	1	mole	equivalent	of	zinc	alongside	silver	to	compare	the	inhibitions	of	these	metals	directly.	As	shown,	 1	 equivalent	 of	 zinc	 also	 significantly	 inhibits	 the	 activity	 of	 the	 enzyme	 (P	 =	0.0035)	but	not	as	significantly	as	with	4	equivalents	or	compared	to	silver	and	copper,	which	inhibit	to	the	greatest	extent	(as	shown	above	also).	The	Irving-Williams	series	of	the	 relative	 stability	 of	 divalent	 metal	 ion	 complexes	 places	 zinc	 lower	 than	 copper,	which	may	explain	the	requirement	of	a	higher	concentration	of	zinc	relative	to	protein	than	 copper	 (or	 silver).	 It	 is	 probable	 that	 zinc	 binds	 to	 a	 similar	 site	 within	 the	structure	as	proposed	for	copper	due	to	the	thiophilic	properties	of	zinc	being	similar	to	those	of	copper,	hence	the	observed	inhibition	of	activity,	but	less	so	than	copper..		 	
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Figure	4.28.	GapA	activity	assay	of	rSaGapA	treated	with	various	metals.	Treatment	of	rSaGapA	with	nickel,	cobalt,	zinc	and	silver.	Values	of	enzyme	activity	and	standard	deviations	obtained	were	(nmoles	NADH	min-1	mg	protein-1);	control	(no	added	metal),	2089,	117.6;	+Ni	(4	equivalents),	1836,	155.7;	+Co	(4	equivalents),	1611,	65.43;	+Zn	(1	equivalent),	 1667,	17.52;	+Zn	 (4	 equivalents),	 454.9,	 16.01;	+Ag	 (1	 equivalent),	 154.3,	4.381;	+Cu	(1	equivalent),	370.1,	22.	In	each	case	the	concentration	of	SaGapA	was	100	nM.			 	
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4.12.	Chapter	4	conclusions		
• rSaGapA	contains	one	accessible	reduced	thiol	under	anaerobic	conditions		
• rSaGapA	does	not	have	copper	bound	without	copper	treatment		
• Binding	of	rSaGapA	to	Cu(I)	inhibits	its	activity	
• Cu(I)	binds	to	rSaGapA	via	its	Cys151	residue	
• The	loss	of	the	His178	residue	from	rSaGapA	does	not	abolish	Cu(I)	binding.	
• rSaGapA(C151A)	shows	no	enzymatic	activity	as	shown	previously114.	
• Nickel,	cobalt,	and	zinc	do	not	inhibit	SaGapA	to	the	same	extent	as	copper	or	silver,	but	do	shown	partial	inhibit,	in	line	with	the	Irving	Williams	series80.	
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Chapter	5.	Discussion	and	unifying	concepts	
	Historically,	copper	has	been	known	since	ancient	times	to	 inhibit	the	spoilage	of	 food	and	drink,	and	has	been	used	in	hospital	settings	more	recently	to	reduce	the	spread	of	infection156.	 These	 uses	 are	 known	 to	 be	 effective.	 Various	 hypotheses	 have	 been	proposed	to	explain	these	phenomena,	yet	a	 firm	mechanistic	conclusion	has	yet	to	be	drawn	from	data	gathered.	As	discussed	in	the	introduction,	copper	has	been	proposed	to	 exhibit	 its	 antimicrobial	 activity	 through	 the	 production	 of	 ROS	 in	 vivo,	 via	 the	depolarisation	 and	 rupture	 of	 the	 cell	 membrane,	 and	 via	 aberrant	 binding	 to	 non-metalloproteins	in	vivo.	None	of	these	mechanisms	has	been	ruled	out	in	all	organisms,	and	 none	 have	 been	 demonstrated	 as	 the	 overwhelming	 cause	 of	 toxicity	 in	 any	organism.		Within	 E.	 coli	 Macomber	 and	 Imlay	 have	 described	 how	 copper	 is	 not	 causative	 of	oxidative	damage	to	DNA70,	and	have	gone	on	to	show	that	it	damages	the	iron	sulphur	clusters	of	that	same	organism66.	This	effect	of	copper	toxicity	on	iron	sulphur	clusters	has	 also	 been	 confirmed	 in	 Bacillus	 subtilis90	 and	 in	Neisseria	 gonorrhoeae91.	 Despite	many	 assumptions	within	 the	 literature	 that	ROS	production	by	 copper	was	 the	main	cause	of	intracellular	damage	it	is	clear	that	the	role	of	aberrant	copper	binding	and	the	identification	 of	 such	 copper	 targets	 has	 been	under-investigated.	One	 reason	 for	 this	may	be	the	difficulty	inherent	to	such	investigations.	Chemically	the	cuprous	ion,	Cu(I),	is	 quite	 unstable	 under	 aqueous,	 aerobic	 environments,	 creating	 a	 requirement	 for	anaerobic	conditions	and	procedures	which	are	technically	complex.	As	part	of	an	on-going	effort	in	the	Waldron	laboratory	to	understand	the	mechanisms	of	copper	toxicity,	and	to	identify	cellular	targets	of	copper	toxicity,	a	metalloproteomic	study	 of	 cellular	 copper	 distribution	 in	 Staphylococcus	 aureus	 under	 conditions	 of	copper	 stress	 is	 being	 undertaken.	 Preliminary	 data,	 obtained	 prior	 to	 the	commencement	 of	 this	 project,	 had	 identified	 several	 possible	 candidate	 proteins	 as	potential	copper	toxicity	targets.	One	of	these	potential	targets	was	the	glyceraldehyde-3-phosphate	dehydrogenase	family	protein,	GapA.	Interest	 in	 S.	 aureus	 specifically	 stemmed	 from	 its	 presence	 in	 the	 community	 and	hospitals,	in	which	settings	it	is	becoming	increasingly	virulent	and	resistant	to	standard	
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treatments	 using	 antibiotics,	 alongside	 the	 fact	 that	 to	 our	 knowledge,	 no	 such	investigation	has	been	undertaken	in	S.	aureus	before.	
5.1.	Effects	of	copper	on	the	growth	of	S.	aureus.	Initial	 investigation	 of	 the	 growth	 of	S.	 aureus	 in	 copper	 demonstrated	 that	 copper	 is	toxic	 to	 this	 organism.	 It	 was	 shown	 that	 the	 concentrations	 of	 copper	 required	 to	inhibit	 growth	 varied	 largely	 depending	 on	 the	media	 used.	 Richer	media,	 such	 as	 LB	and	TSB,	led	to	the	highest	growth	of	S.	aureus,	with	growth	not	strongly	affected	until	concentrations	 of	 above	 1	 mM	 CuSO4	 were	 used,	 whereas	 in	 TM	 we	 found	 that	 a	concentration	of	500	µM	CuSO4	was	enough	to	completely	inhibit	growth.	Investigation	of	the	effect	of	glucose	concentration	on	the	ability	to	resist	copper	toxicity	was	tested	and	 it	was	 found	that	 increasing	glucose	did	not	alter	 the	effects	of	copper	on	growth,	demonstrating	 that	 glucose	 was	 not	 preventing	 copper	 uptake	 through	 chelation.	Glucose	 however	 did	 lead	 to	 increased	 growth	 of	S.	 aureus	 relative	 to	 the	 addition	 of	succinate	or	no	carbon	source,	consistent	with	its	status	as	a	source	of	greater	energy.	The	fact	that	these	richer	media	are	able	to	allow	S.	aureus	to	grow	in	such	high	levels	of	copper	 is	 probably	 due	 to	 a	 combination	 of	 being	 richer	 sources	 of	 energy	 and	 their	copper	chelating	capacity	(although	the	latter	of	these	is	not	caused	by	the	presence	of		glucose).	 It	was	 also	 shown	 that	 cells	 grown	 in	 copper	 had	 a	 higher	 concentration	 of	copper	 within	 their	 cytoplasmic	 extract,	 confirming	 that	 copper	 ions	 enter	 S.	 aureus	cells,	despite	 the	absence	of	any	known	copper	 import	mechanism,	and	accumulate	 in	the	cytosol.	
5.2.	Identification	and	confirmation	of	SaGapA	as	associated	with	copper	in	vivo	
SaGapA	 was	 identified	 initially	 through	 preliminary	 studies	 as	 a	 potential	 copper	binding	protein	using	a	metalloproteomics	approach	(see	Chapter	3).	In	this	study,	the	metalloproteomics	technique	used	previously	was	altered	and	now	included	one	step	of	anion	exchange	chromatography	followed	by	SEC.	As	well	as	analysing	the	SH1000	WT,	here	we	repeated	the	analysis	on	a	SH1000	ΔgapA	mutant.	The	mutant	was	created	by	Anna	Barwinska-Sendra	of	the	Waldron	group.	The	mutant	was	confirmed	its	genotype,	by	 its	 growth	phenotype	 in	 glucose	 (showing	no	 growth),	 by	PCR	amplification	of	 the	mutated	 ORF	 of	 gapA	 and	 by	 restriction	 digest	 of	 the	 rsbU	 gene	 (the	 predominant	difference	between	SH1000	ΔgapA	and	8325-4	ΔgapA,	the	parent	strain,	being	an	11	bp	deletion	in	the	rsbU	gene	of	the	latter),	and	the	absence	of	detectable	GapA	activity.	
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Metalloproteomic	analysis	revealed	that	the	SH1000	ΔgapA	mutant	lost	the	copper	pool	present	in	WT	cells	in	fractions	where	SaGapA	was	present;	demonstrating	that	SaGapA	was	definitely	associated	with	copper	within	these	cells	when	grown	in	copper.		
5.3.	Copper-dependent	inhibition	of	SaGapA	activity	in	S.	aureus	cells.	Activity	assays	of	 the	WT	 fractions	collected	after	metalloproteomic	SEC	revealed	 that	despite	being	bound	to	some	copper,	the	enzyme	showed	some	activity.	This	increased	upon	treatment	of	the	samples	with	the	Cu(I)	specific	chelator	BCS,	reflecting	that	only	part	 of	 the	SaGapA	population	was	bound	 to	 copper,	 and	 the	unbound	part	 remained	functional.	 This	 also	 demonstrates	 the	 unbound	 copper	 had	 not	 been	 oxidised,	confirming	 the	 effectiveness	 of	 our	 anaerobic	 conditions	 and	 implying	 that	 copper	catalysed	 Fenton	 chemistry	 had	 not	 resulted	 in	 the	 oxidation	 of	 the	 unbound	 pool	 of	
SaGapA	in	vivo.	
SaGapA	inhibition	was	also	demonstrated	by	the	addition	of	copper	and	other	metals	to	SH1000	WT	lysates.	Cu(II)	consistent	with	its	strong	binding	properties	according	to	the	Irving	Williams	 series	 of	 divalent	metals80,	 resulted	 in	 complete	 inhibition	 of	 SaGapA	within	 these	 lysates,	 a	 result	 replicated	 by	 silver.	 Zinc	 also	 showed	 some	 inhibition,	although	 not	 complete	 inhibition.	Nickel	 no	 significant	 inhibition,	 and	 cobalt	 the	 least	significant,	 again	 these	 results	 reflect	 the	 expected	 binding	 affinities	 of	 these	 divalent	metal	 ions,	 implying	that	binding	of	 the	metals	(in	 the	case	of	Cu(II)	and	Zn(II))	 is	 the	causative	factor	of	inhibition.	The	lack	of	inhibition	observed	in	cell	lysates	prepared	from	cells	grown	in	copper	could	be	 due	 to	 the	 complexity	 of	 these	 assay	which	 contain	 not	 just	 SaGapA	 but	 all	 of	 the	other	 cytoplasmic	 proteins.	 It	 may	 be	 the	 case	 that	 higher	 concentrations	 within	 the	medium	would	show	inhibition	but	these	were	not	examined	in	the	interest	of	time.	
5.4.	Copper-binding	properties	of	rSaGapA	in	vitro.	The	 mechanism	 of	 catalysis	 of	 G3P	 to	 1,3-BPG	 by	 SaGapA	 has	 been	 investigated	 via	crystal	 structures	by	Mukherjee	et	al.114.	The	 initial	 step	as	reported	by	 them	 involves	the	nucleophilic	attack	of	 the	C1	carbon	of	 the	substrate	 (G3P)	by	 the	Cys151	 thiolate	form	(Figure	5.1).	The	previously	highlighted	propensity	of	such	a	thiolate	ligand	to	bind	Cu(I),	 along	with	data	published	by	Matsumara	et	al.	 (Figures	4.4	and	4.5)150	 showing	copper	bound	to	the	homologous	residue	in	SeGAPDH,	led	to	the	hypothesis	that	copper	was	most	likely	binding	to	SaGapA	at	this	site	within	the	active	site	of	the	protein.	
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Copper	binding	to	such	a	site	would	almost	certainly	lead	to	the	inhibition	of	the	protein,	as	 the	 catalytic	 Cys151	 residue	would	 be	 unable	 to	 initiate	 nucleophilic	 attack	 of	 the	substrate;	 indeed,	 we	 have	 shown	 that	 inhibition	 of	 the	 protein	 does	 occur	 in	 vitro.	His178	forms	a	hydrogen	bond	with	the	substrate	at	the	step	shown	in	Figure	5.1	and	at	no	point	is	thought	to	from	a	covalent	bind	with	the	substrate;	the	significance	of	His178	in	copper	binding	is	therefore	likely	to	be	less	so	than	that	of	Cys151	but	may	certainly	act	to	stabilise	the	interaction.		Other	metals	 have	 also	 been	 shown	 to	 inhibit	 the	 enzyme	 in	 vitro	 and	 the	 pattern	 of	inhibition	 is	 very	 similar	 to	 that	 seen	 in	 lysates	 as	 reported,	 following	 the	 pattern	expected	from	the	Irving	Williams	series80.	Notably	 this	 work	 has	 also	 provided	 evidence	 that	 SaGapA	 binds	 to	 copper	 with	 a	stoichiometry	of	one	Cu(I)	ion	to	each	GapA	monomer.	Such	a	conclusion	can	be	drawn	from	SEC	analysis	of	the	WT	recombinant	protein,	which,	even	when	loaded	with	super-stoichiometric	copper	levels	did	not	appear	to	bind	more	copper	than	protein	present,	although	such	experiments	require	repetition.	LMCT	data	also	showed	a	clear	change	in	gradient	in	the	change	in	absorbance	at	3	different	wavelengths	indicating	that	one	main	high-affinity	site	is	likely,	a	second,	lower	affinity	site,	has	not	yet	been	ruled	out	though.	Competition	 with	 BCS	 for	 Cu(I)	 by	 SaGapA	 also	 points	 toward	 a	 potentially	biochemically	 relevant	affinity	of	 the	enzyme	 for	copper,	 (that	 is;	within	 less	 than	 five	orders	 of	 magnitude	 of	 native	 copper	 binding	 proteins	 in	 S.	 aureus,	 such	 as	 CsoR),	demonstrating	that	the	interaction	is	likely	to	occur	in	vivo.		 	
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Figure	5.1.	The	initial	step	of	 the	catalysis	of	G3P	to	1,3-BPG	by	SaGapA.	Adapted	from	Mukherjee	et	al.114.	Circled	in	red	is	the	catalytic	thiolate	nucleophile	which	attacks	the	 C1	 of	 G3P.	 It	 is	 this	 thiolate	 ligand	 that	 is	 proposed	 binds	 to	 copper,	 hence	inactivating	the	enzyme.			 	
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5.5.	Identification	of	SaGapA	residue	Cys151	as	a	Cu(I)	ligand.	Changes	in	absorbance	of	the	enzyme	SaGapA	caused	by	LMCT	interaction	between	the	thiol	sidechain	of	cysteine	residues	and	Cu(I)	have	been	used	in	this	study	to	investigate	binding	 of	 Cys151	 to	 Cu(I).	 Mutation	 of	 the	 pLEICS-03-SaGapA	 vector	 in	 order	 to	produce	recombinant	SaGapA(C151A)	and	SaGapA(H178A)	have	enabled	comparison	of	the	result	of	Cu(I)	titration	into	these	three	protein	variants.	Figure	4.14	highlights	the	occurrence	of	an	LMCT	when	titrating	Cu(I)	into	WT	rSaGapA.	Figure	4.22	reveals	that	this	 feature	disappears	 in	 the	 case	of	 the	C151A	mutant	and	 is	 retained	 in	 the	H178A	mutant.		Further	 investigation	 of	 these	 rSaGapA	 recombinant	 proteins	 by	 analytical	 SEC	 reveal	that	Cu(I)	binds	to	the	WT	and	H178A	mutant,	but	not	to	the	C151A	mutant.	Such	results	point	firmly	to	the	involvement	of	Cys151	in	the	mechanism	of	copper	binding.	Further	repetition	is	required	however	to	completely	confirm	this	observation.	The	observation	that	 the	His178	residue	 is	not	required	 for	copper	binding	 implies	 that	other	residues	may	stabilise	the	co-ordination	of	Cu(I)	by	Cys151.	Matsumara	et	al.	demonstrated	that	copper	was	bound	to	SeGAPDH	through	the	active	site	histidine	and	cysteine	residues,	which	 were	 accompanied	 by	 a	 threonine	 residue	 (Thr156),	 this	 threonine	 residue	 is	conserved	 in	 SaGapA	 (Thr152)	 and	 maybe	 hypothesised	 to	 stabilise	 copper	 co-ordination	in	this	case	as	well.	
5.6.	Conclusions	and	future	directions.	In	this	study	it	has	been	demonstrated	that	SaGapA	does	indeed	bind	copper	both	in	vivo	and	in	vitro	and	that	this	inhibits	the	activity	of	the	protein,	evidence	for	a	hypothesised	binding	 site	 has	 also	 been	 provided.	What	 has	 proven	more	 difficult	 is	 to	 define	 the	consequences	of	such	an	inhibition.	When	SaGapA	is	inhibited	by	copper	in	the	cell	how	does	the	cell	react?	
5.6.1.	The	effects	of	copper	binding	to	SaGapA	upon	S.	aureus	cells	It	 is	 clear	 that	 relatively	 high	 concentration	 of	 copper	 within	 the	 medium	 (400	 µM	CuSO4)	 do	 not	 significantly	 inhibit	 SaGapA	 when	 it	 is	 grown	 in	 glucose.	 Yet	 in	 these	conditions	cells	uptake	of	copper	is	significant	compared	to	cells	grown	in	a	non-copper	environment	(Figure	3.7).	We	have	also	observed	that	at	much	lower	concentrations	of	copper	 (50	 µM	 CuSO4)	 in	 TSB	 and	 in	 TM	 media,	 copper	 is	 bound	 to	 SaGapA	(metalloproteomics	data,	Chapter	3)	at	least	to	some	extent.	
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The	difference	in	carbon	source	between	such	experiments	is	of	importance.	In	TSB	the	presence	of	glucose	means	that	cells	are	relying	overwhelmingly	on	glucose	metabolism,	meaning	that	SaGapA	is	being	expressed	and	used	for	this	purpose.	In	TM	(as	used	for	metalloproteomics	work	 conducted	 in	 this	 study	 as	 a	 ΔgapA	mutant	will	 not	 grow	 in	glucose)	 glucose	 is	 not	 present;	 cells	 are	 using	 amino	 acids	 as	 their	 primary	 carbon	source,	yet	SaGapA	is	still	present	as	it	can	be	detected	in	such	conditions,	both	through	detection	of	 its	 activity,	 and	on	SDS-PAGE	gels.	Under	 these	 conditions	SaGapA	would	not	 be	 being	 used	 for	 glycolysis	 and	 presumably	 is	 expressed	 for	 its	 alternative	functions	 or	 perhaps	 is	 present	 within	 the	 cell	 constitutively	 in	 order	 to	 be	 able	 to	metabolise	any	glucose	that	does	appear	in	the	environment	efficiently.	The	effects	upon	the	cell	of	copper	binding	to	SaGapA	may	therefore	vary	depending	on	the	conditions.	Thus,	 the	 SH1000	WT	 and	 SH1000	 ΔgapA	mutant	 were	 grown	 in	 succinate	 to	 try	 to	remove	 such	 a	 complication	 (Figure	 3.13).	 It	 was	 assumed	 that	 the	 WT	 and	 mutant	would	grow	in	the	same	manner	in	such	a	medium,	as	they	do	in	a	medium	containing	only	 amino	 acids	 as	 a	 carbon	 source,	 but	 this	 was	 not	 the	 case;	 the	 SH1000	 ΔgapA	mutant	was	significantly	 inhibited	in	 its	growth	in	succinate	compared	to	SH1000	WT.	This	 is	 surprising	 since	 succinate	 enters	 carbon	metabolism	at	 a	 later	point	 in	 carbon	metabolism	than	should	involve	SaGapA.	This	further	implies	that	SaGapA	has	more	far-reaching	effects	 than	 its	 supposed	primary	 role	within	 the	glycolytic	pathway,	but	 the	nature	 of	 such	 a	 phenotype	 hindered	 our	 investigation	 of	 SaGapA	 copper	 dependent	phenotypes	under	such	conditions.	 It	has	 therefore	been	very	difficult	 to	 interpret	 the	consequences	of	copper	binding	to	SaGapA	in	vivo	through	growth	assays.	Nonetheless,	
SaGapA	is	binding	to	copper	under	both	glycolytic	(as	demonstrated	by	preliminary	data	shown	 in	 Chapter	 3	 gather	 by	 Emma	 Tarrant	 of	 the	 Waldron	 Group,	 which	 was	conducted	 with	 glucose	 present	 in	 the	 growth	 media)	 and	 non-glycolytic	 conditions	(Figure	3.22),	for	which	there	surely	are	metabolic	consequences.	The	sensitivity	of	non-copper	proteins	such	as	SaGapA	to	copper	in	vivo	must	be	viewed	from	the	same	perspective	as	has	been	suggested	by	Waldron	et	al157;	that	is	taking	into	account	the	affinity,	allostery	and	access	of	proteins	with	regards	to	copper	binding.	We	are	 not	 aware	 of	 the	 affinity	 or	 allosteric	 based	 differences	 between	 such	 proteins	 in	terms	of	their	interaction	with	copper	as	these	values	have	not	been	published,	but	we	do	know	that	 the	active	site	of	SaGapA	 is	accessible	by	 its	very	nature.	Another	 factor	that	plays	a	role	in	metallation	of	proteins	in	vivo	is	abundance	of	the	protein,	as	this	will	
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affect	 the	 amount	 of	 any	 protein	 binding	 to	 copper,	 and	 determine	 if	 the	 collective	activity	of	that	particular	protein	pool	is	completely	or	partially	inhibited.	It	 is	 thought	 that	 SaGapA	 could	make	 up	 as	much	 as	 2	%	 of	 the	 cytoplasmic	 protein	under	some	conditions115,	or	one	fiftieth,	a	vast	amount	considering	the	vast	number	of	proteins	 being	 expressed	 at	 any	 one	 time	 within	 a	 cell,	 making	 it	 one	 of	 the	 most	abundant	cytoplasmic	proteins.	It	is	not	quite	clear	why	cells	express	so	much	SaGapA,	especially	 as	 other	 glycolytic	 proteins	 are	 not	 expressed	 to	 anywhere	 near	 this	 level	(Waldron	 and	 Saito,	 unpublished	 data).	 However,	 it	 is	 known	 that	SaGapA	 is	 the	 rate	limiting	step	of	glycolysis,	therefore	higher	levels	of	the	protein	may	be	needed	to	keep	glycolysis	 functioning	 efficiently	 relative	 to	 other	 enzymes	 in	 the	 pathway.	 Suspected	moonlighting	 functions	 of	 the	 protein	may	 also	mean	 that	 it	 is	 being	 expressed	more	than	 other	 glycolytic	 proteins	 which	 perhaps	 have	 more	 restricted	 purposes.	Interestingly,	studies	have	suggested	that	in	yeast	and	muscle	tissue	the	concentrations	of	the	GAPDH	tetramer	may	be	as	high	as	210	µM	and	75	µM	respectively110	(with	each	tetramer	 containing	 four	 copper	 binding	 sites).	 This	 is	 a	 huge	 number	 of	 potential	binding	sites	compared	to	the	number	of	copper	ions	per	cell,	which	has	been	estimated	for	E.	coli	cells	to	be	in	the	region	of	10,000	atoms	per	cell,	or	approximately	10	µM72.	It	may	be	the	case	that	such	vast	amounts	of	protein	make	a	population	of	it	susceptible	to	copper	binding	in	high-copper	conditions,	despite	having	a	lower	affinity	than	other	potential	targets	of	copper	binding	toxicity	(such	as	Fe-S	cluster	enzymes	for	example).	Our	data	leads	us	to	hypothesise	that	a	SaGapA	monomer	binds	one	equivalent	of	copper	with	 a	 physiologically	 relevant	 affinity,	 and	with	 such	 a	 high	 total	 number	 of	 SaGapA	tetramers	present,	such	a	pool	would	provide	a	large	number	of	potential	binding	sites.		The	complexities	of	metal	binding	have	been	discussed	in	the	introduction	to	this	work	and	elsewhere.	It	is	tempting	to	envisage	copper	binding	as	being	extremely	defined	but	we	 know	 that	 affinity,	 allostery,	 access	 and	 abundance	 of	 proteins	 change	 with	 the	conditions	 that	cells	are	grown	in,	 thus	 the	distribution	of	metals,	governed	 in	part	by	these	factors,	must	also	be	dynamic.	It	is	also	worth	pointing	out	that	the	parameters	set	by	such	guiding	factors	are	very	unlikely	to	be	sharply	defined.	That	is,	unlike	the	shells	of	 a	 nucleus	 for	 example,	 which	 must	 be	 filled	 systematically,	 copper	 may	 ‘fill’,	 for	example,	the	CsoR	protein	pool	to	75	%	whilst	also	‘filling’	the	CopZ	protein	pool	by	50	%	 (such	musings	 are	 completely	 theoretical	 in	 nature).	 Phrased	 differently;	 at	 which	concentration	of	intracellular	copper	various	proteins	bind	to	that	copper	will	overlap.	
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Teasing	apart	the	details	of	global	copper	binding	would	not	be	easy	to	attempt	but	is	a	long-term	research	goal	of	the	Waldron	lab,	among	others..	Such	overlapping	of	binding	events	may	also	influence	our	ability	to	detect	the	effects	of	copper	binding	using	 techniques	such	as	growth	assays,	RT-PCR	or	using	microarrays.	This	is	because	the	pool	of	protein	bound	may	not	be	proportional	to	the	change	of	the	impact	 of	 that	 particular	protein	pools	 interaction	with	 copper	within	 the	 cell.	 Such	 a	situation	is	analogous	to	certain	organs	in	the	body,	for	instance	the	liver	can	lose	much	of	its	capacity	before	major	overt	effects	of	such	damage	can	be	observed.		Thus	it	may	be	the	case	that	the	effect	of	SaGapA	binding	to	copper	is	not	seen	until	the	concentration	of	copper	within	the	cell	reaches	a	concentration	at	which	it		saturates	a	high	percentage	of	SaGapA,	or	until	it	begins	to	bind	to	other	proteins	which	are	far	less	abundant,	but	 the	effects	of	 copper	binding	on	which	are	much	more	damaging	 to	 the	cell.		
5.6.2.	A	potential	model	for	the	physiological	role	of	copper	binding	to	SaGapA		Life	has	evolved	over	billions	of	years	to	be	prepared	in	numerous	ways	for	the	adverse	conditions	encountered	throughout	the	natural	world.	The	case	could	be	that	in	binding	to	copper,	SaGapA	is	providing	the	cell	with	a	protective	barrier	against	copper	induced	damage;	acting	potential	both	as	a	copper	buffering	agent	and	potentially	as	a	metabolic	switch.		When	an	S.	aureus	cell	enters	a	high	copper	environment,	copper	accumulates	within	the	cytoplasm	 and	 enhances	 expression	 of	 enzymes	 responsible	 for	 copper	 homeostasis.	Upon	 the	 cytoplasm	 reaching	 a	 certain	 concentration	 of	 copper,	 such	 systems	will	 be	overwhelmed	 and	 other	 intracellular	 components	 may	 begin	 to	 be	 effected	 by	 the	presence	of	the	copper,	indeed	this	has	been	demonstrated	by	Macomber	and	Imlay66	as	well	as	being	the	focus	of	this	work.	SaGapA	is	likely	to	be	one	such	component	as	it	has	been,	in	this	work,	shown	to	bind	to	copper	in	vivo.	Inactivation	of	of	SaGapA	could	lead	to	 the	 shut	 down	 of	 glycolysis	within	 the	 cell	 inducing	 the	 aforementioned	metabolic	switch,	leading	the	cell	to	use	alternative	methods	of	energy	production.			
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Under	such	conditions	the	main	pathways	for	energy	generation	likely	to	be	used	are	the	pentose	 phosphate	 pathway	 and	 gluconeogenesis.	 Notably	 these	 pathways	predominantly	produce	as	 their	 reducing	equivalents	NADPH.	NADPH	 is	 an	 important	cofactor	for	many	anabolic	pathways	within	the	cell	and	is	involved	in	the	reduction	of	oxidised	reducing	agents	also.	Thus,	a	shutdown	of	glucose	metabolism	caused	by	the	inactivation	of	SaGapA	by	copper	may	well	 lead	to	activation	of	the	pathways	that	most	enable	the	cell	to	maintain	itself	for	 the	 longest	 possible	 time	 in	 the	 presence	 of	 this	 stress,	 therefore	 increasing	 its	likelihood	 of	 survival.	 Indeed,	 such	 a	 metabolic	 switch	 may	 be	 the	 same	 mechanism	utilised	 in	 other	 cases	 where	 glycolysis	 is	 inhibited,	 such	 as	 inhibition	 of	 different	enzymes	or	via	the	presence	of	different	metals.	
5.6.3.	Alternative	strategies	for	identifying	the	role	of	SaGapA	in	copper	toxicity		The	main	strategy	used	in	this	work	for	trying	to	elucidate	the	wider	effects	of	copper	toxicity	have	been	to	use	growth	assays	 in	different	conditions	when	growing	SH1000	versus	 the	SH1000	ΔgapA	 	mutant.	This	has	 failed	 to	give	an	 insight	 into	how	SaGapA	might	be	affecting	the	cell	metabolically.	There	 are	 several	 further	 options	 that	 could	 have	 been	 explored	 given	 more	 time.	Firstly,	 a	 strain	 non-functional	 in	 CCR	 would	 be	 useful	 as	 this	 would	 allow	 a	 ΔgapA	mutant	 in	 such	 a	 genetic	 background	 to	 grow	 in	 glucose.	 Such	 a	 growth	 phenotype	would	 allow	 for	 direct	 comparison	 of	 the	WT	 to	 the	ΔgapA	mutant	 in	 replete	 glucose	conditions,	 which	 may	 make	 a	 ΔgapA	 growth	 phenotype	 in	 copper	 identifiable.	 The	disadvantages	of	this	would	relate	to	the	regulation	that	is	inherent	to	the	CCR	system,	which	may	make	any	result	completely	artefactual.	Other	 genetic	 backgrounds	 that	 would	 have	 been	 favourable	 for	 looking	 for	 a	remarkable	phenotype	when	growing	in	copper	would	have	been	mutants	of	the	copper	homeostasis	 system;	 that	 is,	mutants	of	copA,	copZ,	 or	csoR.	 Such	mutants	would	have	increased	the	sensitivity	of	S.	aureus	to	copper	and	removed	one	(or	more	in	the	case	of	a	double	or	triple	mutant)	of	the	most	important	copper	chelating	protein	pools,	which	would	allow	any	phenotype	caused	by	the	absence	of	SaGapA	t	become	more	prominent	in	growth	assays.		Whilst	 using	 such	 strains,	 and	 also	 in	 the	 SH1000	WT	 and	 ΔgapA	 mutant	 already	 in	existence	 it	 would	 be	 of	 interest	 to	 use	 other	 methods,	 concurrent	 to	 growth	 assay.	
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These	 include	RT-PCR	and	microarrays	as	well	 as	proteomic	 techniques	 involving	MS.	Towards	the	end	of	this	study,	samples	of	SH1000	WT	that	had	been	grown	in	TSB	and	TM	 containing	 glucose	 at	 various	 concentrations	 of	 copper	 (1	mM,	 2	mM	 and	 5	mM)	(samples	prepared	by	Emma	Tarrant	of	the	Waldron	group)	were	analysed	for	protein	content	by	MS	by	collaborators	(data	not	shown;	Dr	M.	Saito,	Woods	Hole	Oceanographic	Institute).	Such	results	were	 in	broad	agreement	with	data	published	by	Baker	et	al.59.	Some	of	 these	MS	data	 also	 show	a	 change	 in	 proteins	 involved	 in	 other	 pathways	 of	metabolism,	 including	 the	 PPP	 (glucose-phosphate	 dehydrogenase)	 and	 the	TCA	 cycle	(succinate	 dehydrogenase),	 indicating	 that	 these	 pathways	may	 be	 upregulated	when	cells	are	cultured	in	copper,	consistent	with	a	copper-dependent	decrease	in	metabolic	flux	through	glycolysis.	
5.6.4.	Where	does	SaGapA	sit	in	the	context	of	whole	cell	copper	binding?	As	 stated,	 copper	 distribution	 in	 vivo	 is	 governed	 by	 affinity,	 allostery,	 access	 and	abundance	 of	metal	 binding	 species	within	 a	 cell,	 as	well	 as	 the	 concentration	 of	 the	metal	present.	 In	terms	of	the	affinities	of	proteins,	we	have	an	idea	of	copper	binding	for	very	 few	proteins	relative	to	the	number	produced	by	S.	aureus,	and	those	that	we	are	 aware	 of	 are	 mainly	 those	 that	 have	 been	 studied	 for	 their	 native	 metal	 binding	properties.	The	concept	of	copper	(and	metal)	toxicity	involves	aberrant	binding,	which	requires	that	sites	that	under	standard	conditions	should	not	bind	copper	are	examined.	As	 we	 have	 seen,	 the	 identification	 of	 SaGapA	 involved	 the	 matching	 of	 metal	 peaks	within	 separated	 cytoplasmic	 extracts	 to	 corresponding	 protein	 peaks.	 SaGapA	represents	 just	one	of	the	proteins	that	were	identified	with	a	peak,	and	that	has	been	subsequently	 investigated	 further	 to	 confirm	 its	 copper	binding	property.	 Preliminary	work	 to	 this	 also	 identified	 other	 potential	 binding	 targets.	 Such	 targets	 included	 the	amino	acid	synthesis	protein,	RocA,	which	is	involved	in	the	synthesis	of	glutamate	from	proline,	as	well	as	one	of	the	subunits	of	the	pyruvate	dehydrogenase	complex,	LpdA.		Such	targets	are	yet	to	be	fully	investigated	but	may	also	play	a	part	in	copper	toxicity	if	confirmed	 to	 be	bona	 fide	 copper	 binding	 targets	 in	 raised	 copper	 conditions.	 Similar	experiments	 could	 be	 performed	 as	 have	 been	 in	 this	 work	 to	 ascertain	 their	involvement	 in	 toxicity.	Having	 identified	 these	proteins	 amongst	 others,	 as	 targets,	 it	may	be	possible	 to	 conduct	a	wider	 screen	of	 toxicity	 targets	using	growth	 screens	of	copper	homeostasis	mutants	in	various	conditions	in	different	concentrations	of	copper	to	 try	 to	 identify	which	proteins	play	major	 roles	 in	 copper	 toxicity,	 extending	 this	 to	
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double	 or	 even	 triple	 mutants	 to	 attempt	 to	 elicit	 a	 cumulative	 effect.	 Such	 studies	represent	possible	future	research	directions	for	the	Waldron	lab.	
5.6.5.	Overall	conclusions		This	study	has	confirmed	the	binding	of	SaGapA	to	copper	in	vivo	and	in	vitro.	It	has	also	been	demonstrated	 that	 copper	 inhibits	 the	activity	of	 the	protein	 in	vitro	and	 in	vivo.	Moreover,	evidence	for	the	binding	site	has	been	produced,	indicating	that	binding	likely	requires	 the	 presence	 of	 the	 catalytic	 Cys151	 residue	 within	 the	 active	 site	 of	 the	protein,	which	is	the	probable	reason	for	inhibition	of	the	protein.		Whilst	 identification	 of	 potential	 targets	 may	 be	 relatively	 straight	 forward,	investigating	 the	potential	 regulatory	 and	 allosteric	 changes	 that	 copper	may	have	on	proteins	is	more	complex	and	we	have	been	unable	to	confirm	the	precise	consequences	of	 copper	 binding	 to	 SaGapA,	 although	 unpublished	 data	 would	 point	 to	 changes	 in	carbon	metabolism	 in	order	 to	 redirect	 the	 cell	 from	glycolysis	when	 the	 intracellular	pool	 of	 SaGapA	 is	 not	 functioning	 to	 its	 full	 capacity.	 Further	 studies	 of	 the	 cellular	consequences	of	copper	inhibition	of	SaGapA	in	vivo	are	ongoing.		 	
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